

Curriculum Vitae

Dennis Kim
Professor of Medicine

A. Date Curriculum Vitae is Prepared: 2022 February 18

Only includes Activities from July 1995 to February 2022

B. Biographical Information

Primary Office 610 University Ave. 700U 6-222
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
M5G 2M9

1. EDUCATION

Degrees

1998 Mar - 2004 Feb PhD, Hematology, School of Medicine, Kyungpook National University, Daegu, Korea, Republic Of, Supervisor(s): Sung Chul Chae
1996 Mar - 1998 Feb MMS, School of Medicine, Kyungpook National University, Daegu, Korea, Republic Of, Supervisor(s): Kyu Bo Lee
1989 Mar - 1995 Feb MD, School of Medicine, Kyungpook National University, Daegu, Korea, Republic Of

Postgraduate, Research and Specialty Training

2005 Sep - 2007 Dec Clinical fellowship, Adult Hematology, Allogeneic BMT program, Princess Margaret Hospital, Toronto, Ontario, Canada, Supervisor(s): Hans A Messner
2003 Apr - 2004 Feb Clinical fellowship, Hematology/Oncology, Division of Hematology/Oncology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea, Republic Of, Supervisor(s): Sang Kyun Sohn MD
1996 Mar - 2000 Feb Residency, Internal Medicine, Hematology/Oncology Subspecialty, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea, Republic Of
1995 Mar - 1996 Feb Internship program, Medicine (rotational), Kyungpook National University Hospital, Daegu, Korea, Republic Of

Qualifications, Certifications and Licenses

2005 Oct - present Specialist, Hematology/Oncology, Korean Association of Internal Medicine, Korea, Republic Of, License / Membership #: 6-05-259
2005 Sep - present Medical doctor license, College of Physicians and Surgeons of Ontario, Canada, License / Membership #: 83716
2000 Mar - present Board license of Internal Medicine, Internal Medicine, Ministry of Health and Welfare, Seoul, Korea, Republic Of, License / Membership #: 6852
1995 Mar - present Medical doctor license, Ministry of Health and Welfare, Korea, Republic Of, License /

Dennis Dong Hwan KIM

Membership #: 56516

2009 Aug - 2011 Feb

Certified for GCP training, Clinical Trial Center, Samsung Medical Center, Seoul, Korea, Republic Of

2. EMPLOYMENT

Current Appointments

2021 Jul 1 - present Professor of Medicine, Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

2018 Sep 1 - present Associate Faculty Member, IMS-SGS, Medicine, Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada

2011 Mar 1 - present Staff Physician / Clinical Investigator, Medical Oncology and Hematology, Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada

Previous Appointments

CLINICAL

2006 Mar - 2008 Feb Clinical Professor (equivalent to Assistant Professor), Hematology/Oncology, Samsung Medical Center, Seoul, Korea, Republic Of

2004 Mar - 2005 Aug Clinical Professor, Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea, Republic Of

HOSPITAL

2018 Jul 25 - 2020 Feb 11 Medical Director, Orsino Cell Processing Laboratory, Medical Oncology and Hematology, Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada

2018 Jul 1 - 2018 Jul 24 Interim Medical Director, Orsino Cell Processing Laboratory, Medical Oncology and Hematology, Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada
To supervise clinical activity of the cell processing lab which includes stem cell freezing, storage, release for clinical programs of allogeneic/autologous transplant program, and for research activity of clinical trials in cell therapy program.

2000 Mar - 2003 Mar Head, Department of Internal Medicine, Korean-Kazakhstan Friendship Hospital, Almaty, Almaty, Kazakhstan
KOICA, Korean International Cooperation Agency; www.koica.go.kr; alternative to military obligation

UNIVERSITY - RANK

2014 Jul 1 - 2021 Jun 30 Associate Professor, Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

2011 Mar 1 - 2014 Jun 30 Assistant Professor, Medical Oncology and Hematology, Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

2008 Mar - 2011 Feb Assistant Professor, Division of Hematology/Oncology, School of Medicine, Samsung Medical Center / Sungkyunkwan University, Seoul, Korea, Republic Of

3. HONOURS AND CAREER AWARDS

Distinctions and Research Awards

INTERNATIONAL

Received

- 2007 Nov **Scholarship**, ESH Euroconference: TRANSLATIONAL RESEARCH IN TRANSPLANTATION: Integrating Immunity: from genomics to cell therapy, November 23-25, 2007, Paris, France. (Travel award)
Total Amount: 2,000 CAD
- 2007 Jul **Scholarship**, ESH/EBMT Euroconference on GVHD/GVL: A PARADIGM OF HAEMOPOIETIC STEM CELL TRANSPLANTATION, July 6-9, 2007, Sitges, Spain. (Travel award)
Total Amount: 2,000 CAD
- 2006 Jul **Scholarship**, Euroconference on TRANSLATIONAL RESEARCH IN TRANSPLANTATION: IMMUNOGENETICS, PHARMACOGENOMICS, PROTEOMICS AND IMMUNOBIOLOGY, July 2-4, 2006, Leiden, Netherlands. (Travel award)
Total Amount: 2,000 CAD
- 2005 Jun **2005 ASCO foundation Merit Award**, American Society of Clinical Oncology (ASCO), Chicago, United States. (Travel award)
Travel grant for oral presentation of abstract in ASCO meeting. Total Amount: 1,000 USD
- 2004 Dec **Travel award for 2004 Annual meeting of ASH**, American Society of Hematology (ASH). (Travel award)
Travel grant for oral presentation of abstract in ASH meeting. Total Amount: 500 USD

NATIONAL

Received

- 2008 Nov **Wunsch Medical Award, Young Investigator**, Korean Association of Medical Science, Seoul, Korea, Republic Of. (Distinction)
It is the most honorable medical award in South Korea. Two most distinguishable young investigators are usually awarded from clinical and basic fields of medical society in Korea. In the year that I was awarded, there was not winner in basic science and I was the only awardee over clinical and basic fields. Total Amount: 5,000 CAD
- 2004 Aug **Best Presentation Award**, Korean Society of Hematopoietic Stem Cell Transplantation. (Distinction)
- 2004 Jun **Travel award for American Society of Clinical Oncology, Annual meeting 2004**, Korean Cancer Study Group. (Travel award)
Total Amount: 500 USD
- 2004 Feb **Presentation award**, Korean Society of Hematopoietic Stem Cell Transplantation. (Distinction)
- 2003 Aug **Travel award**, Korean Society of Hematopoietic Stem Cell Transplantation, Korea, Republic Of. (Travel award)
Total Amount: 500 USD

Student/Trainee Awards

INTERNATIONAL

Received

- 2021 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Clinical Fellow - Fatima Khadadah. American Society of Hematology, Atlanta, Georgia, United States
Fatima Khadadah won the ASH Abstract Achievement Award for 2021 as her primary supervisor.
- 2021 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Clinical Fellow - Igor Novitzky-Basso. American Society of Hematology, Atlanta, Georgia, United States
Igor Novitzky-Basso won the ASH Abstract Achievement Award for 2021 as his primary supervisor.
- 2021 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Taehyung Kim. American Society of Hematology, Atlanta, Georgia, United States
Taehyung Kim won the ASH Abstract Achievement Award for 2021 as his primary supervisor.
- 2020 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Swe Mar Linn. American Society of Hematology, Orlando, Florida, United States
Swe Mar Linn won the ASH Abstract Achievement Award for 2020 as her primary supervisor.
- 2020 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Igor Novitzky-Basso. American Society of Hematology, Orlando, Florida, United States
Igor Novitzky-Basso won the ASH Abstract Achievement Award for 2020 as his primary supervisor.
- 2020 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Muhned AlHumaid. American Society of Hematology, Orlando, Florida, United States
Muhned AlHumaid won the ASH Abstract Achievement Award for 2020 as his primary supervisor.
- 2019 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Georgina Daher-Reyes. American Society of Hematology, Orlando, Florida, United States
Georgina Daher-Reyes won the ASH Abstract Achievement Award for 2019 with the projects entitled "Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.", that I supervised as a senior author. Total Amount: 500 USD
- 2018 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Taehyung Kim. American Society of Hematology, San Diego, California, United States
Taehyung Kim won the ASH Abstract Achievement Award for 2018 with the projects entitled "RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)" and "Residual Allelic Burden Measured by Nex-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)", that I supervised as a senior auth. Total Amount: 500 USD
- 2018 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Rhida Bautista. American Society of Hematology, San Diego, California, United States
Rhida Bautista won the ASH Abstract Achievement Award for 2018 with the projects entitled "Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Nodel Provides Stratification of Patients According to Probability of SIS Discontinuation", that I supervised as a senior author. Total Amount: 500 USD
- 2018 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Warren Fingrut. American Society of Hematology, San Diego, California, United States
Warren Fingrut won the ASH Abstract Achievement Award for 2018 with the projects entitled "High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate Following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not" that I supervised as a senior author. Total Amount: 500 USD
- 2017 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Taehyung Kim. American Society of Hematology, Atlanta, Georgia, United States
Taehyung Kim won the ASH Abstract Achievement Award for 2017 with the projects entitled

“Next generation sequencing (NGS)-based post-transplant monitoring in acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation (HCT). “ and “Clinical and genetic relevance of somatic mutations in core binding factor (CBF) acute myeloid leukemia (AML) patients using serial sequencing”, that I supervised as a senior author. Total Amount: 500 USD

2016 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Taehyung Kim. American Society of Hematology, San Diego, California, United States
Taehyung Kim won the ASH Abstract Achievement Award for 2016 with the project entitled “Longitudinal Tracking of MDS Patients Using Next Generation Sequencing Provides a Predictive Measure for Azacitidine Response and AML Progression”, that I supervised as a senior author. Total Amount: 500 USD

2016 Jun **EHA travel award**, Supervisor, Awardee Name: Taehyung Kim. European Hematology Association, Copenhagen, Denmark
Taehyung Kim won the EHA travel award for 2016 with the project entitled “DYNAMICS OF SOMATIC MUTATIONS COMMONLY DETECTED IN OTHER MYELOID NEOPLASMS BEYOND THE BCR-ABL GENE REARRANGEMENT IN RESPONSE TO TYROSINE KINASE INHIBITOR THERAPY IN CHRONIC MYELOID LEUKEMIA”, that I supervised as a senior author. Total Amount: 500 EUR

2015 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Sita Bhella. American Society of Hematology, Orlando, Florida, United States
Sita Bhella won the ASH Abstract Achievement Award for 2015 with the project entitled “Incidence and Risk Factors for VzV Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of cGVHD By NIH Consensus Criteria, and No T-Cell Depletion”, that I supervised as a senior author. Total Amount: 500 USD

2013 Dec **ASH Abstract Achievement Award**, Supervisor, Awardee Name: Jieun Uhm. American Society of Hematology, New Orleans, Louisiana, United States
Jieun Uhm won the ASH Abstract Achievement Award for 2013 with the project entitled “Incidence, risk factors and allogeneic stem cell transplant outcomes in chronic sclerotic GVHD: T-cell depletion is preventive and peripheral blood stem cells as risk factor, but not HLA-mismatch with no adverse impact on transplant outcome”, that I supervised as a senior author. Total Amount: 500 USD

2013 Apr **Best poster presentation prize**, Hematology, Supervisor, Awardee Name: Joon Ho Moon. European Group of Bone Marrow Transplantation, London, United Kingdom
One of 2 best poster presentation prize presented in the 33th Annual meeting of European Group of Bone Marrow Transplantation. Total Amount: 1,000 EUR

NATIONAL

Received

2013 Apr **Best oral presentation award**, Supervisor, Awardee Name: Naheed Alam. Canadian Blood and Marrow Transplant Group, Winnipeg, Manitoba, Canada
Naheed Alam won one of the 6 best oral presentations award in the Canadian Blood and Marrow Transplant Group meeting in 2013 with the abstract entitled “The risk of steroid refractory acute graft-versus-host disease can be predicted by the risk model using donor IL6 and IFNG genotype along with gut GVHD”.

2012 Apr **Best oral presentation award**, Supervisor, Awardee Name: Naheed Alam. Canadian Blood and Marrow Transplant Group, Winnipeg, Manitoba, Canada
Naheed Alam 's abstract was selected among the top 8 abstracts for Oral Presentation at the Canadian Blood and Marrow Transplant Group Meeting in Toronto, Canada with the abstract entitled “Peripheral blood stem cell transplant increases the risk of chronic graft-versus-host disease of lung compared to bone marrow transplantation”.

4. PROFESSIONAL AFFILIATIONS AND ACTIVITIES

Professional Associations

2018 Dec - present **Member**, Canadian Hematology Society
2017 Nov - present **Committee Member**, Academy for Continued Advancement in Healthcare Education
2008 Jan - present **Active member**, Canadian Blood and Marrow Transplantation Group
2005 May 1 - present **International Member**, American Society of Hematology, 1003868
2003 Apr - present **Member**, Korean Society of Blood and Marrow Transplantation
2003 Apr - present **Member**, Korean Society of Hematology
2006 - 2008 **Associate Member**, American Association of Cancer Research

Administrative Activities

NATIONAL

Korean Society of Hematology

2009 Jan - 2010 Dec **Secretary**, Academic Committee, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Continuing Education, Seoul, Korea, Republic Of.

Korean Society of Hematopoietic Stem Cell Transplantation

2008 Aug - 2011 Feb **Secretary**, Academic Committee, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Continuing Education, Seoul, Korea, Republic Of.

LOCAL

Allogeneic BMT Program, Department of Medical Oncology & Hematology at the Princess Margaret Cancer Center

2013 Nov - 2014 Jul **Member**, Subcommittee for Developing Care Map for Steroid Refractory GVHD, Toronto, Ontario, Canada.
This subcommittee is initiated by myself in order to improve quality of our current management in steroid refractory GVHD patients. It includes junior faculty (Dr. Uhm and Dr. Alam), clinical associate (Dr. Loach), nursing practitioner (Ms McGillis), nursing manager (Ms Clarke), nurse on 14B floor, social worker, and rehabilitation specialist. We are meeting once a month to develop standardized flow, to improve our current practice and to facilitate recovery and rehabilitation of patients admitted with steroid refractory GVHD.

Department of Medical Oncology & Hematology at the Princess Margaret Cancer Center

2011 Nov - 2020 Feb **Member**, BMT Management Council, Ontario, Canada.

Kyungpook National University

2003 Feb - 2005 Aug **Project Organizer**, Electronic Medical Record Database Task-force Team, Korea, Republic Of.
This is a database project to install the electronic medical record database system in kyungpook national university hospital. I am responsible for doctor's aspects of organization and utilization of electronic medical record database system, structuring database structures, applying it to clinical fields, and beta-testing it. (PI: Lee, Kyungpook National University Hospital; Funded by Kyungpook National University, Biomedical institute).

MPN Program

Dennis Dong Hwan KIM

2014 Sep - present MPN Program Governance Committee, Toronto, Ontario, Canada.

Princess Margaret Cancer Center

2018 Sep - 2020 Feb **Chair**, Orsino Cell Processing Lab Governance Committee, Toronto, Ontario, Canada.

Princess Margaret Cancer Centre

2018 Sep - 2020 Feb **Member**, Messner AlloBMT Program, Governance Committee, Toronto, Ontario, Canada.

Princess Margaret Hospital

2021 Jan - present **Chair**, Princess Margaret Cancer Center Leukemia MRD Working Group, Toronto, Ontario, Canada.

2018 Mar - present **Member**, Research Ethics Board, Toronto, Ontario, Canada.

2013 May - present **Member**, Leukemia Site Group, Toronto, Ontario, Canada.
Member of Leukemia Site Group meeting at the PMCC, and attending this meeting once a month to deal with administrative issues in the leukemia program at the PMCC.

2018 Oct - 2020 Feb **Member**, Apheresis and CPL Quality Committee, Toronto, Ontario, Canada.

2012 Nov - 2020 Feb **Member**, DMOH Quality Committee, Toronto, Ontario, Canada.

Translational Research, Leukemia Program

2014 Apr - present Tissue Committee, BMT Program, Toronto, Ontario, Canada.

Peer Review Activities

GRANT REVIEWS

External Grant Reviewer

2020 Feb 12 - 2020 Feb 13 National Institute of Health, NIH P01, Number of Reviews: 14

2019 Jul 2 University of Montreal, Ste-Justine Hospital Research Center, FIT competition, Number of Reviews: 3

2019 Jun 20 - 2019 Jun 21 National Institute of Health, NIH K08, Number of Reviews: 8

2019 May 22 - 2019 May 23 National Institute of Health, NIH P01, Number of Reviews: 5

2017 Oct National Institute of Health, US, NIH P01 grant review, Number of Reviews: 5

2017 Oct National Institute of Health, US, NIH U01 grant review, Number of Reviews: 1

2017 May Canadian Institutes of Health Research, Canadian Institutes of Health Research Operational Grant, Number of Reviews: 6

2015 Oct Juravinski Cancer Centre Foundation Grant Review Panel, Hamilton, ON, Ontario Registry of Chronic Myeloproliferative Neoplasms and Incident Cardiovascular Disease (ORCHID), Number of Reviews: 1

2013 Nov Canadian Institutes of Health Research, Canadian Institutes of Health Research Operational Grant, Number of Reviews: 3

Reviewer

2020 Oct - 2020 Nov WE-SPARK Health Institute, Funding Organization: WE-SPARK Health Institute
Program Name: Igniting Discovery Grants
Sponsor(s): WE-SPARK Health Institute,
Windsor Cancer Centre Foundation
Program Launch Date: July 31, 2020, Number of Reviews: 1

MANUSCRIPT REVIEWS

Reviewer

2018 May - present Nature Publishing Group, Leukemia, Number of Reviews: 8
2017 Dec - present Blood Advances, Blood Advances, Number of Reviews: 3
2017 Nov - present Cancer Letters, Cancer Letters, Number of Reviews: 1
2017 Nov - present Leukemia Research, Leukemia Research, Number of Reviews: 2
2017 Apr - present Experimental Hematology, Experimental Hematology, Number of Reviews: 1
2016 Dec - present Oncotarget, Oncotarget, Number of Reviews: 2
2016 Oct - present Blood, Journal of the American Society of Hematology, Blood, Journal of the American Society of Hematology, Number of Reviews: 7
2016 Oct - present Transplant Infectious Disease, Transplant Infectious Disease, Number of Reviews: 1
2016 Jan - present Annals of Laboratory Medicine, Annals of Laboratory Medicine, Number of Reviews: 1
2015 Oct - present Cancer, Number of Reviews: 1
2015 May - present Biomarker Insights, Number of Reviews: 1
2014 May - present Clinical Transplantation, Number of Reviews: 4
2013 Apr - present Critical Reviews in Oncology/Hematology, Number of Reviews: 1
2012 Jul - present Cancer Biomarkers, Number of Reviews: 1
2010 Feb - present Current Cancer Drug Targets, Number of Reviews: 1
2010 Jan - present Clinical Medicine Insights: Therapeutics, Number of Reviews: 1
2009 Dec - present Journal of Genetics, Number of Reviews: 1
2009 Dec - present Leukemia & Lymphoma, Number of Reviews: 6
2009 Aug - present European Hematology Association, Haematologica, Number of Reviews: 4
2009 Apr - present Acta Haematologica, Number of Reviews: 6
2008 Jul - present American Society of Blood and Marrow Transplantation, Biology of Blood and Marrow Transplantation, Number of Reviews: 21
2007 Jan - present British Society of Haematology, British Journal of Haematology, Number of Reviews: 11
2007 Jan - present European Blood and Marrow Transplant Registry, Bone Marrow Transplantation, Number of Reviews: 14
2022 Feb 22 eJHaem, eJHaem - reviewing the proof of the eJHaem article Single cell proteogenomic sequencing identifies a relapse-fated AML subclone carrying FLT3-ITD with CN-LOH at chr13q. Number of Reviews: 1
2020 Mar - 2020 May European Hematology Association

ABSTRACT REVIEWER

Reviewer

2015 Aug - 2015 Dec American Society of Hematology, Clinical allogeneic transplantation: Results, Number of Reviews: 1
2015 Mar 18 - 2015 Jun 30 European Hematology Association, CML biology, Number of Reviews: 1

ASH ABSTRACTS 2021: ABSTRACT REVIEWER

Reviewer

2021 Aug 5 - 2021 Aug 15 American Society of Hematology (ASH), Category 635--Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational Includes all basic and preclinical studies of myeloproliferative syndromes, including the molecular basis of myelofibrosis, essential thrombocythemia, polycythemia Vera, mast cell disorders, and chronic eosinophilias. For studies on the use of molecular diagnostic tools for diagnosis or

prognosis, see category 634. Number of Reviews: 85

ASSOCIATE EDITOR

Editor

2019 Sep 9 - present Hematology, Hematology, Number of Reviews: 14

Other Research and Professional Activities

RESEARCH PROJECT

2001 - 2002

Investigator. Korean Populations Project in Kazakhstan. Collaborator(s): Lee (PI), Columbia University; Funded by NIH/NIA.

This is a genetic epidemiology study to investigate how gene and environment influence aging traits by studying ethnic Koreans in Kazakhstan, Korea, and Sweden. I was responsible for all aspects of day-to-day operation of the study in Kazakhstan, including developing study protocols, performing health screening evaluation, supervising research assistants, and supervising clinical chemistry laboratory. Now I am Involved in the analysis of the data.

C. Academic Profile

1. RESEARCH STATEMENTS

2020 Jan - present

Research Activities.

I am an Associate Professor in the Department of Medicine, at the University of Toronto and a hematologist/clinician investigator in the Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre. Since my promotion to Associate Professor in July 2014, my research has focused on the development of genomics-based biomarkers in leukemias and HCT using a novel technology called next-generation sequencing (NGS). The successful completion of the Human Genome project in 2001 has lead to revolutionary changes with the potential to transform modern medicine into precision medicine. Precision medicine requires the precise interpretation of genetic information for which the application of NGS platform is critical in order to decipher the genetic profiles of each individual’s disease and protein expression. The genetic profiling of resistant clones has been shown to be key in guiding treatment decisions to overcome resistance and to improve treatment outcomes in leukemia therapy. In my research portfolio, I have three major subjects of research: 1) genomics in chronic myeloid leukemia (CML), 2) genomic-based leukemia monitoring in leukemia/HCT, and 3) treatment-free remission in CML therapy.

Research activity #1: Genomics in CML

First of all, I have applied the next-generation sequencing technology to reveal changes in the genomic profiles of leukemias, mainly in chronic myeloid leukemia (CML). CML is the only subtype of leukemia that is curable with drug therapy, the tyrosine kinase inhibitors (TKI). However, around 1/3 of patients still fail frontline therapy, due to resistance or intolerance, thus requiring a switch of treatment. Previously, at the time of the initial diagnosis of CML, before starting any therapy, it was impossible to predict who was going to fail therapy. I have investigated many genetic markers and reported two potential candidates; a somatic mutation in an epigenetic modification pathway and germline variants of the HMGCLL1 gene (Leukemia 2019, Ref #1).

My most significant research findings centered on the somatic mutation and the spectrum of mutational dynamics in CML (Blood 2017, Ref #4). Before this work was published in 2017,

we did not have a good understanding of other genetic changes in CML besides the fundamental BCR-ABL gene rearrangement. However, for the first time, my work has led to a better understanding of leukemic clonal structure in CML cells. It revealed that about 30% of CML patients carry somatic mutations particularly in the epigenetic modification pathway (such as ASXL1, DNMT3A or TET2 genes) and that these mutations change over time during treatment for CML. Also, I found that CML patients with mutations in the epigenetic modification pathway responded poorly to CML therapy and experienced a worse outcome. Accordingly, we can identify a group of high-risk patients likely to have a poor response even before starting CML therapy. Now it has been accepted in the CML community as a cornerstone for future genomics in CML. It will facilitate change in our practice of CML management in a near future.

Secondly, I have developed a germline biomarker for response to tyrosine kinase inhibitor (TKI) therapy in CML treatment (Leukemia 2019, Ref #1). By using a genome-wide somatic variant screening method, we have identified a variant on the HMGCLL1 gene and demonstrated its functional implications on the response to TKI therapy (Leukemia 2019). Thus, this germline profile also can help to identify high-risk patients likely to experience treatment failure even before starting TKI therapy. I have participated in the International CML conference as a faculty member, 4 times (2016-2019) over the last 5 years, and have shared this information with the CML community over the last 10 years.

Research activity #2: treatment-free remission attempt in CML management

Another topic in my research portfolio is treatment-free remission (TFR) in CML patients. It is a new concept in leukemia treatment with targeted drug therapy. Originally, cessation of tyrosine kinase inhibitor (TKI) in CML was proscribed because of concerns that the leukemic clone would progress after discontinuation of therapy. The CML community was concerned that the leukemia would eventually recur within 6 months after cessation of TKI therapy, as it was thought that TKI drugs cannot eradicate leukemic stem cells. However, these concerns were refuted after a series of studies including our Canadian trial demonstrated that TKI therapy can be stopped without losing control of the leukemia in about 50% of CML patients who attained deep molecular responses for more than 2-3 years. Because of an urgent need for this kind of clinical practice in Canada, I have been leading a Canadian TKI discontinuation trial (titled as "Treatment-free Remission Accomplished by Dasatinib", or TRAD, NCT#02268370) as a principal investigator in collaboration with 12 Canadian CML treating centers over the last 5 years, since March 2015 (total budget 3.5 million dollars of a research grant from a pharmaceutical company). The result confirms that about 60% of Canadian CML patients can stop TKI therapy successfully without losing their CML control, consistent with the results from other trials performed in other countries. The study suggested that it is doable to stop TKI therapy as a second attempt for treatment-free remission (TFR) after failing 1st attempt of imatinib discontinuation by switching to a 2nd generation TKI. It guides how to manage patients who fail the first attempt of TKI discontinuation. The projects from this trial have resulted in 12 abstract presentations in the conferences of American Society of Hematology, European Hematology Association or International CML conference over the last 5 years. Furthermore, I have been invited to speak to international, national or provincial audiences 51 times on the research and clinical aspects of TFR in the management of CML patients over the last 5 years.

In addition, collaborations during the clinical trial gave us an ideal opportunity to develop a biomarker to predict success in TFR attempts by collecting correlative samples while running the TRAD trial. Right now, there is no biomarker proven to be useful for this purpose. I am currently working with 10 other CML treating international centers/investigators to develop a biomarker for TFR success prediction through International CMF foundation TFR alliance.

Research activity #3: Genomics-based measurable residual disease monitoring in AML/HCT
In addition to CML, I have a very significant research interest in acute leukemia and hematopoietic stem cell transplantation (HCT). Acute myeloid leukemia (AML) is the most frequent indication for allogeneic HCT. Allogeneic HCT is the only curative treatment option in AML. However, still, a substantial proportion of patients experience relapse after allogeneic HCT. Theoretically, we can improve our transplant outcomes by intervening a prophylaxis for

relapse on every patient regardless of their leukemic burden after HCT. However, it could increase the risk of transplant-related mortality. To improve outcomes, we need a sophisticated risk-stratified strategy based on the risk of relapse in each individual. By identifying patients at high risk of relapse, we can deliver therapeutic intervention exclusively to those at risk of relapse while sparing such treatments from those at a low risk of relapse. For this reason, I pursued a research project adopting genomics-based post-transplant monitoring in AML patients (Blood 2018, Ref #2). NGS technology has been applied for this purpose in measurable residual disease (MRD) monitoring. This method increases the sensitivity of detection up to 1 in 100,000 cells in the remission marrow, which is significantly better than the traditional criteria of morphologic remission, i.e. fewer than 5 leukemic cells out of 100 cells. We have successfully demonstrated that patients who have detectable MRD by NGS have a 5 times higher risk of relapse after HCT. My research work was the first report showing that NGS-based MRD monitoring can identify patients at high risk for relapse after HCT. Currently, I am working on the future implementation of this platform into our clinical practice for patients who have received allogeneic HCT. In addition to this work, we have reported other genomic studies to dissect the clonal hierarchy and dynamics of clones during AML therapy (Leukemia 2016, Ref #5) or during AML progression from myelodysplasia (Leukemia 2017, Ref #4).

Overall, the results of my 3 major research works have resulted in the publication of 73 papers since my last promotion in 2014 (30 papers as a senior or principal author), among which 8 papers were published in the journal of impact factor over 10. The total number of my peer-reviewed publications in my career is 433 including abstracts (H-index 37; 4,795 times cited). Also, I was invited to have 45 talks in international meetings (including 27 international talks done outside of my home country, Korea) and 55 talks in national/provincial/local meetings since my last promotion in 2014.

References.

1. Park JH, et al. HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. *Leukemia*. 2019. PMID: 30555164.
2. Kim T, et al. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. *Blood*. 2018 PMID: 30108064.
3. Kim T, et al. The clonal origins of leukemic progression of myelodysplasia. *Leukemia*. 2017 PMID: 28090092
4. Kim T, et al. Spectrum of Somatic Mutation Dynamics in Chronic Myeloid Leukemia Following Tyrosine Kinase Inhibitor Therapy. *Blood*. 2017. PMID: 27733357.
5. Kim T, et al. Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression. *Leukemia*. 2016. PMID: 26424407.

2014 Jul - 2020 Jan

Translational, Genomic and Cancer Researches.

I strive to be a leading researcher in the field of leukemia and hematopoietic stem cell transplant. My primary research goal is discovery of biomarker to identify high risk patients for relapse or transplant-related complications, enabling an individualized management of leukemia patients or allogeneic hematopoietic cell transplant (HCT) recipients based on precision medicine. In order to achieve this goal, I have applied next generation sequencing technology and pharmacogenomics with respect to prognostic stratification of leukemia/HCT patients. Over the years, in collaboration with international groups of scientists, I have published multiple papers published in the in top-tier journals (eg: *Journal of Clinical Oncology*, *Blood* and *Leukemia*) as a senior author. Also, I am currently leading a clinical trial of tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia patients with attempt to achieve operational cure from leukemia (total budget, 3.5 million dollars), in which 12 canadian centres are participating.

Translational, Genomic and Cancer Researches: I have been using next generation sequencing (NGS) technology as my research tool, investigating longitudinal pattern of somatic mutation profiles following a specific therapy in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS) as well as myeloproliferative neoplasms. Also, we have explored clonal hierarchy of leukemia relapse

using NGS. In collaboration with bioinformatic expert, Dr. Zhaolei Zhang (University of Toronto), we have established a pipeline for variant calling for somatic mutation profiles and of copy number change detection using whole exome sequencing data. Currently, we are developing a multi-omics algorithm incorporating somatic mutation profiles, RNA seq and methylation data in leukemias including AML, CML and MDS using targeted sequencing, whole exome sequencing, genome wide methylation array as well as RNA sequencing technology.

1. Kim TH, Yoshida K, Kim YK, et al. Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression. *Leukemia*. 2015 (Senior author)
2. Kim T, Tyndel MS, Joon Kim H, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy Running Title: Dynamic patterns of somatic mutations in CML. *Blood*. 2016;129(1):38–47. (Senior author)
3. T Kim, MS Tyndel, HJ Kim, J-S Ahn, SH Choi, HJ Park, Y-k Kim, D-H Yang, J-J Lee, S-H Jung, SY Kim YM, J-W Cheong, SK Sohn, JH Moon, M Choi, M Lee ZZ and DK. The clonal origins of leukemic progression of myelodysplasia. *Leukemia*. 2017. (Senior author)
4. Kim D, Lee S, et al. A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. *Blood*. 2012;6906–6911. (Principal author)
5. Yi JH, Huh J, Kim H, et al. Adverse Prognostic Impact of Abnormal Lesions Detected by Genome-Wide Single Nucleotide Polymorphism Array – Based Karyotyping Analysis in Acute Myeloid Leukemia With Normal Karyotype. *J Clin Oncol*. 2012;29(35) (Senior author)

I also have performed several pharmacogenetic projects to identify biomarkers predicting transplant outcomes out of 259 single nucleotide polymorphisms (SNPs) in 53 genes from 394 transplant pairs. Several papers focusing on biomarker discovery to predict transplant outcomes (i.e. survival and relapse) and for graft-versus-host disease (GVHD) have already been published.

1. Kim DD, Yun J, Won HH, et al. Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease. *Transplantation* 2012; 94(12):1250-7. (Principal author)
2. Kim D, Won H, Su S, et al. Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models. *Bone Marrow Transplant*. 2014;49(5):1–8. (Senior author)
3. Alam N, Xu W, Atenafu EG, et al. Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD Patient characteristics. *Bone Marrow Transplant*. 2015;50(5):734–742. (Principal author)

Clinical trial for cure of leukemia: Currently I am a lead of a multicenter clinical trial of tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia patients entitled Treatment-free Remission Accomplished with Dasatinib (TRAD; total budget, 3.5 million Canadian dollars), which 12 Canadian centres are participating in. This trial is the first Canadian trial evaluating safety and activity of TKI discontinuation in CML patients who achieved deeper response with intent to demonstrate that active cancer drug can be discontinued successfully without losing leukemia control. In parallel, I am responsible for the genomic and immunologic aspects of correlative investigations of large granular lymphocytes stimulated and expanded by Dasatinib, identifying the mechanism of action of dasatinib-induced LGL expansion and its druggable molecular target and identifying an immunologic biomarker predicting successful discontinuation of TKI. Correlative parts of the study will include 1) prognostic implication of natural killer lymphocyte subset and plasma cytokine levels at the time of TKI discontinuation, 2) deep T-cell RNA seq after dasatinib rechallenge, and 3) impact of somatic mutation profiles with respect to treatment free remission after TKI discontinuation.

2013 Jan - 2014 Jun

Translational, Genomic and Clinical Researches.

Personalizing treatment of leukemia and transplant patients has been my primary research goal and in view of my extensive experience in translational research using next generation sequencing technology and pharmacogenomics I elected to use these methods in my

research. I completed a project entitled "Novel mutation detection using whole exome sequencing analysis in tyrosine kinase inhibitor resistant Philadelphia chromosome positive leukemia patient not harboring tyrosine kinase domain mutation". Initially, 14 pairs of samples underwent whole exome sequencing analysis resulting in a final list of 30 genes for novel mutation validation including TP53, BRCA2, RET, SMAD3 and etc. I am in the process of validating these genes in an independent cohort of 100 patients using MiSeq sequencer. Also, copy number changes were analyzed using ExomeCNV which provided a consistent result with genome wide SNP array based detection methods. By undertaking this project in collaboration with Dr. Zhaolei Zhang (University of Toronto), I was able to establish a bioinformatic algorithm and a pipeline for novel mutation detection in malignant samples (esp in haematological malignancy) and of copy number change detection using whole exome sequencing data.

Futhermore, I was involved in the whole exome sequencing project in acute myeloid leukemia with normal karyotype (AML-NK). This project was entitled "Translational Research for Personalized Medicine in Acute Myeloid Leukemia" was sponsored by the Korean government (Korean Next Generation Genomic Project, P.I: Dr. Hyeoung Joon Kim, Jul 2011-Mar 2013; budget 1.1M CAD). It included 120 pairs of AML-NK samples for whole exome sequencing and another set of 470 samples for validation. I was involved in the study design, data analysis and interpretation of the data as well as in an advisory capacity for technical decisions on genomic experiments through a regular lab meeting (teleconferenced every week). In this project, in addition to the well-known 28 mutations including NPM1, CEBPA, DNMT3A, IDH1/2, NRAS, TET2, CSF3R and SF3B1, 13 novel mutations with different frequencies were identified including SMC1A, FAT1 and DNAH11. The manuscript for publication is currently in preparation by Dr. Hyeoung Joon Kim and myself. I am also working on analyzing copy number changes using exome sequencing data in collaboration with Dr. Zhaolei Zhang, University of Toronto. We are investigating the correlation between copy number changes and mutations in AML-NK.

I have performed several pharmacogenetic projects to identify biomarkers predicting transplant outcomes out of 259 single nucleotide polymorphisms (SNPs) in 53 genes from 394 transplant pairs. Two papers focusing on biomarker discovery to predict transplant outcomes (i.e. survival and relapse) and for graft-versus-host disease (GVHD) have already been accepted or published. I also have three new substudies underway, to identify biomarkers predicting other post-transplant complications including invasive fungal infection, CMV viremia and avascular necrosis which are critical complications leading to morbidity and mortality in this population.

My success in the above translational and genomic projects has provided me with a strong foundation for my research in the future using these methods. In order to secure funding for this research, I am planning to apply for the Leukemia and Lymphoma Society Canada grant in 2014 with the topic of "Dissection of genomic changes in refractory or relapsed acute myeloid leukemia" in collaboration with Dr. Mark Minden and Dr. Zhaolei Zhang. We plan to investigate critical genomic changes and their correlation with resistant/refractory/relapsed leukemia clones using next generation sequencing technologies including exome sequencing and RNAseq, with a focus on mutations, copy number changes, gene rearrangement and splicing variant changes.

I believe I have also made significant progress in my clinical research, including the construction of clinical databases and using these to do retrospective studies and generate prospective clinical trials.

I have developed a clinical database of allogeneic transplant patients (esp. for GVHD and post-transplant complications) and chronic myeloid leukemia patients (esp. for treatment outcomes after tyrosine kinase inhibitor therapy). These are updated annually and this data is being used as a source of multiple retrospective studies. As a result I have completed several retrospective studies with 9 abstracts presented at the American Society of Hematology meeting 2013 and 5 manuscripts submitted for publication. I have another 11

retrospective studies underway with the involvement of hematology residents and fellows. I have been involved in numerous clinical trials as a principal investigator (PI), site PI or co-investigator. These include 9 clinical trials as co-investigator, 3 trials as site PI and a single trial as a PI. I am the principal investigator (PI) for the recently launched trial – A Phase I/II, multi-centre trial of Ruxolitinib therapy in combination with Nilotinib in patients with Philadelphia positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia who have failed tyrosine kinase inhibitor (TKI) therapy. This combination has never been tested in CML patients with TKI failure. This study evaluates a combinational regime of two targeted molecule inhibitors with expected hematologic toxicity. The primary endpoint is to define RP2D (recommended phase 2 dose) in phase I. I am also involved in the development of a pivotal Canadian clinical trial of TKI discontinuation (PIs: Brian Leber at Juravinski Cancer Centre and Jeffrey H. Lipton at Princess Margaret Cancer Centre) as co-principal investigator and as chair of the correlative part of this trial entitled Treatment-free Remission Accomplished with Dasatinib (TRAD; estimated budget, 3.5 M CAD). The study concept was approved by the company and we are currently in discussion regarding the total budget for final approval. In this study, I will be responsible for the genomic and immunologic aspects of correlative investigations of large granular lymphocytes stimulated and expanded by Dasatinib, to try to identify the mechanism of action of dasatinib-induced LGL expansion and its druggable molecular target and to identify an immunologic biomarker to predict good candidates for TKI discontinuation.

In the field of BMT I am the site PI for three important studies including 1) Multi-center, single arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for non-remission Acute Myeloblastic Leukemia using Clofarabine and Busulfan x 4 (CloBu4) regimen; 2) A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in CMV-Seropositive Recipients Undergoing Allogeneic Hematopoietic Cell Transplant; and 3) A Phase II, randomized, comparative trial of standard of care, with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD mutated acute myeloid leukemia. Also, In order to improve post-transplant outcomes in BMT patients, I am working on the development of clinical trials using novel pharmaceutical agents such as Ofatumumab or BTK inhibitors. Unfortunately, a study proposal for the use of Ofatumumab was rejected by the company in Jan 2013, due to their strategic priority of clinical trial development using this compound. I am also involved in the development of a pilot clinical trial using mesenchymal stromal cell therapy for steroid refractory GVHD patients, entitled “Injection of Mesenchymal Stromal Cells and Biomarker discovery in predicting response in patients with steroid refractory acute Graft-Versus-Host Disease” (PI: Maarten Egeler, The Hospital for Sick Children). The protocol is gradually being updated and is currently ready for submission for a CIHR grant application 2014. I will be responsible for clinical application of mesenchymal stromal cell therapy for steroid refractory GVHD patients at Princess Margaret Cancer Centre.

2008 Jan - 2012 Dec

Research statement.

Since my promotion to Assistant Professor in Korea (2008-2011) and my appointment at the University of Toronto (2011-present), my research has focused on the development of biomarker derived risk models predicting treatment outcomes in leukemia and after allogeneic hematopoietic stem cell transplantation (HSCT). I have concentrated on genetic and genomic technology to develop prognostic models that extend beyond the use of current approaches based on clinical information alone. My research interests focus on:

- a) Genomic risk models using biomarkers discovered with genome wide SNP array and next generation sequencing in order to identify patients with leukemia at high risk of treatment failure and death
- b) Genetic risk models utilizing single nucleotide polymorphisms (SNPs) to define patients at high risk for transplant related complications and death
- c) Clinical risk model development to improve the power of prognostic stratification that incorporates both genomic and clinical risk factors
- d) Development of prospective clinical trials to improve treatment outcomes in high risk patients identified by biomarker based risk models

Since 2008, I have used two different technologies in my genomic research: a genome wide single nucleotide polymorphism (SNP) array-based approach and next generation sequencing. A SNP is a genetic variant of nucleotide substitute in the human genome, thus affecting the gene expression and protein function of certain genes. These genetic changes can influence treatment outcomes in leukemia and HSCT. Genome wide SNP array is an established technology used to detect millions of these genetic variants simultaneously at an economical cost, thus potentially enabling the innovative introduction of genomic information into the personalized management of leukemia and HSCT.

Genomic Risk Models in Leukemia:

I have undertaken seven genetic/genomic research projects including 5 projects utilizing genome wide SNP array in diverse subtypes of leukemia including acute myeloid leukemia (AML) with normal karyotype, core-binding factor AML, chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS). Prognostic models based on these SNPs have identified patients at high risk of treatment failure, thus potentially enabling us to test the value of intensifying initial anti-leukemia treatment.

Genome wide SNP arrays have the advantage of detecting copy number changes in the leukemia genome, including gene gain or loss and loss-of-heterozygosity. I demonstrated, for example, that these changes are noted frequently in normal karyotype AML and are associated with a high rate of treatment failure and low survival (Yi, JCO 2011, impact factor 18.372). This finding has been confirmed by others. Also, I reported that copy number changes are associated with a poor prognosis in other diverse subtypes of leukemia, including core-binding factor AML (Huh, Ann Hematol 2012), myelodysplastic syndrome (Yi, Ann Hematol, in press), and chronic myeloid leukemia (CML; Huh, Ann Hematol 2011). My research using genome-wide SNP arrays successfully demonstrated that significant copy number changes in the leukemia genome are of prognostic significance, and thus may serve as clinically relevant biomarkers in diverse subtypes of leukemia. My future research is now investigating methods to improve copy number variant detection in leukemia utilizing exome sequencing data.

Genetic variants (SNPs) and copy number changes are also prognostic in acute and chronic leukemias. First, my genetic study in CML identified three genotypes: ABCG2, SLC22A1 and CYP3A5, which predict response to imatinib therapy (Kim, Clin Cancer Res. 2009, Impact factor 7.742). Based on the results of this study, I conducted a genotype-directed pilot study in CML to define an appropriate dose of imatinib according to the pharmacogenetic profile of each individual. This is the first clinical trial in hematologic malignancy to utilize pharmacogenetic biomarker in defining the dose of imatinib for each CML patient. Further studies are required to determine the utility of this approach. I have also investigated the following genetic variants and revealed their prognostic relevance in leukemia treatment: 1) ERCC1 genotype in CML (Kong, Int J Hematol, 2012), 2) IFNG genotype in CML (Kim, Clin Cancer Res, 2010), 3) VEGFA/VEGFR2 in CML (Kim, Ann Oncol, 2010), and 4) VEGF in AML (Kim, Br J Haematol, 2008). These findings are currently undergoing validation.

In terms of leukemia risk prediction, I conducted a genome wide association study in 2,744 subjects (1,936 Korean and 808 Canadian subjects) showing that genetic variants of 6q25.1 and 17p11.1 are predisposing factors to the development of CML (Kim, Blood 2011, impact factor 10.555). Based on these results, I acquired the patent for the method as well as a kit predicting CML risk (Patent No. 10-2011-0041690, Korea). It was successfully validated in an independent cohort. This study was an extension of my previous genetic investigation revealing the predictive role of BCL2 gene polymorphism on susceptibility to CML (Kim, Blood 2009, impact factor 10.555).

Since my recent appointment at the University of Toronto in 2011, I embarked on genomic research using next generation sequencing technology. The ultimate goal is to understand

the genetic and molecular mechanisms of CML resistant to standard therapy, and to discover novel molecular pathways, which can enable salvage with targeted therapy. Preliminary results suggest that a change in the TP53 gene is associated with treatment failure in CML after targeted therapy and opens up the possibility of more rational and personalized targeted salvage therapy

In addition, I am collaborating with and am an advisor to the Korean group of National Next Generation Project in AML with normal karyotype. The goal of this project is to analyze 120 genomic pairs (comparing the leukemia genome to the germline genome) using the exome sequencing technique. A preliminary analysis has been completed and revealed 22 mutations which are currently being validated. This approach will provide a full list of critical novel mutations, thus enabling us to adopt the personalized selection of targeted drugs to patients according to their mutation profile. Furthermore, I am currently working on the detection of copy number changes utilizing exome sequencing data obtained from resistant AML with normal karyotype.

Genetic Risk Models for Allogeneic Blood and Marrow Transplantation:

Genetic studies based on SNP information also have utility in predicting post HSCT complications and long-term outcomes. One of the most common complications following HSCT is graft-versus-host disease (GVHD) which contributes approximately 90% of deaths in patients developing severe steroid refractory GVHD. Unfortunately, no biomarkers have been successfully validated in predicting severe GVHD risk and death. Prior to 2008, I conducted several SNP studies in HSCT to identify a potential predictive biomarker for GVHD risk, and reported significant associations between the IL-10 genotype and chronic GVHD, between the CCR5 genotype and chronic GVHD and between MDR1 and post HSCT survival. More recently, I proposed a predictive model for GVHD risk using multiple candidate SNPs with biologic relevance. Potential candidate SNP markers of 53 genes were genotyped in 788 samples including 394 HSCT recipients and 394 donors (Kim, Transplantation 2012). The study highlighted the significant role of multiple cytokine genes in GVHD pathogenesis, and also clearly demonstrated the enhanced prognostic power of a combination of genetic and clinical data compared to genetic or clinical data alone. Further detailed research is currently underway to analyze more specific HSCT related complications, including organ specific GVHD, steroid refractory GVHD, viral induced hemorrhagic cystitis, cytomegalovirus infection and invasive fungal infection. My future goal is to develop a pilot clinical trial to tailor different transplant strategies according to their genotype based risk profiles.

Clinical Risk Models in Leukemia & Transplantation:

Clinical factors are also critical in determining the risk of treatment failure or long-term outcomes in leukemia and HSCT. I have investigated clinical risk factors for negative outcomes in leukemia and HSCT, one example is my report of the development of "large granular lymphocytosis (LGL lymphocytosis)" following dasatinib therapy in CML (Kim, Haematologica, 2009, Impact factor 6.424). This study demonstrated that the development of LGL lymphocytosis following dasatinib therapy was associated with significantly higher responses and better survival than those without it. This is the first study suggesting that a novel targeted agent can enhance anti-leukemia or anti-cancer killing activity by augmenting anti-tumor immunity. This finding has been repeatedly confirmed by other investigators. I demonstrated that these lymphocytes are predominantly NK cells or T-lymphocytes, and that NK cytotoxicity was enhanced in subjects with LGL lymphocytosis. Currently, I am designing a clinical trial with Dr. Jeff Lipton (PMH) and will undertake a correlative study to evaluate LGL lymphocytosis and immune function in patients taking dasatinib for molecular relapse after discontinuing imatinib.

Development of Clinical Trials in Leukemia & Transplantation:

In order to improve treatment outcomes in leukemia patients who are especially resistant to standard targeted therapy, I am conducting a phase 2 trial using a combination approach to novel molecular targeted agents including a JAK2 inhibitor (ruxolitinib) and a 2nd generation

BCR/ABL tyrosine kinase inhibitor (nilotinib). In addition, I am developing several clinical trials for transplant recipients using novel pharmaceutical agents to improve transplant outcomes and reduce treatment failure of steroid refractory GVHD.

2. TEACHING PHILOSOPHY

My teaching philosophy is to cultivate an excellent clinician-researcher who equipped strong clinical and research skills and research-oriented mindset. As a clinician investigator, I am highly involved in research supervision of multiple level trainees including 13 clinical fellows in BMT/leukemia programs, 4 research fellows, 2 medical/hematology residents, 1 PhD and 1 master course students over last 5 years. As shown in the TES score cards, my TES was in the range of 4.48-4.67 with highly positive feedback and comments. My trainees whom I met during their training were highly encouraged for the development of their research activity and improvement of their clinical and research skills. It is evidenced by the 5 trainees who won the ASH achievement awards and by testimonials provided by the trainees.

As a teacher, I aim to help trainees learn more effectively by challenging them with clinical and research problems and equipping them with critical thinking and technical skills that can be applied to their clinical practice and research endeavours. It is fundamental for an effective teacher to be a good professional role model for trainees. I value the opportunity to supervise hematology residents and clinical fellows in clinics and during research project. I am respectful of their time and learning needs. I highlight the importance of how to effectively organize their time and resources to manage a busy clinical practice, while also being attentive to patient needs and comprehensive in the provision of critical care. My philosophy of clinical teaching is to allow trainees the freedom to gather their own data independently and formulate independent management plans for their patients. I use individual patient cases to highlight key evidence-based teaching points and ask questions that stimulate further independent inquiry, particularly in the management of post-transplant related complications, graft-versus-host disease and of chronic myeloid leukemia,

My approach to research supervision is similar. I believe that it is very important for trainees to develop their own ideas and I try to appeal to their spirit of inquiry. I ask them to take appropriate responsibility for their research, but I also make myself available to provide support and guidance. Many of our fellows in the Allogeneic Blood and Marrow Transplant Program and Leukemia Program at the Princess Margaret Cancer Centre are foreign-trained and sometimes are not familiar with our structure of research. However, they are generally extremely hard working and motivated to contribute as researchers, but lacking in technical skills to pursue research mainly because of their inexperience. I do believe the best way for them to grow as researchers is to pursue their own research projects. I help assign a research project, enhance their research skills and motivate them for clinical research by supervising them and dedicating my time during the project from study design, through to data collection and analysis, and towards writing a manuscript. I meet with them individually on a regular basis to provide feedback and support. I emphasize their own use of databases and statistical software, thus enabling them to pursue other research projects independently even after leaving the PMH.

During didactic teaching, it is also very important to be enthusiastic about the material that is being taught in order to engage the audience. When lecturing to trainees and colleagues, I develop a slide set that is tailored to the learning needs of the audience. I always try to create clear and concise powerpoint slides that are visually appealing to the audience. I frequently use a case before presenting a key message so that audience can participate in the questions and maintain their interest and attention during long lectures.

As an educator in the faculty of medicine for past three years, I have grown to value my role as an educator and endeavor to improve my skills in this area by attending workshops on innovative teaching skills so I can connect to and engage more trainees, regardless of their interests and levels of motivation.

3. CREATIVE PROFESSIONAL ACTIVITIES STATEMENT

Creative professional activity

My research activities are being translated into clinical practice and international research collaboration. There are two aspects: 1) treatment-free remission (TFR) in the management of the CML patients, and 2) precision medicine in CML for future practice and research collaboration.

With respect to the TFR, our result of Canadian TKI discontinuation trial is leading the change in the CML practice in Canada as well as internationally: This is the first and the only Canadian collaborative clinical trial in CML, with 12 Canadian centers. Based on the result of this study, a lot of community hematologists are adopting this concept of practice into their practice during the CML patient management with good support from Canadian data. Also, I am a founding member of the international CML Foundation (iCMLf) Treatment-Free Remission Alliance including 14 international CML centers (Canada, Australia, USA, UK, Italy, France, Germany, Finland, Japan, Korea, Brazil and Argentina). This consortium was established with support from the International CML Foundation.

Also for the genomic-based biomarker development and its implementation in CML practice, the result from my research proposes that the practice should incorporate the somatic mutation profiling for TKI drug selection and switch. As there was an urgent need for international collaboration in genomic research in CML, I am playing a leadership role in organization of a research consortium and am one of the key founding members of the International CML Genomic Alliance. This alliance was established in 2018 and consisted of 14 CML treating centers from 10 countries over the world (Canada, Australia, USA, UK, Italy, France, Germany, Finland, Korea and Argentina). Our goal is the realization of a precision medicine-based approach to CML practice in the near future, and facilitation of international collaboration in CML genomic research with the support of the International CML Foundation (iCMLf). This collaborative effort resulted in the first publication of a review article summarizing the results of researches in the leukemic genome in CML for which I contributed as one of the co-first authors (Leukemia 2019).

D. Research Funding

1. GRANTS, CONTRACTS AND CLINICAL TRIALS

PEER-REVIEWED GRANTS

FUNDED

2021 Jan - 2021 Dec	Principal Applicant. Establishment of infrastructure to deliver precision medicine platform to newly diagnosed chronic myeloid leukemia patients across the Greater Toronto Area & Ontario: Toronto CML Genomic Alliance in Greater Toronto Area & Ontario. Pfizer Inc. (USA). Pfizer Inc. (USA). PI: Kim Dennis . 150,000 USD. [Grants]
2020 Nov - 2022 Nov	Principal Investigator. Clonal stromapoesis and BM microenvironment in leukemias and HCT. Canadian Cancer Society (CC). Innovations Grant. 706831. 100,000 CAD. [Grants] <i>2-year grant.</i>
2020 Nov - 2022 Nov	Principal Applicant. Clonal stromapoesis and BM microenvironment in leukemias and HCT. Canadian Cancer Society (CCS). Innovation grant. PI: Dennis Kim . 200,000 CAD. [Grants]
2017 Jul - 2018 Jun	Principal Applicant. Impact of clonal hematopoiesis in donors on allogeneic hematopoietic stem cell transplantation outcomes. Leukemia & Lymphoma Society of Canada (The) (LLSC). New Idea Award. PI: Dennis Kim . 75,000 CAD. [Grants]
2010 May - 2011 Feb	Principal Investigator. Genome wide association study to identify genetic markers involved in the pathogenesis of chronic myeloid leukemia, (2010-0010208). Korean Research Foundation. 50,700 CAD. [Grants]
2010 May - 2011 Feb	Principal Investigator. Genome wide SNP array-based approach to enhance the prognosis-prediction of adult patients with acute myeloid leukemia with normal karyotype and to improve their treatment outcomes using pharmacogenomics, (A070001). Korea National Enterprises for Clinical Trials. NCT01066338. 90,900 CAD. [Grants]

- 2009 Sep - 2011 Feb **Principal Investigator.** Genome wide SNP array-based approach to detect micro-cytogenetic lesions and KIT mutation to improve treatment outcomes in patients with core-binding factor positive acute myeloid leukemia, (2009-0088130 & 2010-0028016). Korean Research Foundation. NCT01066286. 96,800 CAD. [Grants]
- 2009 Jun - 2011 Feb **Principal Investigator.** Genome wide SNP array-based karyotyping to enhance the prediction of prognosis in adult acute myeloid leukemia patients with normal karyotype, (A100821). Korean government Ministry for Health, Welfare and Family Affairs. NCT01066338. 50,000 CAD. [Grants]
- 2009 May - 2011 Feb **Principal Investigator.** Genome wide SNP array-based approach to predict the response of decitabine hypomethylating agent in myelodysplastic syndrome patients and to improve their treatment outcomes using pharmacogenomics. Korean government Ministry for Health, Welfare and Family Affairs. A090618. 105,000 CAD. [Grants]
- 2009 May - 2011 Feb **Principal Investigator.** Multiple candidate pathway single nucleotide polymorphisms associated with chemotherapy response, toxicity, recurrence and survival following treatment for adult acute lymphoblastic leukemia, (2009-0066966 & 2010-0015528). Korean Research Foundation. NCT01079507. 94,700 CAD. [Grants]
- 2009 Jan - 2010 Dec **Principal Investigator.** Construction of Predictive model of treatment outcomes in acute myeloid leukemia based on pharmacogenetics and DNA repair pathway polymorphisms. Samsung Biomedical Research Institute. C-A9-206-1. NCT01106144. 36,800 CAD. [Grants]
- 2008 Nov - 2010 Oct **Principal Investigator.** Prospective phase II clinical trial of myeloablative conditioning regimen with fludarabine and busulfan plus 400 cGy total body irradiation for hematologic malignancies. Samsung Medical Center. Clinical Research Development Program CRS109-13-1. NCT00815568. Collaborator(s): Jung, Chulwon. 20,000 CAD. [Clinical Trials]
- 2008 Jul - 2009 Mar **Principal Investigator.** Genotype-directed pilot study to define the dose of imatinib mesylate to achieve comparable treatment outcomes in patients with chronic myeloid leukemia. Korean National Enterprise for Clinical Trials. A070001. 75,400 CAD. [Clinical Trials]

NON-PEER-REVIEWED GRANTS

FUNDED

- 2022 Feb - present **Co-Investigator.** Data Science Innovation and Regenerative Medicine. Canada First Research Excellence Fund. Medicine by Design and Data Science Institute. [Grants] *University of Toronto (U of T) strategic research initiatives Medicine by Design and the Data Sciences Institute (DSI) have co-awarded Catalyst Grants to two research projects that hold promise in furthering both data science innovation and regenerative medicine.*
- 2022 Jan - present **Principal Investigator.** A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease: Jan 2022 – under REB review. [Clinical Trials]
- 2021 Dec - present **Principal Investigator.** A Phase III, Multi-Center, Open-Label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase. Novartis Pharmaceuticals Corporation. Novartis Pharmaceuticals Corporation. [Clinical Trials] *Protocol #: CABL001J12301.*

- 2021 Nov - present **Principal Investigator.** A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors: Nov 2021– under REB review. Novartis Pharmaceuticals Canada Inc. [Clinical Trials]
- 2017 Aug - present **Principal Investigator.** A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors. Novartis Pharmaceuticals Corporation. Novartis Pharmaceuticals Corporation. 200,000 CAD. [Clinical Trials]
- 2013 Jul - present **Site Investigator.** Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years. Bristol-myers squibb. 18,079 CAD. [Clinical Trials]
- 2012 Nov - present **Co-Investigator.** A phase II, single arm, open label study of treatment-free remission after achieving sustained MR4.5 on nilotinib. Novartis Canada. 100,000 CAD. [Clinical Trials]
- 2011 Nov - present **Principal Investigator.** Novel mutation detection using whole exome sequencing analysis in imatinib resistant chronic myeloid leukemia patient not harboring tyrosine kinase domain mutation. Internal fund from Startup grant (PMH). 30,000 CAD. [Clinical Trials]
- 2021 Mar **Principal Investigator.** A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination with Azacitidine After Allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML). [Clinical Trials]
- 2021 Mar **Principal Investigator.** A Phase 1B/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects with Newly Diagnosed Acute Graft Versus Host Disease. [Clinical Trials]
- 2017 Apr - 2020 Dec **Principal Investigator.** A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic transplantation (REACH 3). Novartis Pharma AG (Switzerland). 200,000 CAD. [Clinical Trials]
- 2017 Apr - 2020 Dec **Co-Investigator.** A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination with Corticosteroids versus Placebo in Combination with Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD). Pharmacyclics. 200,000 CAD. [Clinical Trials]
- 2015 Aug - 2019 Aug **Principal Investigator.** Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD (CARE). Canadian National Transplant Research Program (CNT). Canadian National Transplant Research Program. 25,000 CAD. [Clinical Trials]
- 2014 Nov - 2022 Dec **Principal Investigator.** Treatment-free Remission Accomplished with Dasatinib in patients with chronic myeloid leukemia. Bristol-Myers Squibb. 3,688,755 CAD. [Clinical Trials]
- 2014 Nov - 2019 Dec **Co-Investigator.** A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (AV001). Avillion Development 1 Limited. PI: Jeffrey H Lipton. 100,000 CAD. [Clinical Trials]
- 2014 Jun - 2017 Dec **Co-Investigator.** A Phase 1B Dose Escalation Study to Investigate the Safety,

Tolerability and Preliminary Efficacy for the Combination of Dasatinib (BMS-354825) plus Nivolumab (BMS-936558) in Patients with Chronic Myeloid Leukemia (CML) (CA180373). Bristol-myers squibb. PI: Jeffrey H. Lipton. [Clinical Trials]

- 2013 Dec - 2017 Dec **Principal Site Investigator.** A Phase II, randomized, comparative trial of standard of care, with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD mutated acute myeloid leukemia. Novartis Global. 86,000 CAD. [Clinical Trials]
- 2013 Nov - 2017 Dec **Principal Site Investigator.** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety and Efficacy of Two CMX001 Dose Regimens for the Prevention of CMV Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients. Chimerix, Inc. 60,000 CAD. [Clinical Trials]
This is a randomized, double-blind, placebo-controlled, parallel group, multicenter study of two CMX001 dosing regimens in CMV-seropositive subjects who have undergone allogeneic HSCT. The study will comprise a screening evaluation, a treatment phase of 9 to 13 weeks duration (through Week 14 posttransplant), depending on when study treatment is initiated relative to the date of transplant, followed by a 10-week posttreatment follow-up phase (from Weeks 15 to 24 posttransplant),.
- 2013 Nov - 2017 Dec **Principal Site Investigator.** A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT). Astellas Pharma Global Development, Inc. (APGD). 267,000 CAD. [Clinical Trials]
- 2013 Mar - 2015 Feb **Principal Site Investigator.** Multi-center, single arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for non-remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) regimen. University of Michigan. PI: Mineishi Shin. 43,850 CAD. [Clinical Trials]
- 2012 Dec - 2013 Nov **Principal Investigator.** Phase I/II trial of Ruxolitinib therapy in combination with Nilotinib in patients with Philadelphia positive chronic myeloid leukemia or acute lymphoblastic leukemia who have failed tyrosine kinase inhibitor therapy. Novartis Pharma Canada Inc. (Investigator initiated trial). Collaborator(s): Lipton, Jeffrey. 198,300 CAD. [Clinical Trials]
- 2012 Aug - 2013 Nov **Co-Investigator.** A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. ARIAD pharmaceutical Inc. 648,071 CAD. [Clinical Trials]
- 2011 Aug - 2017 Dec **Co-Investigator.** A single-arm dose-finding phase Ib multicenter study of the oral smoothed antagonist LDE225 in combination with nilotinib in chronic phase chronic myeloid leukemia patients who have failed prior therapy with other BCR-ABL tyrosine-kinase inhibitors (Protocol CAMN107Y2102). Novartis Pharma Canada Inc. PI: Jeffrey H Lipton. 49,274 CAD. [Clinical Trials]
- 2011 Jun - 2015 Dec **Co-Investigator.** Extending molecular responses with nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtend) (Protocol CAMN107E2401). Novartis Pharma Canada Inc. PI: Jeffrey H. Lipton. Collaborator(s): \$9,795.5 per case funded and 23 patients were enrolled. 225,296.5 CAD. [Clinical Trials]
- 2011 Jan - 2017 Dec **Co-Investigator.** Dasatinib (BMS-354825) combined with SMO inhibitor (BMS-833923; XL139) in CML with resistance or suboptimal response to a prior TKI (Protocol CA180323). Bristol-myers squibb. 74,760 CAD. [Clinical Trials]

- 2010 Nov - 2011 Sep **Co-Investigator.** A Pivotal Phase II Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ acute lymphoblastic leukemia. ARIAD Pharmaceuticals Inc. [Clinical Trials]
- 2010 Oct - 2018 Jan **Principal Investigator.** Genome wide high density single nucleotide polymorphism (SNP) array to predict the response and the resistance to tyrosine kinase inhibitors (TKIs) treatment for chronic myeloid leukemia. Internal fund. Collaborator(s): Lipton, Jeffrey. 15,000 CAD. [Grants]
- 2010 Aug - 2011 Feb **Co-Investigator.** A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy. GSK Korea. [Clinical Trials]
- 2010 Jul - 2015 Dec **Co-Investigator.** A Randomized Trial of Thymoglobulin® to Prevent Chronic Graft versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation from Unrelated Donors (CBMTG 0801). Canadian Blood and Marrow Transplantation Group. PI: John Kuruvilla. 236,000 CAD. [Clinical Trials]
- 2010 Jun - 2011 Feb **Co-Investigator.** An Open Label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia. Antisoma. [Clinical Trials]
- 2010 Feb - 2011 Feb **Principal Investigator.** Evaluation of antifungal prophylaxis against invasive fungal infections during corticosteroid containing therapy for graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Janssen Korea. 50,000 CAD. [Clinical Trials]
- 2010 Jan - 2014 Feb **Co-Investigator.** Mobilization of leukemic cells using Plerixafor as part of a myeloablative preparative regimen for patients with AML undergoing allografting: Assessment of feasibility and efficacy. Genzyme. PI: Hans A Messner. 36,000 CAD. [Clinical Trials]
- 2009 Dec - 2011 Feb **Co-Investigator.** Randomized trial of prophylaxis with intravenous micafungin during allogeneic hematopoietic stem cell transplantation (Phase 2 study). Investigator initiated study. [Clinical Trials]
- 2009 Sep - 2011 Feb **Principal Investigator.** Clinical relevance of DNA methyltransferase (DNMT) and Histone Deacetylase (HDAC) gene single nucleotide polymorphism on the response to decitabine therapy for myelodysplastic syndrome. Janssen Korea. 36,000 CAD. [Industrial Grants]
- 2009 Mar - 2011 Feb **Co-Investigator.** An open-label, single arm, multi-center clinical trial of Exjade® for the treatment of transfusion-related iron overload in the patients with acute leukemia who achieved complete remission after chemotherapy (Phase 4 study). Investigator initiated study. [Clinical Trials]
- 2009 Feb - 2020 Dec **Site Investigator.** An open label, Randomized study of Nilotonib vs. Imatinib (400mg/600mg) Comparing kinetics of Complete Molecular Response for CML -CP Patients with Evidence of Persistent Leukemia by RQ-PCR. Novartis Pharma Canada Inc. Collaborator(s): \$7,020 per case and 16 patients were enrolled. 112,320 CAD. [Clinical Trials]
- 2008 Dec - 2009 Sep **Co-Investigator.** Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine compared to Daunorubicin in Combination with Cytarabine in subjects with Secondary Acute Myeloid Leukemia(sAML): ACCED study. Antisoma. [Clinical

Trials]

- 2008 Dec - 2009 Sep **Co-Investigator.** A longitudinal 2-year bone marrow study of eltrombopag olamine (SB-497115-GR) in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) (Phase 2 study). GSK. [Clinical Trials]
- 2008 Aug - 2008 Dec **Site principal investigator (for multicenter study).** Study for defervescence and response rate in immunocompromised patients treated with Sporanox IV as an empiric antifungal therapy (Phase IV study). Janssen Korea. 10,000 CAD. [Clinical Trials]
- 2008 May - 2008 Oct **Site principal investigator (for multicenter study).** Efficacy and safety of micafungin in empirical therapy for transplant or malignant disease patients with febrile neutropenia (Phase 2 study). Astellas Korea. 20,000 CAD. [Clinical Trials]
- 2008 Jan - 2011 Feb **Co-Investigator.** Transfusion-related iron-overloaded patients with acute leukemia, myelodysplastic syndrome (MDS), or aplastic anemia (AA) who will receive allogeneic transplantation and response to deferasirox therapy (Phase 2 study). Investigator initiated study. [Clinical Trials]
- 2008 Jan - 2011 Feb **Co-Investigator.** Alemtuzumab (Anti-CD52 Monoclonal Antibody) for Steroid Refractory Idiopathic Thrombocytopenic Purpura (Pilot study). Investigator initiated study. [Clinical Trials]
- 2008 Jan - 2011 Feb **Co-Investigator.** A Phase IV Study for Nilotinib in patients with Imatinib-resistant or intolerant Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in chronic or accelerated phase. Novartis. [Clinical Trials]
- 2008 Jan - 2009 Dec **Site principal investigator (for multicenter trial).** GLIVEC (IMATINIB) PLUS MULTI-AGENT CHEMOTHERAPY FOR NEWLY-DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (Phase 2 study). Investigator initiated study. 10,000 CAD. [Clinical Trials]
- 2008 Jan - 2008 Oct **Co-Investigator.** Open-labelled, Multicenter Phase II Study of Rituximab in Patients with Steroid-refractory chronic graft-versus-host disease (Phase 2 study). Roche Korea. [Clinical Trials]
- 2005 Jun - 2010 Jun **Site principal investigator (for multicenter study).** A PHASE II STUDY OF EARLY ESCALATED DOSE OF DAUNORUBICIN FOR PHILADELPHIA CHROMOSOME NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA. Investigator initiated study. 10,000 CAD. [Clinical Trials]

E. Publications

1. MOST SIGNIFICANT PUBLICATIONS

1. Park JH, Woo YM, Youm EM, Hamad N, Won HH, Naka K, Park EJ, Park JH, Kim HJ, Kim SH, Kim HJ, Ahn JS, Sohn SK, Moon JH, Jung CW, Park S, Lipton JH, Kimura S, Kim JW, **Kim DDH**. HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. *Leukemia*. 2019 Jun 1;33(6):1439-1450. PMID: 30555164. Impact Factor 9.944. **Senior Responsible Author**.

There is no biomarker known to predict the deep molecular response (DMR) following tyrosine kinase inhibitor (TKI) therapy in CML patients, although its development is strongly demanding in the context that DMR is a prerequisite for treatment-free remission attempt with TKI discontinuation. Also, there is no germline biomarker available to predict the response to CML therapy. This study discovered that the HMGCLL1 variant is highly predictive for DMR following TKI therapy in CML patients and demonstrated its biological relevance based on functional study of HMGCLL1 blockade. It highlights that the HMGCLL1 gene polymorphism is a novel genetic biomarker for intrinsic sensitivity to imatinib therapy in CML that predicts DMR in this setting.

2. Kim T, Moon JH, Ahn JS, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Choi SH, Lee JY, Tyndel MS, Shin MG, Lee YJ, Sohn SK, Park SK, Zhang Z, Kim HJ, **Kim DDH**. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. *Blood*. 2018 Oct 11;132(15):1604-1613. PMID: 30108064. Impact Factor 16.562 (Trainee publication, Taehyung Kim). **Senior Responsible Author**.

Next-generation sequencing (NGS) has been applied to define clinically relevant somatic mutations and classify subtypes in acute myeloid leukemia (AML). Persistent allelic burden after chemotherapy is associated with higher relapse incidence, but the presence of allelic burden in AML patients after receiving allogeneic hematopoietic cell transplantation (HCT) has not been examined longitudinally. Using a targeted gene panel, we performed NGS in 104 AML patients receiving HCT using samples collected at diagnosis, pre-HCT, and post-HCT on day 21 (post-HCTD21). Higher post-transplant variant allele frequency (VAF) at day 21 over 0.2% is associated with an increased risk of relapse (56.2% vs 16.0% at 3 years; $P < .001$) and worse overall survival (OS; 36.5% vs 67.0% at 3 years; $P = .006$). This is the first study demonstrating that NGS based MRD detection method is feasible for post-transplant monitoring in AML patients after allogeneic HCT.

3. Kim T, Tyndel MS, Kim HJ, Ahn JS, Choi SH, Park HJ, Kim YK, Yang DH, Lee JJ, Jung SH, Kim SY, Min YH, Cheong JW, Sohn SK, Moon JH, Choi M, Lee M, Zhang Z, **Kim DDH**. The clonal origins of leukemic progression of myelodysplasia. *Leukemia*. 2017 Sep 1;31(9):1928-1935. PMID: 28090092. Impact Factor 10.023 (Trainee publication). **Senior Responsible Author**.

The genetics behind the progression of myelodysplasia to secondary acute myeloid leukemia (sAML) is poorly understood. In this study, we profiled somatic mutations and their dynamics using next generation sequencing on serial samples from a total of 124 patients, consisting of a 31 patient discovery cohort and 93 patients from two validation cohorts. Whole-exome analysis on the discovery cohort revealed that 29 of 31 patients carry mutations related to at least one of eight commonly mutated pathways in AML. Mutations in genes related to DNA methylation and splicing machinery were found in T-cell samples, which expand at the initial diagnosis of the myelodysplasia, suggesting their importance as early disease events. On the other hand, somatic variants associated with signaling pathways arise or their allelic burdens expand significantly during progression. Our results indicate a strong association between mutations in activated signaling pathways and sAML progression. Overall, we demonstrate that distinct categories of genetic lesions play roles at different stages of sAML in a generally fixed order.

- Kim T, Tyndel MS, Kim HJ, Ahn JS, Choi SH, Park HJ, Kim YK, Kim SY, Lipton JH, Zhang Z, **Kim DD**. Spectrum of Somatic Mutation Dynamics in Chronic Myeloid Leukemia Following Tyrosine Kinase Inhibitor Therapy. *Blood*. 2017 Jan 5;129(1):38-47. PMID: 27733357. Impact Factor 15.132 (Trainee publication, Taehyung Kim). **Senior Responsible Author**.

This study represents dynamics of somatic mutation profiles in CML patients treated with tyrosine kinase inhibitor therapy for the first time. We performed targeted deep sequencing on a total of 300 serial samples from 100 CML patients. This study demonstrates that patterns of mutation acquisition, persistence, and clearance vary but have a number of interesting correlations with clinical outcomes. Mutation burden often persisted despite successful TKI response (Pattern 1), providing indirect evidence that these mutations also originated from preleukemic mutations, while patients exhibiting mutation clearance (Pattern 3) showed mixed clinical outcomes. Unsurprisingly, patients acquiring new mutations during treatment failed TKI therapy (Pattern 2). These patterns show that CML mutation dynamics following TKI therapy are markedly distinct from other myeloid neoplasms.

- Kim T, Yoshida K, Kim YK, Tyndel MS, Park HJ, Choi SH, Ahn JS, Jung SH, Yang DH, Lee JJ, Kim HJ, Kong G, Ogawa S, Zhang Z, Kim HJ, **Kim DD**. Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression. *Leukemia*. 2016 Feb 1;30(2):295-302. PMID: 26424407. Impact Factor 11.702. **Senior Responsible Author**.

This study represents a 9-year, whole-exome sequencing study of a single case at 12 time points, from the initial diagnosis until a fourth relapse, including 6 remission samples in between. We used these time series data to track the hierarchy and order of variant acquisition, and subsequently analyzed the evolution of somatic variants to infer clonal structure. From this, we postulate the development and extinction of subclones, as well as their anticorrelated expansion via varying drug responses. In particular, we show that new subclones started appearing after the first complete remission. The presence and absence of different subclones during remission and relapses implies differing drug responses among subclones. Our study shows that time series analysis contrasting remission and relapse periods provides a much more comprehensive view of clonal structure and evolution.

2. PEER-REVIEWED PUBLICATIONS

Journal Articles

- Krishnan V, **Kim DDH**, Hughes TP, Branford S, Ong ST. Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. *Haematologica*. 2022 Feb 1;107(2):358-370. **Coauthor or Collaborator**.
- Gurnari C, Pagliuca S, Guan Y, Adema V, Hershberger CE, Ni Y, Awada H, Kongkiatkamon S, Zawit M, Coutinho DF, Zalcberg IR, Ahn JS, Kim HJ, **Kim DDH**, Minden MD, Jansen JH, Meggendorfer M, Haferlach C, Jha BK, Haferlach T, Maciejewski JP, Visconte V. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. *Blood Adv*. 2022 Jan 11;6(1):100-107. **Coauthor or Collaborator**.
- Novitzky-Basso I, Remberger M, Chen C, Pasić I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, **Kim DD**, Kumar R, Mattsson J, Michelis FV. Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. *Eur J Haematol*. 2022 Jan 1;108(1):61-72. **Coauthor or Collaborator**.
- Nee A, Lipton JH, **Kim DDH**. Early prediction of stable MR4.5 by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib. *Leuk Lymphoma*. 2022 Jan 1;63(1):162-169. **Senior Responsible Author**.
- Biezuner T; Brilon Y; Arie A; Kadam A; Oron B; Danin A; Saar-Furer N; Minden M; **Kim DH**; Shapira S; Arber N; Dick J; Thavendiranathan P; Moskovitz Y; Kaushansky N; Chapal-Ilani, N; Shlush, L. An Improved Molecular Inversion Probe Based Targeted Sequencing Approach For Low Variant Allele Frequency. *NAR Genomics and Bioinformatics*. 2021 Dec 9. **Coauthor or Collaborator**.

6. Salas MQ, Atenafu EG, Law AD, Lam W, Pasic I, Chen C, **Kim DDH**, Michelis FV, Gerbitz A, Lipton JH, Mattsson J, Kumar R, Viswabandya A. Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. *Leuk Lymphoma*. 2021 Dec 1;62(14):3373-3383. **Coauthor or Collaborator**.
7. Pasic I, Alanazi W, Dranitsaris G, Lieberman L, Viswabandya A, **Kim DDH**, Lipton JH, Michelis FV. Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use. *Hematol Oncol Stem Cell Ther*. 2021 Dec 1;14(4):302-310. **Coauthor or Collaborator**.
8. Linn SM, Vasudevan Nampoothiri R, Chen C, Pasic I, Al-Shaibani Z, Lam W, Law AD, Michelis FV, **Kim DDH**, Gerbitz A, Lipton J, Kumar R, Mattsson J, Viswabandya A. Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. *Hematol Oncol Stem Cell Ther*. 2021 Nov 24. **Coauthor or Collaborator**.
9. Jang HJ, Woo YM, Naka K, Park JH, Han HJ, Kim HJ, Kim SH, Ahn JS, Kim T, Kimura S, Zarabi S, Lipton JH, Minden MD, Jung CW, Kim HJ, Kim JW, **Kim DDH**. Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors. *Cancers (Basel)*. 2021 Nov 4;13(21). **Coauthor or Collaborator**.
10. Cyriac S, Prem S, Salas MQ, Chen S, Al-Shaibani Z, Lam W, Law A, Gupta V, Michelis FV, **Kim DDH**, Lipton J, Kumar R, Mattsson J, Viswabandya A. Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. *Eur J Haematol*. 2021 Nov 1;107(5):517-528. Article in European Journal of Haematology is now posted in the CDTRP, U of T Hematology and CTTC communities on Sosido. **Coauthor or Collaborator**.
11. Nampoothiri RV, Ho L, McEwan C, Pasic I, Lam W, Law AD, Michelis FV, Thyagu S, **Kim DDH**, Gerbitz A, Viswabandya A, Lipton JH, Mattsson J, Kumar R. Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2021 Oct 1;56(10):2471-2476. **Coauthor or Collaborator**.
12. Hyeok-Jae Jang, Young Min Woo, Kazuhito Naka, Jong-Ho Park, Ho-Jae Han, Hee-Jin Kim, Sun-Hee Kim, Jae Sook Ahn, Taehyung Kim, Shinya Kimura, Sarah Zarabi, Jeffrey H. Lipton, Mark D. Minden, Chul Won Jung, Hyeoung-Joon Kim, Jong-Won Kim *, **Dennis Dong Hwan Kim***. Statins Synergistically Potentiate the Eradication of Leukemic Stem Cells and Enhance the Molecular Response in Chronic Myeloid Leukemia When Combined with Tyrosine Kinase Inhibitors. *Cancers*. 2021 Sep 9. In Press. **Senior Responsible Author**.
13. Novitzky-Basso I, Chen C, Chen S, Lipton JH, **Kim DD**, Viswabandya A, Kumar R, Lam W, Law A, Al-Shaibani Z, Gerbitz A, Pasic I, Mattsson J, Michelis FV. Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. *Eur J Haematol*. 2021 Sep 1;107(3):354-363. **Coauthor or Collaborator**.
14. Daher-Reyes G, Kim T, Novitzky-Basso I, Kim KH, Smith A, Stockley T, Capochichi JM, Al-Shaibani Z, Pasic I, Law A, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Schimmer A, McNamara C, Murphy T, Maze D, Gupta V, Sibai H, Chan S, Yee K, Minden M, Zhang Z, Schuh A, **Kim DDH**. Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. *Bone Marrow Transplant*. 2021 Aug 1;56(8):1908-1918. **Senior Responsible Author**.
15. Smith E, Huang J, Viswabandya A, Maze D, Malik S, Cheung V, Siddiq N, Claudio J, Arruda A, Kennedy J, Bankar A, Law AD, Lam W, Michelis FV, **Kim D**, Lipton J, Kumar R, Mattsson J, McNamara C, Sibai H, Xu W, Gupta V. Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. *Transplant Cell Ther*. 2021 Jul 1;27(7):600.e1-600.e8. **Coauthor or Collaborator**.
16. Al-Shaibani E, Cyriac S, Chen S, Lipton JH, **Kim DD**, Viswabandya A, Kumar R, Lam W, Law A, Al-Shaibani Z, Gerbitz A, Pasic I, Mattsson J, Michelis FV. Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia. *Clin Lymphoma Myeloma Leuk*. 2021 Jun 1;21(6):e559-e568. **Coauthor or Collaborator**.
17. Vasudevan Nampoothiri R, Chen S, Pasic I, Al-Shaibani Z, Lam W, Michelis FV, **Kim DDH**, Viswabandya A, Gerbitz A, Lipton JH, Kumar R, Mattsson J, Law AD. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation. *Hematol Oncol Stem Cell Ther*. 2021 Jun 1;14(2):134-140. **Coauthor or Collaborator**.

18. Lee H, Basso IN, **Kim DDH**. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. *Int J Hematol*. 2021 May 1;113(5):632-641. **Senior Responsible Author**.
19. **Kim DDH**, Novitzky-Basso I, Kim TS, Atenafu EG, Forrest D, Savoie L, Bence-Bruckler I, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneville P, Lipton JH, Kamel-Reid S, Leber B. Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. *Br J Haematol*. 2021 May 1;193(4):779-791. **Principal Author**.
20. Ahn JS, Kim T, Jung SH, Ahn SY, Jung SY, Song GY, Kim M, Yang DH, Lee JJ, Choi S, Lee JY, Park SK, Moon JH, Lee HY, Kim KH, Cai Y, Yi SY, Novitzky-Basso I, Zhang Z, Kim HJ, **Kim DDH**. Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing. *Bone Marrow Transplant*. 2021 May 1;56(5):1159-1170. **Senior Responsible Author**.
21. Law AD, Bhella S, Pasic I, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Kumar R, Lipton JH, Mattsson J, **Kim DDH**. Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. *Ann Hematol*. 2021 May 1;100(5):1311-1319. **Senior Responsible Author**.
22. Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A, Rowley SD, **Kim DDH**, Hernandez D, Rajkhowa T, Haines K, Bonifacio G, Rine P, Purkayastha D, Fernandez HF. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. *Bone Marrow Transplant*. 2021 May 1;56(5):1180-1189. **Coauthor or Collaborator**.
23. Salas MQ, Atenafu EG, Law AD, Lam W, Pasic I, Chen C, Dong Hwan Kim D, Michelis FV, Gerbitz A, Lipton JH, Mattsson J, Kumar R, Viswabandya A. Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. *Transplant Cell Ther*. 2021 May 1;27(5):428.e1-428.e9. **Coauthor or Collaborator**.
24. Novitzky-Basso I, AlHayli S, Shin E, Pasic I, Al-Shaibani Z, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton JH, Kumar R, Mattsson J, **Kim DDH**. Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. *Eur J Haematol*. 2021 Apr 1;106(4):508-519. **Senior Responsible Author**.
25. Vasudevan Nampoothiri R, Law AD, Lam W, Chen C, Al-Shaibani Z, Loach D, Michelis FV, **Kim DDH**, Mattsson J, Kumar R, Lipton JH, Viswabandya A. Predictors of outcomes of therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. *Hematol Oncol Stem Cell Ther*. 2021 Mar 19. **Coauthor or Collaborator**.
26. Prem S, Remberger M, Salas MQ, Al-Shaibani Z, Lam W, Law AD, **Kim DDH**, Michelis FV, Lipton JH, Mattsson J, Kumar R, Ellison C, Viswabandya A. Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. *Bone Marrow Transplant*. 2021 Mar 1;56(3):689-691. **Coauthor or Collaborator**.
27. Fingrut W, Law A, Lam W, Michelis FV, Viswabandya A, Lipton JH, Kumar R, Mattsson J, **Kim DDH**. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level. *Ann Hematol*. 2021 Mar 1;100(3):789-798. **Senior Responsible Author**.
28. Alotaibi AS, Prem S, Chen S, Lipton JH, **Kim DD**, Viswabandya A, Kumar R, Lam W, Law AD, Mattsson J, Michelis FV. Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option. *Am J Hematol*. 2021 Feb 1;96(2):179-187. **Coauthor or Collaborator**.
29. Salas MQ, Ezzat S, Lam W, Law AD, Pasic I, Michelis FV, **Kim DDH**, Gerbitz A, Al-Shaibani Z, Viswabandya A, Kumar R, Mattsson J, Lipton JH. Prolactin, a potential biomarker for chronic GVHD activity. *Eur J Haematol*. 2021 Feb 1;106(2):158-164. **Coauthor or Collaborator**.
30. Salas MQ, Atenafu EG, Bascom O, Wilson L, Lam W, Law AD, Pasic I, **Kim DDH**, Michelis FV, Al-Shaibani Z, Gerbitz A, Viswabandya A, Lipton JH, Mattsson J, Alibhai SMH, Kumar R. Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2021 Jan 1;56(1):60-69. **Coauthor or Collaborator**.

31. Alblooshi R, Kanfar S, Lord B, Atenafu EG, Michelis FV, Pasic I, Gerbitz A, Al-Shaibani Z, Viswabandya A, **Kim DDH**, Lam W, Law A, Mattsson J, Kumar R, Lipton JH. Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. *Eur J Haematol*. 2021 Jan 1;106(1):32-39. **Coauthor or Collaborator**.
32. Salas MQ, Prem S, Remberger M, Lam W, **Kim DDH**, Michelis FV, Al-Shaibani Z, Gerbitz A, Lipton JH, Viswabandya A, Kumar R, Kumar D, Mattsson J, Law AD. High incidence but low mortality of EBV-reactivation and PTLN after alloHCT using ATG and PTCy for GVHD prophylaxis. *Leuk Lymphoma*. 2020 Dec 1;61(13):3198-3208. Article in Leukemia & Lymphoma is now posted in the CDTRP, U of T Hematology and CTTC communities on Sosido. **Coauthor or Collaborator**.
33. Kim T, Moon JH, Ahn JS, Ahn SY, Jung SH, Yang DH, Lee JJ, Shin MG, Choi SH, Lee JY, Tyndel MS, Lee HY, Kim KH, Cai Y, Lee YJ, Sohn SK, Min YH, Cheong JW, Kim HJ, Zhang Z, **Kim DDH**. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. *Sci Rep*. 2020 Nov 18;10(1):20119. **Senior Responsible Author**.
34. Salas MQ, Prem S, Atenafu EG, Datt Law A, Lam W, Al-Shaibani Z, Loach D, **Kim DDH**, Michelis FV, Lipton JH, Kumar R, Mattsson J, Viswabandya A. Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. *Bone Marrow Transplant*. 2020 Sep 1;55(9):1773-1783. PMID: 32024990. **Coauthor or Collaborator**.
35. Salas MQ, Chen S, Lam W, Pasic I, Gerbitz A, Michelis FV, **Kim DDH**, Al-Shaibani Z, Lipton JH, Mattsson J, Kumar R, Viswabandya A, Law AD. Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. *Biol Blood Marrow Transplant*. 2020 Aug 1;26(8):1511-1519. **Coauthor or Collaborator**.
36. Vasudevan Nampoothiri R, Law AD, Lam W, Chen C, Al-Shaibani Z, Loach D, Michelis FV, **Kim DDH**, Mattsson J, Kumar R, Lipton JH, Viswabandya A. Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. *Eur J Haematol*. 2020 Jul 1;105(1):24-29. **Coauthor or Collaborator**.
37. Pasic I, Lipton JH, **Kim DD**, Viswabandya A, Kumar R, Lam W, Law AD, Mattsson J, Michelis FV. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. *Ann Hematol*. 2020 Jun 1;99(6):1377-1387. **Coauthor or Collaborator**.
38. Alanazi W, Chen S, Lipton JH, **Kim DD**, Viswabandya A, Kumar R, Lam W, Law AD, Al-Shaibani Z, Mattsson J, Michelis FV. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Acta Haematol*. 2020 May 19:1-8. **Coauthor or Collaborator**.
39. Alblooshi RM, Deotare U, Michelis FV, Thyagu S, **Kim DDH**, Lipton JH, ElGohary GM, Viswabandya A. My jamais vu in post allogeneic hematopoietic cell transplant: a review on secondary hemophagocytosis in adults. *Bone Marrow Transplant*. 2020 May 1;55(5):867-872. PMID: 31611631. Impact Factor 4.674. **Coauthor or Collaborator**.
40. Mayo SJ, Messner HA, Rourke SB, Howell D, Victor JC, Lipton JH, Kuruvilla J, Gutpa V, **Kim DDH**, Michelis FV, Metcalfe K. Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2020 May 1;55(5):918-928. PMID: 31745248. Impact Factor 4.674. **Coauthor or Collaborator**.
41. Bacopoulos AJ, Ho L, Yang A, Ng P, Dara C, Loach D, Deotare U, Michelis FV, Viswabandya A, **Kim DD**, Lipton JH, Messner HA, Thyagu S. Safety of two-hour intermittent intravenous infusions of tacrolimus in the allogeneic hematopoietic stem cell transplantation unit. *J Oncol Pharm Pract*. 2020 Mar 17:1078155220908948. PMID: 32183586. **Coauthor or Collaborator**.
42. **Kim DDH**. Are we ready to use precision medicine in chronic myeloid leukemia practice? *Haematologica*. 2019 Dec 1;104(12):2327-2329. PMID: 31787613. Impact Factor 7.57. **Senior Responsible Author**.
43. Salas MQ, Lam W, Law AD, **Kim DDH**, Michelis FV, Loach D, Al-Shaibani Z, Lipton JH, Kumar R, Mattsson J, Viswabandya A. Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis. *Eur J Haematol*. 2019 Dec 1;103(6):597-606. PMID: 31514253. Impact Factor 2.217. **Coauthor or Collaborator**.

44. Salas MQ, Prem S, Atenafu EG, Law AD, Lam W, Al-Shaibani Z, Loach D, **Kim DDH**, Michelis FV, Lipton JH, Kumar R, Mattsson J, Viswabandya A. Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. *Eur J Haematol*. 2019 Nov 1;103(5):510-518. PMID: 31449699. Impact Factor 2.217. **Coauthor or Collaborator**.
45. Prem S, Atenafu EG, Avena J, Bautista R, Law A, Lam W, Michelis FV, **Kim DDH**, Viswabandya A, Lipton JH, Mattsson J, Kumar R. Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment. *Eur J Haematol*. 2019 Nov 1;103(5):483-490. PMID: 31418930. Impact Factor 2.217. **Coauthor or Collaborator**.
46. Prem S, Al-Shaibani Z, Michelis FV, **Kim D**, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Law A, Lam W. Epstein-Barr virus associated post-transplant lymphoproliferative disorder mimicking acute graft versus host disease. *Eur J Haematol*. 2019 Nov 1;103(5):519-522. PMID: 31389104. Impact Factor 2.217. **Coauthor or Collaborator**.
47. Salas MQ, Atenafu EG, Bautista MR, Prem S, Lam W, Datt Law A, Shaibani ZA, **Kim DDH**, Michelis FV, Lipton JH, Viswabandya A, Mattsson J, Kumar R. Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. *Eur J Haematol*. 2019 Sep 23;104(1):36-45. PMID: 31549435. Impact Factor 2.217. **Coauthor or Collaborator**.
48. Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, **Kim D**, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks DI, Nemecek E, Nishihori T, Saad A, Savani BN, Schriber J, Seo S, Socié G, Teshima T, Verdonck LF, Waller EK, Wirk M, Spellman SR, Arora M, Chhabra S. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2019 Sep 1;25(9):1744-1755. PMID: 31158502. Impact Factor 3.599. **Coauthor or Collaborator**.
49. Shapiro RM, Shin E, Law AD, Lam W, Michelis FV, Viswabandya A, Kumar R, Lipton JH, Messner H, Mattsson J, **Kim DDH**. Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2019 Sep 1;25(9):1761-1769. PMID: 31170520. Impact Factor 3.599. **Senior Responsible Author**.
50. Branford S, **Kim DDH**, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP, International CML Foundation Genomics Alliance. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. *Leukemia*. 2019 Aug 1;33(8):1835-1850. PMID: 31209280. Impact Factor 9.944. **Co-Principal Author**.
51. Ahn JS, Kim T, Kim YK, Cho YC, Cho S, Jung SH, Ahn SY, Jung SY, Yang DH, Lee JJ, Choi S, Lee JY, Shin MG, Yoshida K, Ogawa S, Kim IC, Zhang Z, Kim HJ, **Kim DDH**. Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone. *Exp Hematol*. 2019 Jul 1;75:26-30. PMID: 31199945. Impact Factor 2.462. **Senior Responsible Author**.
52. Prem S, Atenafu EG, Al-Shaibani Z, Loach D, Law A, Lam W, Michelis FV, Thyagu S, **Kim DDH**, Howard Lipton J, Kumar R, Viswabandya A. Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. *Eur J Haematol*. 2019 Jun 1;102(6):486-493. PMID: 30924973. Impact Factor 2.217. **Coauthor or Collaborator**.
53. Michelis FV, Hedley DW, Malhotra S, Chow S, Loach D, Gupta V, **Kim DD**, Kuruvilla J, Lipton JH, Viswabandya A, Messner HA. Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability. *Biol Blood Marrow Transplant*. 2019 Jun 1;25(6):1158-1163. PMID: 30654137. Impact Factor 3.599. **Coauthor or Collaborator**.
54. Park JH, Woo YM, Youm EM, Hamad N, Won HH, Naka K, Park EJ, Park JH, Kim HJ, Kim SH, Kim HJ, Ahn JS, Sohn SK, Moon JH, Jung CW, Park S, Lipton JH, Kimura S, Kim JW, **Kim DDH**. HMGCL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. *Leukemia*. 2019 Jun 1;33(6):1439-1450. PMID: 30555164. Impact Factor 9.944. **Senior Responsible Author**.

55. Pasic I, Da'na W, Lam W, Law A, Lipton JH, Viswabandya A, **Kim DD**, Thyagu S, Messner HA, Michelis FV. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML. *Eur J Haematol*. 2019 Apr 1;102(4):368-374. PMID: 30706524. Impact Factor 2.21. **Coauthor or Collaborator**.
56. Woo YM, Kim S, Park JH, Lee NY, Kim JW, **Kim DDH**. Evidence that 6q25.1 variant rs6931104 confers susceptibility to chronic myeloid leukemia through RMND1 regulation. *PLoS One*. 2019 Jan 1;14(6):e0218968. PMID: 31237926. Impact Factor 2.776. **Senior Responsible Author**.
57. Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, **Kim D**, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. *Biol Blood Marrow Transplant*. 2019 Jan 1;25(1):73-85. PMID: 30153491. Impact Factor 3.599. **Coauthor or Collaborator**.
58. Shapiro RM, **Kim DDH**. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. *Curr Opin Hematol*. 2018 Nov 1;25(6):425-432. PMID: 30281033. Impact Factor 2.864. **Senior Responsible Author**.
59. Law AD, Salas MQ, Lam W, Michelis FV, Thyagu S, **Kim DDH**, Lipton JH, Kumar R, Messner H, Viswabandya A. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. *Biol Blood Marrow Transplant*. 2018 Nov 1;24(11):2259-2264. PMID: 30009980. Impact Factor 3.599. **Coauthor or Collaborator**.
60. Kim T, Moon JH, Ahn JS, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Choi SH, Lee JY, Tyndel MS, Shin MG, Lee YJ, Sohn SK, Park SK, Zhang Z, Kim HJ, **Kim DDH**. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. *Blood*. 2018 Oct 11;132(15):1604-1613. PMID: 30108064. Impact Factor 16.562 (Trainee publication, Taehyung Kim). **Senior Responsible Author**.
61. Khalil MMI, Messner HA, Lipton JH, **Kim DD**, Viswabandya A, Thyagu S, Deotare U, Michelis FV. Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. *Ann Hematol*. 2018 Oct 1;97(10):1975-1985. PMID: 29947975. Impact Factor 2.85. **Coauthor or Collaborator**.
62. Savoie ML, Bence-Bruckler I, Huebsch LB, Lalancette M, Hillis C, Walker I, Lipton JH, Forrest DL, **Kim DDH**. Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era. *Leuk Res*. 2018 Oct 1;73:67-75. PMID: 30227318. Impact Factor 2.066. **Senior Responsible Author**.
63. Coomes EA, Wolfe Jacques A, Michelis FV, **Kim DDH**, Thyagu S, Viswabandya A, Lipton JH, Messner HA, Deotare U. Efficacy of Cidofovir in Treatment of BK Virus-Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients. *Biol Blood Marrow Transplant*. 2018 Sep 1;24(9):1901-1905. PMID: 29679772. Impact Factor 3.599. **Coauthor or Collaborator**.
64. So M, Mamdani MM, Morris AM, Lau TTY, Broady R, Deotare U, Grant J, **Kim D**, Schimmer AD, Schuh AC, Shajari S, Steinberg M, Bell CM, Husain S. Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled study. *Clin Microbiol Infect*. 2018 Aug 1;24(8):882-888. PMID: 29138099. Impact Factor 6.425. **Coauthor or Collaborator**.
65. Park S, Choi H, Kim HJ, Ahn JS, Kim HJ, Kim SH, Mun YC, Jung CW, **Kim DDH**. Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. *Ann Hematol*. 2018 Jun 1;97(6):955-965. PMID: 29500710. Impact Factor 2.615 (Trainee publication, 2.850). **Senior Responsible Author**.
66. Uhm J, Shin E, Michelis FV, Thyagu S, Viswabandya A, Lipton JH, Messner HA, **Kim DDH**. Therapeutic efficacy of azathioprine in addition to prednisone-based regimens as first-line chronic graft-versus-host disease treatment. *Bone Marrow Transplant*. 2018 Mar 1;53(3):334-338. PMID: 29247219. Impact Factor 4.497. **Senior Responsible Author**.

67. Aljaseem HA, Messner HA, Lipton JH, **Kim DDH**, Viswabandya A, Thyagu S, Deotare U, Michelis FV. Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience. *Eur J Haematol.* 2018 Mar 1;100(3):308-314. PMID: 29240253. Impact Factor 2.217. **Coauthor or Collaborator.**
68. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehler JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, **Kim DDH**, Weisdorf D, van der Velden W, Dörfel D. Be. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. *Nat Med.* 2018 Mar 1;24(3):282-291. PMID: 29431743. Impact Factor 30.641. **Coauthor or Collaborator.**
69. Khalil MMI, Lipton JH, Atenafu EG, Gupta V, **Kim DD**, Kuruvilla J, Viswabandya A, Messner HA, Michelis FV. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia. *Eur J Haematol.* 2018 Feb 1;100(2):198-205. PMID: 29168234. Impact Factor 2.217. **Coauthor or Collaborator.**
70. Beswick J, Shin E, Michelis FV, Thyagu S, Viswabandya A, Lipton JH, Messner H, Marras TK, **Kim DDH**. Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant.* 2018 Feb 1;24(2):366-372. PMID: 28986190. Impact Factor 3.599. **Coauthor or Collaborator.**
71. Ahn JS, Kim HJ, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Park HJ, Lee JY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Lee YJ, Won JH, Kim SH, Zhang Z, Kim T, **Kim DDH**. Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. *Oncotarget.* 2018 Jan 12;9(4):4961-4968. PMID: 29435155. **Senior Responsible Author.**
72. Deotare U, Atenafu EG, Loach D, Michelis FV, **Kim DD**, Thyagu S, Lipton JH, Messner HA, Viswabandya A. Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation. *Bone Marrow Transplant.* 2017 Dec 21;52(6):907-909. PMID: 29269806. Impact Factor 4.497. **Coauthor or Collaborator.**
73. Aghel N, Lipton JH, Atenafu EG, **Kim DDH**, Delgado DH. Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up. *Clin Lymphoma Myeloma Leuk.* 2017 Dec 1;17(12):870-878.e1. PMID: 28803825. Impact Factor 2.308. **Coauthor or Collaborator.**
74. Bourlon C, Lipton JH, Deotare U, Gupta V, **Kim DD**, Kuruvilla J, Viswabandya A, Thyagu S, Messner HA, Michelis FV. Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1. *Eur J Haematol.* 2017 Sep 1;99(3):234-239. PMID: 28556258. Impact Factor 2.595. **Coauthor or Collaborator.**
75. Kim T, Tyndel MS, Kim HJ, Ahn JS, Choi SH, Park HJ, Kim YK, Yang DH, Lee JJ, Jung SH, Kim SY, Min YH, Cheong JW, Sohn SK, Moon JH, Choi M, Lee M, Zhang Z, **Kim DDH**. The clonal origins of leukemic progression of myelodysplasia. *Leukemia.* 2017 Sep 1;31(9):1928-1935. PMID: 28090092. Impact Factor 10.023 (Trainee publication). **Senior Responsible Author.**
76. Poch Martell M, Hamad N, Shin E, Moon JH, Sohn SK, Uhm J, Michelis FV, Viswabandya A, Lipton JH, Messner HA, **Kim DDH**. Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data. *Eur J Haematol.* 2017 Aug 1;99(2):160-168. PMID: 28449187. Impact Factor 2.595. **Senior Responsible Author.**
77. Natori Y, Humar A, Lipton J, **Kim DD**, Ashton P, Hoschler K, Kumar D. A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients. *Bone Marrow Transplant.* 2017 Jul 1;52(7):1016-1021. PMID: 28263288. Impact Factor 4.497. **Coauthor or Collaborator.**

78. Hamilton BK, Rybicki L, Abounader D, Adekola K, Advani A, Aldoss I, Bachanova V, Bashey A, Brown S, DeLima M, Devine S, Flowers CR, Ganguly S, Jagasia M, Kennedy VE, **Kim DDH**, McGuirk J, Pullarkat V, Romee R, Sandhu K, Smith M, Ueda M, Viswabandya A, Vu K, Wall S, Zeichner SB, Perales MA, Majhail NS. Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. *Biol Blood Marrow Transplant.* 2017 Jul 1;23(7):1117-1121. PMID: 28396160. Impact Factor 4.484. **Coauthor or Collaborator.**
79. Kim T, Tyndel MS, Zhang Z, Ahn J, Choi S, Szardenings M, Lipton JH, Kim HJ, **Kim D.** Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. *Leukemia Res.* 2017 Jun 16;59:142-148. PMID: 28667884. Impact Factor 2.319. **Senior Responsible Author.**
80. Bourlon C, Alamoudi S, Kumar D, Viswabandya A, Thyagu S, Michelis FV, **Kim DD**, Lipton JH, Messner HA, Deotare U. A short tale of blood, kidney and brain: BK virus encephalitis in an allogeneic stem cell transplant recipient. *Bone Marrow Transplant.* 2017 Jun 1;52(6):907-909. PMID: 28218753. Impact Factor 4.497. **Coauthor or Collaborator.**
81. Moon JH, Hamad N, Sohn SK, Uhm J, Alam N, Gupta V, Lipton JH, Messner HA, Seftel M, Kuruvilla J, **Kim DD.** Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. *Ann Hematol.* 2017 May 1;96(5):805-815. PMID: 28214979. Impact Factor 2.845. **Senior Responsible Author.**
82. Michelis FV, Kotchetkov R, Grunwald RM, Azeem A, Atenafu EG, Lipton JH, Loach D, Gupta V, Kuruvilla J, **Kim DD**, Viswabandya A, Deotare U, Messner HA. Long term incidence of secondary malignancies following allogeneic hematopoietic cell transplantation: a single center experience. *Biol Blood Marrow Transplantation.* 2017 Feb 27;23(6):945-951. PMID: 28254442. Impact Factor 4.484. **Coauthor or Collaborator.**
83. Law AD, Dong Hwan Kim D, Lipton JH. Pregnancy: part of life in chronic myelogenous leukemia. *Leuk Lymphoma.* 2017 Feb 1;58(2):280-287. PMID: 27389567. Impact Factor 2.644. **Coauthor or Collaborator.**
84. Ahn JS, Kim HJ, Kim YK, Lee SS, Ahn SY, Jung SH, Yang DH, Lee JJ, Park HJ, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Michael S, Minden MD, **Kim DD.** 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. *Oncotarget.* 2017 Jan 31;8(5):8305-8314. PMID: 28039446. **Senior Responsible Author.**
85. Kim T, Tyndel MS, Kim HJ, Ahn JS, Choi SH, Park HJ, Kim YK, Kim SY, Lipton JH, Zhang Z, **Kim DD.** Spectrum of Somatic Mutation Dynamics in Chronic Myeloid Leukemia Following Tyrosine Kinase Inhibitor Therapy. *Blood.* 2017 Jan 5;129(1):38-47. PMID: 27733357. Impact Factor 15.132 (Trainee publication, Taehyung Kim). **Senior Responsible Author.**
86. Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, **Kim DD**, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2017 Jan 1;52(1):59-65. PMID: 27427921. Impact Factor 4.497. **Coauthor or Collaborator.**
87. Lam W, Al-Shaibani Z, Kumar D, Viswabandya A, Thyagu S, Michelis FV, **Kim DD**, Lipton JH, Messner HA, Deotare U. Progressive multifocal leukoencephalopathy due to John Cunningham (JC) virus following allogeneic haematopoietic cell transplantation. *Antivir Ther.* 2017 Jan 1;22(8):721-725. PMID: 28362268. Impact Factor 2.146. **Coauthor or Collaborator.**
88. Sibai H, Falcone U, Deotare U, Michelis FV, Uhm J, Gupta V, Kuruvilla J, Lipton JH, Seftel MD, Messner HA, **Kim DDH.** Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis. *Biol Blood Marrow Transplant.* 2016 Dec 1;22(12):2270-2275. PMID: 27596129. Impact Factor 4.704 (Trainee publication). **Senior Responsible Author.**
89. Yoichiro N, Humar A, Lipton J, **Kim D**, Hoschler K, Ashton P, Kumar D. A Pilot Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients. *Open Forum Infect Dis.* 2016 Oct 25;3(Suppl 1):1355. Impact Factor 0.14. **Coauthor or Collaborator.**

90. Lam W, Viswabandya A, Hussain S, Messner HA, Michelis FV, **Kim DD**, Lipton JH, Deotare U. A unique case of tuberculosis dissemination presenting as cutaneous lesions in a post allogeneic stem cell transplant patient. *Bone Marrow Transplant*. 2016 Oct 1;51(10):1385-1386. PMID: 27183093. Impact Factor 3.874. **Coauthor or Collaborator**.
91. Deotare U, **Kim DD**, Michelis FV, Lipton JH. Allogeneic Hematopoietic Stem Cell Transplants in Blastic Plasmacytoid Dendritic Cell Neoplasm in first complete remission: an effective therapy for a rare disease. *Leuk Lymphoma*. 2016 Aug 1;57(8):1942-4. PMID: 26699933. Impact Factor 2.755. **Coauthor or Collaborator**.
92. Mayo S, Messner HA, Rourke SB, Howell D, Victor JC, Kuruvilla J, Lipton JH, Gupta V, **Kim DD**, Piescic C, Breen D, Lambie A, Loach D, Michelis FV, Alam N, Uhm J, McGillis L, Metcalfe K. Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2016 Jun 1;51(6):841-7. PMID: 26926230. Impact Factor 3.874. **Coauthor or Collaborator**.
93. Deotare U, **Kim DD**, Lipton JH. Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase. *Drugs Aging*. 2016 May 1;33(5):335-45. PMID: 26961697. Impact Factor 2.769. **Coauthor or Collaborator**.
94. Zheng Q, Cao J, Hamad N, Kim HJ, Moon JH, Sohn SK, Jung CW, Lipton JH, **Kim DD**. Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. *J Transl Med*. 2016 Mar 24;14:82. PMID: 27009330. Impact Factor 3.786. **Senior Responsible Author**.
95. Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, **Kim DD**. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. *Ann Hematol*. 2016 Mar 1;95(4):625-35. PMID: 26692090. Impact Factor 3.083. **Senior Responsible Author**.
96. Kim T, Yoshida K, Kim YK, Tyndel MS, Park HJ, Choi SH, Ahn JS, Jung SH, Yang DH, Lee JJ, Kim HJ, Kong G, Ogawa S, Zhang Z, Kim HJ, **Kim DD**. Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression. *Leukemia*. 2016 Feb 1;30(2):295-302. PMID: 26424407. Impact Factor 11.702. **Senior Responsible Author**.
97. Ahn JS, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, **Kim DD**. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2016 Jan 1;22(1):61-70. PMID: 26234722. Impact Factor 4.704. **Senior Responsible Author**.
98. Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, **Kim DD**. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. *Ann Hematol*. 2016 Jan 1;95(2):301-10. PMID: 26537612. Impact Factor 3.083. **Senior Responsible Author**.
99. Michelis FV, Messner HA, Atenafu EG, McGillis L, Lambie A, Uhm J, Alam N, Seftel MD, Gupta V, Kuruvilla J, Lipton JH, **Kim DD**. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. *Bone Marrow Transplant*. 2015 Nov 1;50(11):1405-10. PMID: 26168067. Impact Factor 3.636 (Trainee publication, Fotios Michelis). **Senior Responsible Author**.
100. Alam N, Atenafu EG, Kuruvilla J, Uhm J, Lipton JH, Messner HA, **Kim DH**, Seftel M, Gupta V. Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation. *Bone Marrow Transplant*. 2015 Sep 1;50(9):1180-6. PMID: 26121109. Impact Factor 3.636 (Trainee publication, Naheed Alam). **Coauthor or Collaborator**.
101. Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Lee IK, Kim NY, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim N, Yoshida K, Ogawa S, **Kim DD**. Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. *Haematologica*. 2015 Sep 1;100(9):e351-3. PMID: 26045292. Impact Factor 6.671. **Senior Responsible Author**.

102. Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, **Kim DH**, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH, Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. *Blood*. 2015 Aug 6;126(6):746-56. PMID: 26065651. Impact Factor 11.847. **Coauthor or Collaborator**.
103. Michelis FV, Atenafu EG, Gupta V, **Kim DD**, Kuruvilla J, Lipton JH, Loach D, Seftel MD, Uhm J, Alam N, Lambie A, McGillis L, Messner HA. Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission. *Bone Marrow Transplant*. 2015 Jul 1;50(7):907-13. PMID: 25822226. Impact Factor 3.636 (Trainee publication). **Coauthor or Collaborator**.
104. Hamad N, Shanavas M, Michelis FV, Uhm J, Gupta V, Seftel M, Kuruvilla J, Lipton JH, Messner HA, **Kim DD**. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation. *Am J Hematol*. 2015 May 1;90(5):392-9. PMID: 25615933. Impact Factor 5 (Trainee publication, Nada Hamad). **Senior Responsible Author**.
105. Alam N, Xu W, Atenafu EG, Uhm J, Seftel M, Gupta V, Kuruvilla J, Lipton JH, Messner HA, **Kim DD**. Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD. *Bone Marrow Transplant*. 2015 May 1;50(5):734-42. PMID: 25774595. Impact Factor 3.636 (Trainee publication, Naheed Alam). **Senior Responsible Author**.
106. Uhm J, Hamad N, Shin EM, Michelis FV, Shanavas M, Gupta V, Kuruvilla J, Lipton JH, Messner HA, Seftel M, **Kim DD**. Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2014 Nov 1;20(11):1751-7. PMID: 25042736. Impact Factor 3.404 (Trainee publication, Jieun Uhm). **Senior Responsible Author**.
107. Hamad N, Del Bel R, Messner HA, **Kim D**, Kuruvilla J, Lipton JH, Uhm J, Seftel M, Alam N, Xu W, Gupta V. Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate-dose alemtuzumab-based conditioning. *Biol Blood Marrow Transplant*. 2014 Nov 1;20(11):1722-8. PMID: 25017761. Impact Factor 3.404. **Coauthor or Collaborator**.
108. Michelis FV, Messner HA, Loach D, Uhm J, Gupta V, Lipton JH, Seftel MD, Kuruvilla J, **Kim DD**. Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts. *Eur J Haematol*. 2014 Oct 1;93(4):273-80. PMID: 24725056. Impact Factor 2.066. **Senior Responsible Author**.
109. Zheng Q, Wu H, Yu Q, **Kim DH**, Lipton JH, Angelini S, Soverini S, Vivona D, Takahashi N, Cao J. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. *Pharmacogenomics J*. 2014 Sep 23;15(2):127-134. PMID: 25245580. Impact Factor 4.229. **Coauthor or Collaborator**.
110. Shanavas M, Messner HA, Atenafu EG, **Kim DH**, Kuruvilla J, Lipton JH, Uhm J, Seftel M, Alam N, Gupta V. Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. *Bone Marrow Transplant*. 2014 Sep 1;49(9):1162-9. PMID: 24978138. Impact Factor 3.57. **Coauthor or Collaborator**.
111. Uhm J, Hamad N, Michelis F, Shanavas M, Kuruvilla J, Gupta V, Lipton JH, Messner HA, Seftel MD, **Kim D**. The Risk of Polyomavirus BK-associated Haemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation Is Increased with Myeloablative Conditioning, Cytomegalovirus Viremia, and Severe Grade of Acute Graft-versus-Host Disease. *Bone Marrow Transplant*. 2014 Aug 11. PMID: 25111517. Impact Factor 3.57 (Trainee publication, Jieun Uhm). **Senior Responsible Author**.
112. **Kim DD**, Hamad N, Lee HG, Kamel-Reid S, Lipton JH. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. *Am J Hematol*. 2014 Jun 1;89(6):626-32. PMID: 24619861. Impact Factor 3.798. **Principal Author**.

113. Michelis FV, Messner HA, Atenafu EG, **Kim DD**, Kuruvilla J, Lipton JH, Uhm J, Loach D, Gupta V. Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant. *Biol Blood Marrow Transplant*. 2014 Apr 1;20(4):474-9. PMID: 24345422. Impact Factor 3.404. **Coauthor or Collaborator**.
114. Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, **Kim DD**, Uhm J, Lambie A, Ellis L, Lipton JH. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. *Clin Lymphoma Myeloma Leuk*. 2014 Feb 1;14(1):87-92. PMID: 24252361. Impact Factor 2.02. **Coauthor or Collaborator**.
115. Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, **Kim DH**. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. *Biol Blood Marrow Transplant*. 2014 Jan 18;20(4):556-63. PMID: 24447907. Impact Factor 3.404 (Trainee publication, Moon JH - visiting professional (Princess Margaret Hospital)). **Senior Responsible Author**.
116. Inamoto Y, **Kim DD**, Storer BE, Moon JH, Lipton JH, Kuruvilla J, Martin PJ, Flowers ME. Application of CIBMTR risk score to NIH chronic GVHD at individual centers. *Blood*. 2014 Jan 16;123(3):453-5. PMID: 24435000. Impact Factor 10.452. **Co-Principal Author**.
117. **Kim DH**, Hong HH, Su S, Cheng L, Xu W, Hamad N, Uhm J, Gupta V, Kuruvilla J, Messner HA, Lipton JH. Risk stratification of organ specific graft-versus-host disease can be improved by multiple single nucleotide polymorphisms based risk models. *Bone Marrow Transplant*. 2014 Jan 8;49(5):649-56. PMID: 2458362. Impact Factor 3.57. **Principal Author**.
118. Alam N, Atenafu EG, Tse G, Viswabandya A, Gupta V, **Kim D**, Lipton JH, Messner HA, Kuruvilla J. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease. *Clin Transplant*. 2013 Nov 1;27(6):930-7. PMID: 24304375. Impact Factor 1.486. **Coauthor or Collaborator**.
119. Choi H, Jung C, Sohn SK, Kim S, Kim HJ, Kim YK, Kim T, Zhang Z, Shin ES, Lee JE, Moon JH, Kim SH, Kim KH, Mun YC, Kim H, Park J, Kim J, **Kim D**. Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype. *Br J Haematol*. 2013 Oct 1;163(1):62-71. PMID: 24159609. Impact Factor 4.959. **Senior Responsible Author**.
120. **Kim D**, Al-Dawsari G, Chang H, Panzarella T, Gupta V, Kuruvilla J, Lipton JH, Messner HA. Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-SCT. *Bone Marrow Transplant*. 2013 Aug 1;48(8):1104-11. PMID: 23396405. Impact Factor 3.466. **Principal Author**.
121. Michelis FV, Atenafu EG, Gupta V, **Kim DD**, Kuruvilla J, Lambie A, Lipton JH, Loach D, Messner HA. Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR. *Bone Marrow Transplant*. 2013 May 20. PMID: 23686095. Impact Factor 3.466. **Coauthor or Collaborator**.
122. Yi JH, Huh J, Kim HJ, Kim SH, Kim SH, Kim KH, Do YR, Mun YC, Kim H, Kim MK, Kim HJ, Kim T, **Kim DD**. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment. *Ann Hematol*. 2013 Apr 1;92(4):459-69. PMID: 23262795. Impact Factor 2.396 (Trainee publication, Jun Ho Yi - fellow (Samsung Medical Center)). **Senior Responsible Author**.
123. **Kim DD**, Lee H, Kamel-Reid S, Lipton JH. BCR/ABL transcript level at 3 months can predict subsequent treatment outcomes following second generation tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients who failed Imatinib. *Br J Haematol*. 2013 Mar 24;160(5):630-639. PMID: 23278256. Impact Factor 4.959. **Principal Author**.
124. Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, **Kim DH**, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. *Ann Oncol*. 2013 Mar 1;24(3):756-60. PMID: 23117072. Impact Factor 6.578. **Coauthor or Collaborator**.

125. Park S, Lee SJ, Kim K, Jang JH, **Kim DH**, Lee KH, Lee JH, Lee JH, Kim DY, Jang DY, Kim H, Park JH, Ryoo HM, Bae SH, Kim MK, Hyun MS, Joo YD, Lee WS, Lee SM, Jung CW. Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL). *Int J Hematol*. 2013 Mar 1;97(3):388-96. PMID: 23397209. Impact Factor 1.679. **Coauthor or Collaborator**.
126. Kim J, Sohn I, Son DS, **Kim DH**, Ahn T, Jung SH. Prediction of a time-to-event trait using genome wide SNP data. *BMC Bioinformatics*. 2013 Feb 19;14:58. PMID: 23418752. Impact Factor 2.672. **Coauthor or Collaborator**.
127. Kim HJ, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO, Kim SH, Kim YK, Kim HJ, Sohn SK, Kim SH, Lee WS, Kim KH, Mun YC, Kim H, Park J, Min WS, Kim HJ, **Kim DH**, L/MDS working party, Korean Society of Hematology. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. *Ann Hematol*. 2013 Jan 1;92(2):163-71. PMID: 23053179. Impact Factor 2.396. **Senior Responsible Author**.
128. Huh J, Jung CW, Kim HJ, Kim YK, Moon JH, Sohn SK, Kim HJ, Min WS, **Kim DH**. Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category. *Genes Chromosomes Cancer*. 2013 Jan 1;52(1):44-55. PMID: 23023762. Impact Factor 3.836. **Senior Responsible Author**.
129. Kim J, Sohn I, **Kim DD**, Jung SH. SNP selection in genome-wide association studies via penalized support vector machine with MAX test. *Comput Math Methods Med*. 2013 Jan 1;2013:340678. PMID: 24174989. Impact Factor 0.766. **Coauthor or Collaborator**.
130. **Kim DD**, Yun J, Won HH, Cheng L, Su J, Xu W, Uhm J, Gupta V, Kuruvilla J, Messner HA, Lipton JH. Multiple Single-Nucleotide Polymorphism-Based Risk Model for Clinical Outcomes After Allogeneic Stem-Cell Transplantation, Especially for Acute Graft-Versus-Host Disease. *Transplantation*. 2012 Dec 27;94(12):1250-1257. PMID: 23169244. Impact Factor 3.073 (Trainee publication, Jina Yun - Co-first author, fellow (Samsung Medical Center)). **Principal Author**.
131. Alam N, Marras TK, Atenafu EG, Gupta V, Kuruvilla J, Lipton JH, Messner HA, **Kim DD**. Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation. *Biol Blood Marrow Transplant*. 2012 Dec 1;18(12):1905-10. PMID: 22835425. Impact Factor 3.94 (Trainee publication, Naheed Alam - fellow (Princess Margaret Hospital)). **Senior Responsible Author**.
132. Huh J, Kim HJ, Jung CW, Kim HJ, Kim SH, Kim YK, Kim HJ, Shin MG, Moon JH, Sohn SK, Kim SH, Lee WS, Won JH, Mun YC, Kim H, Park J, Min WS, **Kim DH**, AML/MDS working party, Korean Society of Hematology. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. *Am J Hematol*. 2012 Oct 1;87(10):961-8. PMID: 22886749. Impact Factor 4.003. **Senior Responsible Author**.
133. Wong KM, Atenafu EG, **Kim D**, Kuruvilla J, Lipton JH, Messner H, Gupta V. Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2012 Oct 1;18(10):1589-99. PMID: 22531490. Impact Factor 3.94. **Coauthor or Collaborator**.
134. Kong JH, Mun YC, Kim S, Choi HS, Kim YK, Kim HJ, Moon JH, Sohn SK, Kim SH, Jung CW, Dennis Kim DH. Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia. *Int J Hematol*. 2012 Sep 1;96(3):327-33. PMID: 22821389. Impact Factor 1.681 (Trainee publication, Kong, JH (fellow, Samsung Medical Center)). **Senior Responsible Author**.
135. Song I, Yi CA, Han J, **Kim DH**, Lee KS, Kim TS, Chung MJ. CT findings of late-onset noninfectious pulmonary complications in patients with pathologically proven graft-versus-host disease after allogeneic stem cell transplant. *AJR Am J Roentgenol*. 2012 Sep 1;199(3):581-7. PMID: 22915397. Impact Factor 2.897. **Coauthor or Collaborator**.
136. Moon JH, Sohn SK, Kim SN, Park SY, Yoon SS, Kim IH, Kim HJ, Kim YK, Min YH, Cheong JW, Kim JS, Jung CW, **Kim DH**. Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. *Med Oncol*. 2012 Jun 1;29(2):1179-85. PMID: 21472487. Impact Factor 2.147. **Senior Responsible Author**.

137. Kim S, **Kim DH**, Jang JH, Jung CW, Jang MA, Ki CS, Kim JW, Kim SH, Kim HJ. Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype. *Ann Lab Med.* 2012 Mar 1;32(2):153-7. PMID: 22389883. **Coauthor or Collaborator.**
138. Ahn HK, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW, **Kim DH**. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. *Am J Hematol.* 2012 Jan 1;87(1):37-41. PMID: 22120708. Impact Factor 4.003 (Trainee publication, HK Ahn - fellow (Samsung Medical Center)). **Senior Responsible Author.**
139. Yi JH, Huh J, Kim HJ, Kim SH, Kim HJ, Kim YK, Sohn SK, Moon JH, Kim SH, Kim KH, Won JH, Mun YC, Kim H, Park J, Jung CW, **Kim DH**. Adverse prognostic impact of abnormal lesions detected by genome-wide single-nucleotide polymorphism-array based karyotyping analysis in acute myeloid leukemia with normal karyotype. *J Clin Oncol.* 2011 Dec 10;29(35):4702-8. PMID: 22084373. Impact Factor 18.372 (Trainee publication, JH Yi - fellow (Samsung Medical Center)). **Senior Responsible Author.**
140. Kim JW, Kim BS, Bang SM, Kim I, **Kim DH**, Kim WS, Yang DH, Lee JJ, Lee JH, Kim JS, Sohn SK, Yhim HY, Kwak JY, Yoon SS, Lee JS, Park S, Kim BK, Korean Society of Blood and Marrow Transplantation. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. *Ann Hematol.* 2011 Dec 1;90(12):1409-18. PMID: 21468694. Impact Factor 2.615. **Coauthor or Collaborator.**
141. Park S, Kim K, **Kim DH**, Jang JH, Kim SJ, Kim WS, Jung CW, Koh KC. Changes of Hepatitis B Virus Serologic Status after Allogeneic Hematopoietic Stem Cell Transplantation and Impact of Donor Immunity on Hepatitis B Virus. *Biol Blood Marrow Transplant.* 2011 Nov 23;17(11):1630-7. PMID: 21565276. Impact Factor 3.873. **Coauthor or Collaborator.**
142. Huh J, Jung CW, Kim JW, Kim HJ, Kim SH, Shin MG, Kim YK, Kim HJ, Suh JS, Moon JH, Sohn SK, Nam GH, Lee JE, **Kim DH**. Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia. *Ann Hematol.* 2011 Nov 1;90(11):1255-64. PMID: 21384125. Impact Factor 2.615. **Senior Responsible Author.**
143. Lee SH, Cheuh H, Yoo KH, Kim YJ, Sung KW, Koo HH, **Kim DH**, Kim SJ, Kim K, Jang JH, Jung CW. Hematopoietic stem cell transplantation from a related donor infected with influenza H1N1 2009. *Transpl Infect Dis.* 2011 Oct 1;13(5):548-50. PMID: 21348910. Impact Factor 2.216. **Coauthor or Collaborator.**
144. **Kim DH**, Lee ST, Won HH, Kim S, Kim MJ, Kim HJ, Kim SH, Kim JW, Kim HJ, Kim YK, Sohn SK, Moon JH, Jung CW, Lipton JH. A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. *Blood.* 2011 Jun 23;117(25):6906-11. PMID: 21540461. Impact Factor 9.898. **Principal Author.**
145. Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, **Kim DH**, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. *Leuk Lymphoma.* 2011 Jun 1;52(6):1024-9. PMID: 21463107. Impact Factor 2.58. **Coauthor or Collaborator.**
146. Yun J, **Kim DH**, Kong JH, Kim HJ, Kim SH, Kim K, Jang JH, Jung CW. External validation of newly proposed cytogenetic risk classification in patients who have myelodysplastic syndrome: a retrospective analysis at a single institution. *Clin Lymphoma Myeloma Leuk.* 2011 Jun 1;11(3):273-9. PMID: 21658655. Impact Factor 1.88. **Coauthor or Collaborator.**
147. Lee SJ, Jung CW, Kim DY, Lee KH, Sohn SK, Kwak JY, Kim HJ, Kim IH, Park S, **Kim DH**. Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. *Am J Hematol.* 2011 Apr 1;86(4):346-50. PMID: 21442637. Impact Factor 4.671 (Trainee publication, SJ Lee - fellow (Samsung Medical Center)). **Senior Responsible Author.**

148. Won YW, Yi SY, Jang JH, Kim K, Kim SJ, Kim WS, Jung CW, **Kim DH**. Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation. *Int J Hematol*. 2011 Mar 1;93(3):383-388. PMID: 21360008. Impact Factor 1.268 (Trainee publication, YW Won - fellow (Samsung Medical Center)). **Senior Responsible Author**.
149. Kim H, Kim BS, **Kim DH**, Hyun MS, Kim SH, Bae SH, Choi JH, Sohn SK, Shin HJ, Won JH, Yoon SS, Jo DY, Joo YD, Park JH, Lee KH. Comparison between Matched Related and Alternative Donors of Allogeneic Hematopoietic Stem Cells Transplanted into Adult Patients with Acquired Aplastic Anemia: Multivariate and Propensity Score-Matched Analysis. *Biol Blood Marrow Transplant*. 2011 Jan 8;17(9):1289-98. PMID: 21220035. Impact Factor 3.873. **Coauthor or Collaborator**.
150. Hong JY, Choi MK, **Kim DH**, Kim SJ, Kim K, Kim WS, Chung CW, Kim HO, Min YH, Jang JH. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. *Transplant Proc*. 2010 Nov 1;42(9):3723-8. PMID: 21094846. Impact Factor 0.993. **Coauthor or Collaborator**.
151. **Kim DH**, Sriharsha L, Jung CW, Kamel-Reid S, Radich JP, Lipton JH. Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter? *Am J Hematol*. 2010 Nov 1;85(11):856-62. PMID: 20882527. Impact Factor 3.576. **Principal Author**.
152. **Kim DH**, Kong JH, Byeun JY, Jung CW, Xu W, Liu X, Kamel-Reid S, Kim YK, Kim HJ, Lipton JH. IFN- γ (interferon-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. *Clin Cancer Res*. 2010 Nov 1;16(21):5339-5350. PMID: 20959405. Impact Factor 7.338. **Principal Author**.
153. Kim ST, Lee MH, Kim SY, Kim SJ, **Kim DH**, Jang JH, Kim K, Kim WS, Jung CW. A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation. *Int J Hematol*. 2010 Jun 1;91(5):886-91. PMID: 20454943. Impact Factor 1.324. **Coauthor or Collaborator**.
154. **Kim DH**, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S, Lipton JH. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. *Ann Oncol*. 2010 Jun 1;21(6):1179-88. PMID: 19875757. Impact Factor 6.452. **Principal Author**.
155. Moon JH, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, **Kim DH**. BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. *Leuk Res*. 2010 Feb 1;34(2):166-72. PMID: 19520430. Impact Factor 2.555 (Trainee publication, JH Moon - Samsung Medical Center). **Senior Responsible Author**.
156. Park JS, **Kim DH**, Choi CW, Jeong SH, Choi JH, Kim K, Kim SJ, Jung CW, Yang DH, Jang JH. Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases. *Acta Haematol*. 2010 Jan 1;124(2):92-7. PMID: 20664196. Impact Factor 1.316. **Coauthor or Collaborator**.
157. Jang JH, Yoo EH, Kim HJ, **Kim DH**, Jung CW, Kim SH. Acute myeloid leukemia with del(X)(p21) and cryptic RUNX1/RUNX1T1 from ins(8;21)(q22;q22q22) revealed by atypical FISH signals. *Ann Clin Lab Sci*. 2010 Jan 1;40(1):80-4. PMID: 20124335. Impact Factor 1.017. **Coauthor or Collaborator**.
158. Chang MH, Kim KH, Kim HS, Jun HJ, **Kim DH**, Jang JH, Kim K, Jung CW. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. *Eur J Haematol*. 2009 Nov 12;154-159. Impact Factor 2.785 (Trainee publication, MH Chang - fellow (Samsung Medical Center)). **Corresponding Author**.
159. **Kim DH**, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH. Clinical relevance of a pharmacogenetic approach using multiple candidate gene polymorphisms to predict response and resistance to imatinib mesylate therapy in chronic myeloid leukemia. *Clin Cancer Res*. 2009 Jul;15(14):4750-8. Impact Factor 7.742. **Principal Author**.
160. **Kim DH**, Popradi G, Xu W, Gupta V, Kuruvilla J, Wright J, Messner HA, Lipton JH. Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant*. 2009 Apr;15(4):471-82. Impact Factor 3.873. **Principal Author**.

161. Park YH, Sohn SK, Kim JG, Lee MH, Song HS, Kim MK, Jung JS, Lee JJ, Kim HJ, **Kim DH**. Interaction between BCL2 and Interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following Rituximab plus CHOP chemotherapy. *Clin Cancer Res*. 2009 Mar;15(6):2107-15. Impact Factor 7.742. **Senior Responsible Author**.
162. **Kim DH**, Xu W, Ma C, Liu X, Siminovitch K, Messner HA, Lipton JH. Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. *Blood*. 2009 Mar;113(11):2517-25. Impact Factor 10.555. **Principal Author**.
163. **Kim DH**, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. *Haematologica*. 2009 Jan;94(1):135-9. Impact Factor 6.424. **Principal Author**.
164. **Kim DH**, Lee NY, Lee MH, Sohn SK. Vascular endothelial growth factor (VEGFA) gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: Preventive effect of VEGF on acute GVHD. *Biol Blood Marrow Transplant*. 2008 Dec;14(12):1408-16. Impact Factor 3.873. **Principal Author**.
165. **Kim DH**, Kumar D, Messner HA, Minden M, Gupta V, Kuruvilla J, Chae YS, Sohn SK, Lipton JH. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation. *Clin Transplant*. 2008 Nov;22(6):770-9. Impact Factor 1.915. **Principal Author**.
166. Park MJ, Kim HJ, Kim SH, **Kim DH**, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome?: External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison to IPSS. *Eur J Haematol*. 2008 Nov;81(5):364-73. Impact Factor 2.614. **Coauthor or Collaborator**.
167. **Kim DH**, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. *Cancer*. 2008 Aug;113(4):772-81. Impact Factor 4.771. **Principal Author**.
168. **DH Kim**, G Popradi, L Sriharsha, PJ Laneville, HA Messner, JH Lipton. Risk Factors and Management of Patients with Pulmonary Abnormalities and Philadelphia Chromosome-Positive Leukemia After Treatment with Dasatinib: Results from Two Institutions. *Clinical Leuk*. 2008 May;2(1):55-63. Impact Factor 1.601. **Principal Author**.
169. **Kim DH**, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J, Lipton J. Factors influencing varicella-zoster-virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. *Transplant Infectious Disease*. 2008 Apr;10(2):90-8. Impact Factor 2.216. **Principal Author**.
170. **Kim DH**, Lee NY, Lee MH, Sohn SK, Do YR, Park JY. Vascular endothelial growth factor (VEGF) gene polymorphism can predict the prognosis in acute myeloid leukemia patients. *Br J Haematol*. 2008 Jan;140(1):71-79. Impact Factor 4.491. **Principal Author**.
171. Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, **Kim DH**, Suh C, Kim SJ, Eom HS, Bae SH. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. *Bone Marrow Transplant*. 2007 Nov;40(10):919-24. Impact Factor 3.746. **Coauthor or Collaborator**.
172. Siegal D, Keller A, Xu W, Bhuta S, **Kim DH**, Kuruvilla J, Lipton JH, Messner H, Gupta V. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. *Biol Blood Marrow Transplant*. 2007 Nov;13(11):1369-1379. Impact Factor 3.873. **Coauthor or Collaborator**.
173. **Kim DH**, Jung HD, Lee NY, Sohn SK. Single nucleotide polymorphism of CC chemokine ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host disease and its severity after allogeneic transplantation. *Transplantation*. 2007 Oct;84(7):917-925. Impact Factor 4.003. **Principal Author**.

174. **Kim DH**, Sohn SK, Baek JH, Lee KH, Lee JH, Choi SJ, Shin IH. Time to first flare-up episode of GVHD can stratify patients according to their prognosis during clinical course of progressive- or quiescent-type chronic GVHD. *Bone Marrow Transplant*. 2007 Oct;40(8):779-84. Impact Factor 3.746. **Principal Author**.
175. **Kim DH**, Jamal N, Saragosa R, Loach D, Wright J, Gupta V, Kuruvilla J, Lipton JH, Minden M, Messner HA. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. *Biol Blood Marrow Transplant*. 2007 Oct;13(10):1233-1243. Impact Factor 3.873. **Principal Author**.
176. Stakiw J, **Kim DH**, Kuruvilla J, Gupta V, Messner H, Lipton JH. Evidence of graft-versus-Waldenstrom's macroglobulinemia effect after allogeneic stem cell transplantation: Single centre experience. *Bone Marrow Transplant*. 2007 Aug;40(4):369-72. Impact Factor 3.746. **Coauthor or Collaborator**.
177. Lee JJ, **Kim DH**, Lee NY, Sohn SK, Kim JG, Kim HJ, Do YR, Park YH. Interleukin-10 gene polymorphism influences on the prognosis of T-cell non-Hodgkin's lymphomas. *Br J Haematol*. 2007 May;137(4):329-36. Impact Factor 4.941. **Co-Principal Author**.
178. Baek JH, Sohn SK, **Kim DH**, Kim JG, Yang DH, Kim YK, Lee JJ, Kim HJ. Pilot Remission Induction Therapy with Idarubicin, plus an Intensified Dose of Ara-C and Priming with Granulocyte Colony-Stimulating Factor for Acute Myeloid Leukemia. *Acta Haematol*. 2007;117(2):109-114. Impact Factor 1.354. **Coauthor or Collaborator**.
179. Sohn SK, Kim JG, **Kim DH**. Tailored strategy for AML patients receiving allogeneic peripheral blood stem cell transplantation. *J Clin Apher*. 2006 Oct;21(3):207-13. Impact Factor 1.933. **Senior Responsible Author**.
180. **Kim DH**, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. *Blood*. 2006 Oct;108(8):2720-5. Impact Factor 10.555. **Principal Author**.
181. Jung JT, **Kim DH**, Kwak EK, Kim JG, Park TI, Sohn SK, Do YR, Kwon KY, Song HS, Park EH, Lee KB. Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas. *Ann Hematol*. 2006 Sep;85(9):575-81. Impact Factor 2.615. **Co-Principal Author**.
182. Kim H, Sohn HJ, Kim S, Kim K, Lee JH, Bang SM, **Kim DH**, Sohn SK, Lee JJ, Suh C. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy. *Biol Blood Marrow Transplant*. 2006 Aug;12(8):837-44. Impact Factor 3.873. **Coauthor or Collaborator**.
183. **Kim DH**, Won DI, Lee NY, Sohn SK, Suh JS, Lee KB. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation. *Biol Blood Marrow Transplant*. 2006 Jul;12(7):719-28. Impact Factor 3.873. **Principal Author**.
184. Kim JG, Sohn SK, Chae YS, **Kim DH**, Baek JH, Lee KB, Lee JJ, Chung IJ, Kim HJ, Yang DH, Lee WS, Joo YD, Sohn CH. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. *Cancer Chemother Pharmacol*. 2006 Jul;37(1):35-9. Impact Factor 2.833. **Coauthor or Collaborator**.
185. **Kim DH**, Sohn SK, Won DI, Lee NY, Suh JS, Lee KB. Rapid helper T-cell recovery above $200 \times 10^6/l$ at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2006 Jun;37(12):1119-28. Impact Factor 3.746. **Principal Author**.
186. **Kim DH**, Park JY, Sohn SK, Lee NY, Suh JS, Lee KB. The association between multidrug resistance-1 gene polymorphisms and outcomes of allogeneic HLA-identical stem cell transplantation. *Haematologica*. 2006 Jun;91(6):848-51. Impact Factor 6.424. **Principal Author**.
187. **Kim DH**, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, Kim JG, Suh JS, Do YR, Lee KB. Multidrug resistance-1 gene polymorphism associated with the treatment outcomes in de novo acute myeloid leukemia. *Int J Cancer*. 2006 May;118(9):2195-2201. Impact Factor 5.444. **Principal Author**.

188. Park YH, Lee JJ, Ryu MH, Kim SY, **Kim DH**, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. *Ann Hematol.* 2006 Apr;85(4):257-62. Impact Factor 2.615. **Coauthor or Collaborator.**
189. Sohn SK, **Kim DH**, Baek JH, Kim JG, Lee KB, Lee KH, Lee JH, Choi SJ, Lee JH, Shin IH. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2006 Apr;37(7):699-708. Impact Factor 3.746. **Coauthor or Collaborator.**
190. **Kim DH**, Lee NY, Baek JH, Kim JG, Sohn SK, Suh JS, Lee KS, Lee KB. Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia. *Leuk Lymphoma.* 2006 Mar;47(3):461-7. Impact Factor 2.58. **Principal Author.**
191. **Kim DH**, Sohn SK, Baek JH, Kim JG, Lee NY, Won DI, Suh JS, Lee KB. Clinical Significance of Platelet Count at day +60 After Allogeneic Peripheral Blood Stem Cell Transplantation. *J Korean Med Sci.* 2006 Feb;21(1):46-51. Impact Factor 0.993. **Principal Author.**
192. Choe YS, Kim JG, Sohn SK, **Kim DH**, Baek JH, Lee KB, Do YR, Kwon KY, Song HS, Lee MH, Park TI. c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas. *Leuk Lymphoma.* 2006 Feb;47(2):267-70. Impact Factor 2.58. **Coauthor or Collaborator.**
193. **Kim DH**, Sohn SK, Jeon SB, Baek JH, Kim JG, Lee NY, Suh JS, Lee KB, Shin IH. The prognostic value of platelet recovery pattern after allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2006 Jan;37(1):101-8. Impact Factor 3.746. **Principal Author.**
194. **Kim DH**, Won DI, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS, Lee KB. Survival benefit of asymptomatic cytomegalovirus reactivation and early lymphocyte recovery after HLA-identical allogeneic peripheral blood stem cell transplantation. *Transplantation.* 2006 Jan;81(1):101-8. Impact Factor 4.003. **Principal Author.**
195. **Kim DH**, Jung HD, Kwack DH, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS, Lee KB, Shin IH. Predicting outcomes of HLA-identical allogeneic stem cell transplants from variable number of tandem repeat disparity between donors and recipients. *Haematologica.* 2006 Jan;91(1):71-7. Impact Factor 6.424. **Principal Author.**
196. Kim JG, Sohn SK, **Kim DH**, Baek JH, Chae YS, Bae NY, Kim SY, Lee KB. Effectiveness of transdermal fentanyl patch for treatment of acute pain due to oral mucositis in patients receiving stem cell transplantation. *Transplant Proc.* 2005 Dec;37(10):4488-91. Impact Factor 1.005. **Coauthor or Collaborator.**
197. Seo KW, **Kim DH**, Sohn SK, Lee NY, Chang HH, Kim SW, Jeon SB, Baek JH, Kim JG, Suh JS, Lee KB. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2005 Dec;36(12):1089-95. Impact Factor 3.746. **Co-Principal Author.**
198. Sung WJ, **Kim DH**, Sohn SK, Kim JG, Baek JH, Jeon SB, Moon JH, Ahn BM, Lee KB. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia. *Jpn J Clin Oncol.* 2005 Oct;35(10):612-6. Impact Factor 1.852. **Coauthor or Collaborator.**
199. **Kim DH**, Sohn SK, Lee NY, Baek JH, Kim JG, Won DI, Suh JS, Lee KB, Shin IH. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. *Eur J Hematol.* 2005 Oct;75(4):299-308. Impact Factor 2.614. **Principal Author.**
200. Lee KH, Choi SJ, Lee JH, Lee JS, Kim WK, Lee KB, Sohn SK, Kim JG, **Kim DH**, Seol M, Lee YS, Lee JH. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. *Haematologica.* 2005 Jul;90(7):939-48. Impact Factor 6.424. **Coauthor or Collaborator.**
201. Kim JG, Sohn SK, **Kim DH**, Baek JH, Sung WJ, Park JY, Kim TB, Jung HY, Yu W, Lee KB. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. *Oncology.* 2005 Jul;68(2-3):190-195. **Coauthor or Collaborator.**

202. **Kim DH**, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS, Lee KB, Shin IH. IL-10 promoter gene polymorphism and impact on chronic GVHD after allogeneic peripheral blood stem cell transplantation. *Transplantation*. 2005 Jun;79(11):1615-1622. Impact Factor 4.003. **Principal Author**.
203. Kim JG, Sohn SK, **Kim DH**, Baek JH, Lee NY, Suh JS, Chae SC, Lee KS, Lee KB. Clinical implications of angiogenic factors in patients with hematological malignancies: HGF levels have a prognostic impact especially in patients with AML. *Leuk Lymphoma*. 2005 Jun;46(6):885-91. Impact Factor 2.58. **Coauthor or Collaborator**.
204. Kim JG, Sohn SK, **Kim DH**, Baek JH, Lee KB, Min WS, Kim CC, Lee MH, Lee JJ, Chung IJ, Kim HJ, Lee JW. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. *Bone Marrow Transplant*. 2005 Mar;35(5):489-95. Impact Factor 3.746. **Coauthor or Collaborator**.
205. **Kim DH**, Sohn SK, Kim JG, Lee NY, Sung WJ, Baek JH, Suh JS, Lee KS, Lee KB. Parameters for predicting allogeneic PBSC outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation. *Ann Hematol*. 2005 Jan;84(1):25-32. Impact Factor 2.615. **Principal Author**.
206. **Kim DH**, Lee NY, Kim JG, Sohn SK, Won DI, Suh JS, Lee GS, Chae SC, Lee KB. Daunorubicin efflux assay in determining multidrug resistance of the patients with acute myeloid leukemia. *Leuk Lymphoma*. 2005 Jan;46(1):63-70. Impact Factor 2.58. **Principal Author**.
207. **Kim DH**, Sohn SK, Baek JH, Kim JG, Lee JW, Min WS, Kim DW, Choi SJ, Lee JH, Lee KH, Lee MH, Lee JJ, Kim HJ, Kim CC, Lee KB. Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen. *Acta Haematologica*. 2005;113(4):220-7. Impact Factor 1.354. **Principal Author**.
208. **Kim DH**, Lee NY, Sung WJ, Baek JH, Kim JG, Sohn SK, Suh JS, Lee KS, Lee KB. Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes. *Acta Haematologica*. 2005;114(2):78-83. Impact Factor 1.354. **Principal Author**.
209. **Kim DH**, Bae NY, Sung WJ, Kim JG, Kim SW, Sohn SK, Lee KB. Hickman catheter site infections after allogeneic stem cell transplantation: Single center experience. *Transplant Proceeding*. 2004 Dec;36(5):1569-73. Impact Factor 1.005. **Principal Author**.
210. Kim JG, Sohn SK, **Kim DH**, Baek JH, Park TI, Lee KB. Phase II study of cyclophosphamide, epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin's lymphoma. *Korean J Med Sci*. 2004 Dec;19(6):820-25. Impact Factor 0.993. **Coauthor or Collaborator**.
211. **Kim DH**, Kim JG, Lee NY, Sung WJ, Sohn SK, Suh JS, Lee KS, Lee KB. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection. *Bone Marrow Transplant*. 2004 Jul;34(1):21-7. Impact Factor 3.746. **Principal Author**.
212. Kim JG, Sohn SK, **Kim DH**, Lee NY, Suh JS, Lee KS, Lee KB. Different efficacy of Mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. *Eur J Hematology*. 2004 Jul;73(1):56-61. Impact Factor 2.614. **Coauthor or Collaborator**.
213. Sohn SK, **Kim DH**, Kim JG, Lee NY, Suh JS, Lee KS, Lee KB. Transplantation outcome in allogeneic PBSC patients according to new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset. *Bone Marrow Transplant*. 2004 Jul;34(1):63-8. Impact Factor 3.746. **Coauthor or Collaborator**.
214. Sohn SK, Kim JG, **Kim DH**, Baek JH, Lee KB. Diverse clinical applications utilizing advantages of allogeneic peripheral blood stem cell harvesting. *Int J Hematology*. 2004 Jun;79(5):457-61. Impact Factor 1.268. **Coauthor or Collaborator**.
215. Sohn SK, **Kim DH**, Kim JG, Sung WJ, Baek JH, Lee NY, Won DI, Suh JS, Lee KS, Lee KB. Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases. *Eur J Hematology*. 2004 Jun;72(6):430-6. Impact Factor 2.614. **Coauthor or Collaborator**.

216. **Kim DH**, Sohn SK, Kim JG, Suh JS, Lee KS, Lee KB. Clinical impact of Hyperacute graft-versus-host disease on results of allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2004 May;33(10):1025-30. Impact Factor 3.746. **Principal Author.**
217. **Kim DH**, Kim JG, Sohn SK, Sung WJ, Suh JS, Lee KS, Lee KB. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. *Br J Haematol.* 2004 Apr;125(2):217-24. Impact Factor 4.941. **Principal Author.**
218. Kim JG, Sohn SK, **Kim DH**, Lee NY, Suh JS, Lee KS, Lee KB. A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant. *Bone Marrow Transplant.* 2004 Jan;33(2):231-6. Impact Factor 3.746. **Coauthor or Collaborator.**
219. Sohn SK, Jung JT, **Kim DH**, Kim JG, Kwak EK, Park Ti, Shin DG, Sohn KR, Lee KB. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. *Am J Hematol.* 2003 Jun;73(2):101-7. Impact Factor 4.671. **Coauthor or Collaborator.**
220. SK Sohn, JG Kim, **DH Kim**, JT Jung, NY Lee, JS Suh, KB Lee. Impact of transplanted CD 34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. *Bone Marrow Transplant.* 2003 Jun;31(11):967-72. Impact Factor 3.746. **Coauthor or Collaborator.**
221. Sohn SK, Kim JG, **Kim DH**, Lee KB. Cardiac morbidity in advanced chronic myelogenous leukemia patients treated by successive allogeneic stem cell transplantation with busulfan/ cyclophosphamide conditioning after imatinib mesylate administration. *Br J Haematol.* 2003 May;121:469. Impact Factor 4.941. **Coauthor or Collaborator.**
222. Sohn SK, Kim JG, Chae YS, **Kim DH**, Lee NY, Suh JS, Lee KB. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with Fenwal CS 3000 Plus from normal healthy donors: Predictors of CD34+ cell yield and collection efficiency. *J Clin Apheresis.* 2003;18:10-15. Impact Factor 1.933. **Coauthor or Collaborator.**
223. Sohn SK, Kim JG, Sung WJ, **Kim DH**, Suh JS, Lee KS, Lee KB. Harvesting peripheral blood stem cells from healthy donors on 4th day of cytokine mobilization. *J Clin Apheresis.* 2003;18(4):186-9. Impact Factor 1.933. **Coauthor or Collaborator.**
224. YS Chae, SB Jeon, WJ Sung, JW Lim, **DH Kim**, JG Kim, TI Park, SK Sohn, JS Suh, KB Lee. Clinical outcomes according to transplanted CD34+ cell dose in allogeneic peripheral blood stem cell transplantation. *Korean J Hematol.* 2003;38:24-31. (in Korean). **Coauthor or Collaborator.**
225. Sohn SK, Jung JT, **Kim DH**, Lee NY, Seo KW, Chae YS, Park SW, Kim JG, Suh JS, Lee KB. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. *Cancer.* 2002 Jan;94:18-24. Impact Factor 4.771. **Coauthor or Collaborator.**
226. Sohn SK, Ahn BC, Lee SW, **Kim DH**, Chun KA, Kim JG, Park SH, Song HS, Lee B, Lee J. Bone marrow immunoscintigraphy using technetium-99m anti-granulocyte antibody in multiple myeloma. *Eur J Nucl Med.* 2002;29:591-596. Impact Factor 4.991. **Coauthor or Collaborator.**
227. DS Kwak, YT Lee, YS Chae, KW Seo, SW Park, JH Baek, JG Kim, **DH Kim**, JT Jung, SH Park, SK Sohn, JS Suh, KB Lee. Stem cell mobilization with GM-CSF alone or a combination with GM-CSF and G-CSF from normal healthy donors. *Korean J Hematol.* 2001;36:25-34. (in Korean). **Coauthor or Collaborator.**
228. KW Seo, **DH Kim***, WJ Sung, SW Park, JG Kim, JT Jung, TI Park, SH Kim, DG Shin, SK Sohn, KB Lee. The clinical significance of Ann Arbor and Musshoff's staging system in primary gastrointestinal non-Hodgkin's lymphoma : a retrospective analysis. *Korean J Hematol.* 2001;36:275-285. (in Korean)* / * Authors contributed equally. **Co-Principal Author.**
229. JH Baek, SW Park, **DH Kim**, JT Jung, DS Kwak, SH Park, SK Sohn, JS Suh, KS Lee, JT Lee, KB Lee. The Frequency and Clinical Significance of Multidrug Resistance-1 (MDR-1) Gene Expression in Acute Myeloid Leukemia. *Korean J Hematol.* 2000 May;35(2):117-125. (in Korean). **Coauthor or Collaborator.**

230. SW Lee, J Lee, KA Chun, DY Kang, **DH Kim**, YK Cho, SC Chae, KB Lee. Prognostic value of normal exercise 99mTc-MIBI myocardial perfusion SPECT: comparison with exercise electrocardiography and coronary angiography. Korean J Nucl Med. 2000;34:199-206. (in Korean). **Coauthor or Collaborator**.
231. **DH Kim**, SK Sohn, JT Jung, KY Kim, DS Kwak, TI Park, SH Park, HI Bae, JS Suh, KB Lee. Mantle cell lymphoma presented as multiple lymphomatous polyposis : clinical review of 4 cases. Korean J Med. 2000;59:413-422. (in Korean). **Principal Author**.
232. Sohn SK, Baek JH, **Kim DH**, Jung JT, Kwak DS, Park SH, Suh JS, Lee KB. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma : a case report and literature review on the evidence of GVL effects in MCL. Am J Hematol. 2000;65:75-80. **Coauthor or Collaborator**.
233. SK Sohn, SW Park, JH Baek, **DH Kim**, DW Hyun, DS Kwak, J Lee, KB Lee. The effect of anti-TCR monoclonal antibody in mixed lymphocyte culture and as a part of immunosuppressive regimens in the allogeneic stem cell transplantation. Korean J Stem Cell Transplant. 1999;4:211-222. (in Korean). **Coauthor or Collaborator**.
234. JT Jung, YS Chae, SW Park, JH Baek, **DH Kim**, SH Park, SK Sohn, JS Suh, J Lee, KB Lee. Erythrocyte depletion effect of compression method with 6% hydroxyethyl starch in human umbilical cord blood. Korean J Blood Transfusion. 1999;10:179-186. (in Korean). **Coauthor or Collaborator**.
235. YH Lee, J Lee, JH Baek, **DH Kim**, JT Jung, KA Chun, DW Hyun, BC Ahn, SK Sohn, KB Lee. Scintigraphic evaluation of hematologic diseases with Tc-99m labeled antigranulocyte antibody. Korean J Hematol. 1998;33:206-214. (in Korean). **Coauthor or Collaborator**.
236. DW Hyun, JH Baek, **DH Kim**, JT Jung, YH Lee, SK Sohn, KB Lee, KA Chun, J Lee. A case of thrombotic thrombocytopenic purpura with neurologic symptoms identified only by 99m-Tc-HMPAO brain SPECT. Korean J Hematol. 1998;33:104-109. (in Korean). **Coauthor or Collaborator**.
237. **DH Kim**, J Lee, JH Baek, JT Jung, DW Hyun, KA Chun, YH Lee, SK Sohn, HS Song, KB Lee. Bone marrow scintigraphy with antigranulocyte antibody in multiple myeloma: comparison with simple radiography and bone scintigraphy. Korean J Nucl Med. 1998;32:354-364. (in Korean). **Principal Author**.
238. DW Hyun, **DH Kim**, JT Jung, YH Lee, JK Kim, SG Bae, SK Sohn, KB Lee, DG Shin, KS Hwang. Clinical characteristics and therapeutic efficacy of low dose cytarabine in high risk myelodysplastic syndrome. Korean J Hematol. 1998;33:94-103. (in Korean). **Coauthor or Collaborator**.
239. JT Jung, SW Park, JH Baek, **DH Kim**, DS Kwak, SH Park, SK Sohn, J Lee, KB Lee. Thymidine kinase as a prognostic factor in acute leukemia. Kyungpook Med J. 1998;39:229-236. (in Korean). **Coauthor or Collaborator**.

Case Reports

1. Baek JH, Sohn SK, **Kim DH**, Kim JG, Lee HW, Park SP, Lee KB. Wernicke's encephalopathy after allogeneic stem cell transplantation. 2005 Apr. 2005 35(8):829-30. Impact Factor 3.746. **Coauthor or Collaborator**.
2. **DH Kim**, SK Sohn, JT Jung, KY Kim, DS Kwak, SH Park, HG Lee, KH Lee, JS Suh, MS Hyun, CH Park, KB Lee. Allogeneic peripheral blood stem cell transplantation with donor lymphocyte infusions in mantle cell lymphoma relapsed after autologous PBSCT. 2000. Korean J Hematol. 35:72-80.(in Korean). **Principal Author**.
3. JT Jung, JH Baek, **DH Kim**, DS Kwak, SH Park, SK Sohn, JS Suh, KB Lee. An ALL case with Trichosporon beigelii pneumonia developed during severe pancytopenic period after salvage chemotherapy. 2000. Korean J Hematol. 35:162-165.(in Korean). **Coauthor or Collaborator**.
4. DW Hyun, SW Park, JH Baek, **DH Kim**, JT Jung, DG Shin, SK Sohn, KB Lee. A case of multiple myeloma with multiple intrahepatic extramedullary plasmacytomas. 1999. Korean J Hematol. 34:143-147.(in Korean). **Coauthor or Collaborator**.
5. DW Hyun, **DH Kim**, JT Jung, SK Sohn, J Lee, KB Lee. A case of invasive aspergillosis involving lung and brain in patient with acute leukemia. 1998. Korean J Hematol. 33:273-278.(in Korean). **Coauthor or Collaborator**.

Dennis Dong Hwan KIM

6. DW Hyun, **DH Kim**, JT Jung, SK Sohn, KB Lee. A case of invasive aspergillosis characterized by the formation of large bronchial cast in patient with acute myelogenous leukemia. 1998. J Korean Cancer Assoc. 30:1021-1025.(in Korean). **Coauthor or Collaborator**.
7. DW Hyun, **DH Kim**, JT Jung, Sk Sohn, J Lee, KB Lee. A case of Epstein-Barr virus infection presented as Evans syndrome. 1998. Korean J Hematol 33:438-442.(in Korean). **Coauthor or Collaborator**.
8. DW Hyun, JH Baek, **DH Kim**, JT Jung, SK Sohn, J Lee, KB Lee. A case of relapsed multiple myeloma presented as intracranial extramedullary plasmacytoma. 1998. Korean J Hematol 33:460-465.(in Korean). **Coauthor or Collaborator**.
9. Sohn SK, Ahn T, **Kim DH**, Jung JT, Hyun DW, Lee YH, Suh CS, Lee J, Lee KB. Hepatosplenic T-cell lymphoma: prolymphocytic transformation 18 months after splenectomy. 1997 Aug. Int J Hematol. 66:227-232. **Coauthor or Collaborator**.
10. SK Bae, **DH Kim**, JT Jung, CD Kim, JG Kim, Yh Lee, TH Kwon, SK Sohn, YL Kim, DK Cho, KB Lee. A case of primary B-cell lymphoma of the central nervous system after renal transplantation : A case report. 1997. Korean J Med. 53:451-454.(in Korean). **Coauthor or Collaborator**.

Book Chapters

1. Alam, N, **Kim, D**
University of Toronto, Ontario, Canada. Transplantation of Haematopoietic Stem Cells. In: eLS. (Canada): John Wiley & Sons, Ltd.; 2013. Published online: 19 Sep 2013. **Co-Principal Author**.

Letters to Editor

1. HIRAMA T, Brode SK, Beswick J, Law AD, Lam W, Michelis FV, Thyagu S, Viswabandya A, Lipton JH, Messner HA, **Kim DDH**, Marras TK. Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic haematopoietic stem cell transplant. Eur Respir J. 2018 May 1;51(5). PMID: 29545280. Impact Factor 11.807. **Coauthor or Collaborator**.
2. Choi ER, Ko YH, Kim SJ, Jang JH, Kim K, Kang WK, Jung CW, **Kim DH**. Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol. 2009 Nov 16. Impact Factor 18.372 (Trainee publication, Choi ER (medical resident, Samsung Medical Center, Korea)). **Senior Responsible Author**.
3. **Kim DH**, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS, Hyun MS, Sohn SK. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007 Oct;21(10):2227-30. Impact Factor 9.561. **Principal Author**.

3. NON-PEER-REVIEWED PUBLICATIONS

Journal Articles

1. Salas MQ, Pasic I, Remberger M, Novitzky-Basso I, Law AD, Lam W, Chen C, **Kim DDH**, Michelis FV, Gerbitz A, Viswabandya A, Lipton JH, Kumar R, Mattsson J. Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Centre Experience. Transplant Cell Ther. 2022 Feb 6. **Coauthor or Collaborator**.

Book Chapters

1. Chapter 12. The impact of polymorphisms on the clinical outcomes of monoclonal antibody therapy against hematologic malignancies. In: Federico Innocenti, editor(s). GENOMICS AND PHARMACOGENOMICS IN ANTICANCER DRUG DEVELOPMENT AND CLINICAL RESPONSE. Humana Press; 2008. (ISBN 9781588296467). **Principal Author**.

F. Intellectual Property

1. PATENTS

- 2011 May **Method for predicting chronic myeloid leukemia risk and kit for diagnosing chronic myeloid leukemia risk.** Patents #: 10-2011-0041690, Korea, Republic Of. Joint Holder Name(s): Samsung Advanced Institute of Technology, Jong Won Kim.
This method provides early identification of high risk group of patients for chronic myeloid leukemia at least in east asian and caucasian populations.

G. Presentations and Special Lectures

1. INTERNATIONAL

Invited Lectures and Presentations

- 2021 Nov 28 **Invited Lecturer.** Across the Horizon in GVHD in GVHD Treatment 2021: The Present and Future. Shanghai Hematology Summit, Shanghai General Hospital. Shanghai, China. Presenter(s): **Kim DH.** Via Zoom Live Webinar (approx. 500 ppl).
- 2021 Oct 22 **Invited Lecturer.** Update of GVHD Treatment in 2021 - Focusing on Ruxolitinib Therapy. Novartis Hematology Medical Symposium. Korea, Republic Of. Presenter(s): **Kim DH.** Via Zoom Live Webinar (approx. 300 ppl).
- 2021 Sep 30 **Invited Lecturer.** Patient Case: A Case of Abdominal Distention with Underlying Steroid Induced Myopathy. Oncology Scientific Exchange: Meet The Expert Session (Novartis). Switzerland. Presenter(s): **Kim DH.** Via Zoom Live Webinar.
- 2021 Sep 16 **Invited Lecturer.** Patient Case: Ruxolitinib Rechallenge in Acute GVHD Flare-UP After Ruxolitinib Discontinuation. Oncology Scientific Exchange: Meet The Expert Session (Novartis). Switzerland. Presenter(s): **Kim DH.** Via Zoom Live Webinar.
- 2021 Jul 22 **Invited Lecturer.** Update of GVHD Treatment in 2021 - Focusing on Ruxolitinib Therapy. Heme Expert Meeting, Novartis. Brazil. Presenter(s): **Kim DH.** Via Zoom Live Webinar (approx. 500 ppl).
- 2021 Apr 7 **Invited Lecturer.** CML Horizon: Past, Present and Future. Saudi Society for Blood Disorders (SSBD). Saudi Arabia. Presenter(s): **Kim DH.** Via Zoom Live Webinar: CML (approx. 200 ppl).
- 2020 Nov 21 **Invited Speaker.** How to Enhance a Minimal Residual Disease Detection in AML Patients receiving HCT. International Hematology Conference. Shanghai, China. Presenter(s): **Kim DH.** Shanghai 2020, Virtual - audience 300.
- 2020 Nov 21 **Invited Speaker.** CML Research. The Leukemia & Lymphoma Society of Canada (LLSC) - National Leukemia Conference 2020. Presenter(s): **Kim DH.** Virtual. Audience 600.
- 2020 Oct 3 **Invited Speaker.** BCR-ABL1 transcript doubling time after Imatinib discontinuation for treatment-free remission in chronic myeloid leukemia in chronic phase: Early predictive surrogate for treatment-free remission failure after Imatinib discontinuation. ESH International CML Conference. Presenter(s): **Kim DH.** Virtual Meeting - audience 500
22nd Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy
October 01 - October 04, 2020 - ONLINE CONFERENCE.
- 2020 Oct 3 **Invited Speaker.** Risk factor analysis for treatment-free remission failure after Imatinib discontinuation in patients with chronic myeloid leukemia in chronic phase: The optimal duration of total Imatinib treatment

and MR4 response from a Canadian tyrosine kinase inhibitor discontinuation trial. ESH International CML Conference. Presenter(s): **Kim DH**. Virtual Meeting - audience 500
22nd Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy
October 01 - October 04, 2020 - ONLINE CONFERENCE.

- 2020 Apr 3 **Invited Speaker**. 1. Treatment-Free Remission 2020 Breaking News. 2. How to Try Treatment -Free Remission in my Patients. LM Club. São Paulo, Brazil. Presenter(s): **Kim DH**. Approximately 200 participants.
- 2020 Mar 6 **Invited Speaker**. 1. Treatment-Free Remission in CML. 2. Therapeutic Innovation in Chronic Myeloid Leukemia. Annual Saudi Society of Hematology Congress 2020. Riyadh, Saudi Arabia. Presenter(s): **Kim DH**. Approximately 500 participants.
- 2019 Dec 6 **Invited Speaker**. TFR biomarker study - TRAD biomarker. iCMLf Treatment Free Remission Alliance Meeting. Orlando, Florida, United States. Presenter(s): **Kim DH**.
- 2019 Nov 2 **Invited Speaker**. Next generation sequencing based pre and post-transplant molecular monitoring in acute myeloid leukemia. Hematology Experts Summit Forum 2019. Shanghai, China. Presenter(s): **Kim DH**.
- 2019 Nov 1 **Invited Speaker**. Next generation sequencing based pre and post-transplant molecular monitoring in acute myeloid leukemia. The 5th National Hematology and Blood Transfusion Congress. Ho Chi Minh, thanh pho [Sai Gon], Viet Nam. Presenter(s): **Kim DH**.
- 2019 Oct 19 **Invited Speaker**. 1. Midostaurin in AML: Based on the experiences in actual practice 2. Frontline drug selection in the context of TFR - focusing on Nilotinib discontinuation and Asciminib. International Symposium on Hematology. Seoul, Korea, Republic Of. Presenter(s): **Kim DH**.
- 2019 Oct 18 **Invited Speaker**. Precision medicine in CML management. Asian Medical Center. Seoul, Korea, Republic Of. Presenter(s): **Kim DH**. Grand Round.
- 2019 Oct 18 **Invited Speaker**. Precision medicine in CML management. Korea University Medical Center. Seoul, Korea, Republic Of. Presenter(s): **Kim DH**. Grand Round.
- 2019 Oct 17 **Invited Speaker**. Recent advances in therapeutics in myeloid leukemias. Korean Hospital. Daegu, Korea, Republic Of. Presenter(s): **Kim DH**. Grand Round.
- 2019 Sep 7 **Invited Speaker**. Operational cure as a real and practical goal of CML therapy in 2019 - Role of Dasatinib. The 7th Hematology Academy Meeting. Kyôto [Kyoto], Japan. Presenter(s): **Kim DH**.
- 2019 Sep 6 **Invited Speaker**. Operational cure as a real and practical goal of CML therapy in 2019 - Role of Dasatinib. Scientific Seminar. Ôsaka [Osaka], Japan. Presenter(s): **Kim DH**.
- 2019 Sep 5 **Invited Speaker**. Operational cure as a real and practical goal of CML therapy in 2019 - Role of Dasatinib. Scientific Seminar. Okayama, Japan. Presenter(s): **Kim DH**.
- 2019 Mar 15 **Invited Speaker**. Is CML a Single Hlt Disorder? - Future CML Management in the Era of Precision Medicine. International Conference of Korean Society of Hematology. Seoul, Korea, Republic Of. Presenter(s): **Kim DH**.
- 2018 Nov 11 **Invited Speaker**. Post-Transplant Cyclophosphamide with ATG as GVHD Prophylaxis: PMH Experience. Hematology Experts Sumit Forum - Shanghai General Hospital. Shanghai, China. Sponsored by Shanghai General Hospital.
- 2018 Nov 10 **Invited Speaker**. NGS-Based Post-Transplant Monitoring in AML Patients After Allogeneic HCT. Hematology Experts Sumit Forum - Shanghai General Hospital. Shanghai, China. Sponsored by Shanghai General Hospital.
- 2018 Oct 27 **Invited Speaker**. Precision Medicine in CML: Biomarker for Response to TKI Therapy and TFR. CML Scientific Seminar. Tôkyô [Tokyo], Japan.

- 2018 Oct 26 **Invited Speaker.** Precision Medicine in CML: Biomarker for Response to TKI Therapy and TFR. CML Scientific Seminar. Japan.
- 2018 Oct 25 **Invited Speaker.** Precision Medicine in CML: Biomarker for Response to TKI Therapy and TFR. CML Scientific Seminar. Hukuoka [Fukuoka], Japan.
- 2018 Sep 15 **Invited Speaker.** Molecular Predictor for TFR After Imatinib Discontinuation: BCR-ABL1 qPCR Level and qPCR Doubling Time (DT). ESH-iCMLf Conference. Miami, Florida, United States.
- 2018 Sep 14 **Invited Speaker.** HMGLL1 is a Predictive Biomarker for Deep Molecular Response to Imatinib Therapy in CML. ESH-iCMLf Conference. Miami, Florida, United States.
- 2018 Aug 10 **Invited Speaker.** Chronic Myeloid Leukemia: Recent Advances & EHA Updates. Soonchonhyang University Seol Hospital. Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic Of. Seminar - Sponsored by Soonchonhyang University Seol Hospital.
- 2018 Aug 10 **Invited Speaker.** Genomics in Liquid Tumors and Allogeneic Transplantation. Scientific Seminar. Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic Of.
- 2018 Aug 8 **Invited Speaker.** Chronic Myeloid Leukemia: Recent Advances & EHA Updates. Hwasun Chonnam National University Hospital. Gwangju Gwang'yeoksi [Kwangju-Kwangyokshi], Korea, Republic Of. Seminar - Sponsored by Hwasun Chonnam National University Hospital.
- 2018 Aug 8 **Invited Speaker.** Chronic Myeloid Leukemia: Recent Advances & EHA Updates. Kyungpook National University Hospital. Daegu Gwang'yeoksi [Taegu-Kwangyokshi], Korea, Republic Of. Seminar - Sponsored by Kyungpook National University Hospital.
- 2018 Jun 15 **Invited Speaker.** Genomic Testing for CML - Questions and Barriers. CML Genomic Alliance. Stockholms län [SE-01], Sweden. Presenter(s): **DH Kim.**
- 2017 Dec 9 **Presenter.** Interim Results of the Canadian Tyrosine Kinase Inhibitor Discontinuation Trial for 2nd attempt of Treatment Free Remission: Treatment Free Remission Accomplished by Dasatinib (TRAD). 59th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Dec 8-12 ASH. Poster Presentation.
- 2017 Nov 18 **Invited Speaker.** Optimization of CML treatment towards DMR via Immunomodulatory activity of Dasatinib. Bristol Myers Squibb. Sapporo, Japan. Presenter(s): **Kim DH.**
- 2017 Nov 17 **Invited Speaker.** Optimization of CML treatment towards DMR via Immunomodulatory activity of Dasatinib. Bristol Myers Squibb. Tôkyô [Tokyo], Japan. Presenter(s): **Kim DH.**
- 2017 Nov 16 **Invited Speaker.** Optimization of CML treatment towards DMR via Immunomodulatory activity of Dasatinib. Bristol Myers Squibb. Hirosima [Hiroshima], Japan. Presenter(s): **Kim DH.**
- 2017 Oct 15 **Invited Speaker.** Interim Analysis of the Candian Tyrosine Kinase Inhibitor Discontinuation Trial: Treatment Free Remission Accomplished By Dasatinib (TRAD). ESH - 19th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy. Estoril, Portugal. Presenter(s): **Kim DH.** Session: TFR and Clinical trials.
- 2017 Sep 2 **Invited Speaker.** Evolution in CML treatment: From survival to CMR & Operational cure. Bristol Myers Squibb. Taipei, Taiwan, Province Of China. Presenter(s): **Kim DH.**
- 2017 Sep 2 **Invited Speaker.** Immunomodulatory effect of Dasatinib to optimize CML treatment towards CMR. Bristol Myers Squibb. Taipei, Taiwan, Province Of China. Presenter(s): **Kim DH.**
- 2017 Sep 1 **Invited Speaker.** Immunomodulatory effect of Dasatinib to optimize CML treatment towards CMR. Bristol Myers Squibb. Taipei, Taiwan, Province Of China. Presenter(s): **Kim DH.**
- 2017 Jul 24 **Invited Speaker.** Cardiovascular events and CML therapy in Canada (webcast). Australian Hematologist. Presenter(s): **Kim DH.** Cardiovascular events and CML Therapy in Canada. Webcast.

Dennis Dong Hwan KIM

- 2017 Jun 25 **Invited Speaker.** Cardiovascular events and CML therapy in Canada. Spain, Australian Hematologist. Presenter(s): **Kim DH.**
- 2017 Jun 24 **Invited Speaker.** Serial sequencing reveals clonal origins and strategies for early detection of post-allogeneic hematopoietic stem cell transplantation (HCT) relapse in acute myeloid leukemia (AML). European Hematology Association. Madrid, Spain. Presenter(s): **Kim DH.**
- 2017 Jun 16 **Invited Speaker.** Leukemia Stem Cell Eradication in CML: Updates in 2017. Seoul, Korea Samsung Medical Center. Not Required, Korea, Republic Of. Presenter(s): **Kim DH.** Seminar.
- 2017 Jun 15 **Invited Speaker.** Active issues in CML management: Treatment-free remission & Dasatinib. Daegu, Korea Keimyung University Dongsan Medical Center. Not Required, Korea, Republic Of. Presenter(s): **Kim DH.** Seminar.
- 2017 Jun 14 **Invited Speaker.** Active issues in CML management: Treatment-free remission & Dasatinib. Gwangju, Korea Hwasun Chonnam National University Hospital. Not Required, Korea, Republic Of. Presenter(s): **Kim DH.** Seminar.
- 2017 Jun 14 **Invited Speaker.** Preleukemic Mutations in Leukemias. Daegu, Korea Kyungpook National University Hospital. Not Required, Korea, Republic Of. Presenter(s): **Kim DH.** Seminar.
- 2016 Sep 16 **Invited Speaker.** Dynamics Spectrum of somatic mutations in TKI therapy on CML. ESH - 18th Annual John Goldman Conference. Houston, Texas, United States. Presenter(s): **Kim, Dennis.** Royal Sonesta Hotel – Houston, Texas, USA
September 15-18, 2016.
- 2016 Aug 24 **Invited Speaker.** Patient oriented therapy in CML: Focusing on TKI switch and TFR. Kyungpook National University Hospital. Not Required, Korea, Republic Of. Presenter(s): **Kim Dennis.** Seminar.
- 2016 Aug 23 **Invited Speaker.** Patient oriented therapy in CML: Focusing on TKI switch and TFR. SoonChunHyang University Hospital. Korea, Republic Of. Presenter(s): **Kim Dennis.** Seminar.
- 2016 Aug 22 **Invited Speaker.** Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. International Symposium. Gwangju, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2016 May 21 **Invited Speaker.** How to improve TFR success in CML. CML Symposium. Tôkyô [Tokyo], Japan. Presenter(s): **Kim DH.**
- 2016 May 20 **Invited Speaker.** How to improve TFR success in CML. CML Scientific Seminar in Tokyo. Tôkyô [Tokyo], Japan. Presenter(s): **Kim DH.**
- 2016 May 19 **Invited Speaker.** How to improve TFR success in CML. CML Scientific Seminar in Osaka. Ôsaka [Osaka], Japan. Presenter(s): **Kim DH.**
- 2015 Oct 22 **Chair.** Cancer Treatment in 2016: applying molecular medicine to the benefits of patients. DMOH Grand Rounds, Princess Margaret Cancer Centre. Toronto, Ontario, Canada. Presenter(s): Dr. Carlo Gambacorti-Passerini. Invited presenter Dr. Carlo Gambacorti-Passerini, Italian Oncologist & Hematologist, Professor of Internal Medicine at the University of Milan Bicocca, Director of the Clinical Research Unit at S. Gerardo Hospital, Monza, Italy.
- 2015 Sep 2 **Lecturer.** Patient centricity in CML management. Daegu, Korea, Republic Of. Presenter(s): **Kim DH.** Lecture - around 20 Hematologists.
- 2015 Sep 1 **Lecturer.** Patient centricity in CML management. Seoul, Korea, Republic Of. Presenter(s): **Kim DH.** Round table - around 50 Hematologists.
- 2013 Nov 9 **Invited Speaker.** Controversies in CML management. Korean Society of Hematology, CML working party. Changwon, Gyeongsangnamdo [Kyongsangnam-do], Korea, Republic Of. Presenter(s): **Kim DH.**
- 2012 Feb 7 **Invited Speaker.** SNPs and Next Generation Sequencing in Leukemia. National Center for Cancer Genomics and the National Center for Translational Genomics. Seoul, Seoul Teugbyeolsi [Seoul-

T'ukpyolshij], Korea, Republic Of. Presenter(s): **Kim DH.**

- 2011 Sep 24 **Invited Speaker.** SNPs as biomarker in CML management. The 13th International CML conference: Chronic myeloid leukemia. Estoril, Portugal. Presenter(s): **Kim DH.** one of 3 main speaker in the scientific workshop.
- 2011 Jan 19 **Invited Speaker.** Unfavorable prognostic impact of D816 C-KIT mutation and preliminary results of genome-wide SNP-array based karyotyping in CBF (+) AML. JALSG (Japan Acute Leukemia Study Group). Nagoya, Japan. Presenter(s): **Kim DH.**
- 2010 Dec 19 **Invited Speaker.** Unfavorable prognostic impact of D816 C-KIT mutation and preliminary results of genome-wide SNP-array based karyotyping in CBF (+) AML. Japan-Korea AML symposium, JALSG. Nagoya, Japan.
- 2010 Jun 19 **Invited Speaker.** Large granular lymphocytosis for dasatinib therapy in chronic myeloid leukemia. Korea-Japan Collaborative Symposium on Chronic Myelogenous Leukemia. Seoul, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2009 Aug 28 **Invited Speaker.** Empirical antifungal therapy in neutropenic patients. Korea-China Workshop for Invasive Fungal Infections. Seoul, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2008 Dec 19 **Invited Speaker.** Clinical experiences in the treatment of acute lymphoblastic leukemia in Korea. Nagoya First Red Cross Hospital, Department of Hematology, Research Symposium. Nagoya, Japan. Presenter(s): **Kim DH.**

Presented Abstracts

- 2020 Dec 8 **Presenter.** Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥ 2 Tyrosine Kinase Inhibitors (TKIs). 62nd Annual Meeting & Exposition of American Society of Hematology (ASH All-Virtual). United States. Presenter(s): **Kim DH.** a. Session name: Late-breaking Abstracts (LBA-4)
b. Date: Tuesday, December 8, 2020
c. Presentation time: 7:30 AM-9:00 AM
d. Co-author. (Trainee Presentation).
- 2020 Dec 7 **Presenter.** Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic GVHD Treatment Including Ruxolitinib, Ibrutinib and Imatinib. 62nd Annual Meeting & Exposition of American Society of Hematology (ASH All-Virtual). United States. Presenter(s): **Kim DH,** Linn SM. a. Session name: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III (3316)
b. Date: Monday, December 7, 2020
c. Presentation time: 7:00 a.m. - 3:30 p.m. (Pacific Time)
d. Last author. (Trainee Presentation).
- 2020 Dec 6 **Presenter.** Multicenter, retrospective study to evaluate the therapeutic efficacy of Ruxolitinib in patients heavily pretreated for steroid-resistant chronic GVHD. 62nd Annual Meeting & Exposition of American Society of Hematology (ASH All-Virtual). United States. Presenter(s): **Kim DH.** a. Session name: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II
b. Date: Sunday, December 6, 2020
c. Presentation time: 7:00 AM-3:30 PM
d. Last author. (Trainee Presentation).
- 2020 Dec 6 **Presenter.** ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-A and HLA-B Mismatched Unrelated donor. 62nd Annual Meeting & Exposition of American Society of Hematology (ASH All-Virtual). United States. Presenter(s): **Kim DH,** Novitzky-Basso I.
a. Session name: 732. Clinical Allogeneic Transplantation: Results: Poster II (2428)
b. Date: Sunday, December 6, 2020
c. Presentation time: 7:00 AM-3:30 PM

- d. Co-author. (Trainee Presentation).
- 2020 Dec 6 **Presenter.** Proposed Title: CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study. 62nd Annual Meeting & Exposition of American Society of Hematology (ASH All-Virtual). United States. Presenter(s): **Kim DH**, Andrews C. a. Session name: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster II
- b. Date: Sunday, December 6, 2020
- c. Presentation time: 7:00 AM-3:30 PM
- d. Co-author. (Trainee Presentation).
- 2020 Dec 6 **Presenter.** Clinical relevance of multiparameter flow cytometry-based measureable residual disease assessment in patients with acute myeloid leukemia harboring DNMT3A/TET2/ASXL1 mutation. 62nd Annual Meeting & Exposition of American Society of Hematology (ASH All-Virtual). United States. Presenter(s): **Kim DH**. a. Session name: 613. Acute Myeloid Leukemia: Potpourri of Potential Practice Changing Studies (Oral, 463)
- b. Date: Sunday, December 6, 2020:
- c. Presentation time: 3:15 PM
- d. Co-last author. (Trainee Presentation).
- 2020 Dec 5 **Presenter.** Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre – a Prospective Observational Study. 62nd Annual Meeting & Exposition of American Society of Hematology (ASH All-Virtual). United States. Presenter(s): **Kim DH**, Nampootheri R. a. Session name: 901. Health Services Research—Non-Malignant Conditions: Poster I (1565)
- b. Date: Saturday, December 5, 2020
- c. Presentation time: 7:00 AM-3:30 PM
- d. Co-author. (Trainee Presentation).
- 2020 Dec 5 **Presenter.** Increased risk of secondary malignancy associated with the use of Azathioprine for chronic graft-versus-host disease treatment. 62nd Annual Meeting & Exposition of American Society of Hematology (ASH All-Virtual). United States. Presenter(s): **Kim DH**, Novitzky-Basso I. a. Session name: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I (1498)
- b. Date: Saturday, December 5, 2020
- c. Presentation time: 7:00 a.m. - 3:30 p.m. (Pacific Time)
- d. Last author. (Trainee Presentation).
- 2020 Dec 5 **Presenter.** Allogeneic transplant can abrogate the relapse risk in the patients with detectable measureable residual disease by multicolor flow-cytometry at the time of assessment of acute myeloid leukemia patients in first remission. 62nd Annual Meeting & Exposition of American Society of Hematology (ASH All-Virtual). United States. Presenter(s): **Kim DH**. a. Session name: 732. Clinical Allogeneic Transplantation: Results: Poster I (1530)
- b. Date: Saturday, December 5, 2020
- c. Presentation time: 7:00 AM-3:30 PM
- d. Last author. (Trainee Presentation).
- 2020 Dec 5 **Presenter.** BCR-ABL1 transcript doubling time after imatinib discontinuation for treatment-free remission in chronic myeloid leukemia in chronic phase: Predictor for treatment-free remission failure. 62nd Annual Meeting & Exposition of American Society of Hematology (ASH All-Virtual). United States. Presenter(s): **Kim DH**. a. Session name: 632. Chronic Myeloid Leukemia: Therapy: Poster I (1234)
- b. Date: Saturday, December 5, 2020
- c. Presentation time: 7:00 a.m. - 3:30 p.m. (Pacific Time)
- d. First author. (Trainee Presentation).
- 2020 Dec 5 **Presenter.** Optimal duration of imatinib treatment / deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. 62nd Annual Meeting & Exposition of American Society of Hematology (ASH All-Virtual). United States. Presenter(s): **Kim DH**. a. Session name: 632. Chronic Myeloid Leukemia: Therapy: Poster I (1247)

- b. Date: Saturday, December 5, 2020
- c. Presentation time: 7:00 a.m. - 3:30 p.m. (Pacific Time)
- d. First author. (Trainee Presentation).

- 2020 Aug 29 **Co-Author.** The presence of age-related clonal hematopoiesis (ARCH) in donor does not increase the risk of late secondary malignancies after allogeneic hematopoietic stem cell transplantation: Result from 372 donor and recipient pairs with a medium follow-up duration of 13 years. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Presenter(s): **Kim DH.** Kyoung Ha Kim, TaeHyung Kim, Jae-Soon, Ivan Pasic, Zeyad-Al Shaibani, Arjun Law, Wilson Lam, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattson, Zhaolei Zhang, Tamir biezuner, Lian Shlush, Dennis Dong Hwan Kim. (Trainee Presentation).
- 2020 Aug 29 Experience using Dual T-Cell depletion with ATG and PTCy for GVHD Prophylaxis in RIC alloHCT using in 10/10 Matched Related and Unrelated Donors. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Maria Queralt Salas, Eshetu G. Atenafu, Arjun Datt Law, Wilson Lam, Zeyad Al-Shaibani, Ivan Pasic, **Dennis Dong Hwan Kim**, Fotios V. Michelis, Armin Gerbitz, Jeffrey Howard Lipton, Jonas Mattsson, Rajat Kumar, Auro Viswabandya. (Trainee Presentation).
- 2020 Aug 29 Comparison of outcomes post-second allogeneic hematopoietic cell transplantation with donor lymphocyte infusions in allogeneic hematopoietic cell transplant patients. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Eshrak Al-Shaibani, Jeffrey H. Lipton, Dennis D.Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun Law, Zeyad Al-Shaibani, Armin Gerbitz, Ivan Pasic, Jonas Mattsson, Fotios V. Michelis. (Trainee Presentation).
- 2020 Aug 29 Prognostic significance of donor-specific isoagglutinin re-appearance in ABO-mismatched stem cell transplant recipient. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Maryam Pourabdollah, Eshetu Atenafu, Ivan Pasic, Zeyad Al-Shaibani, Arjan Law, Wilson Lam, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattson. (Trainee Presentation).
- 2020 Aug 29 The impact of allogeneic transplantation in AML and MDS with chromosome abnormalities. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Maria Rhida Bautista, Shiyi Chen, Wilson Lam, Fotios V. Michelis, Dennis (Dong Hwan) **Kim**, Jeffrey Howard Lipton, Auro Viswabandya, Rajat Kumar, Ivan Pasic, Armin Gerbitz, Jonas Mattson, Zeyad Al-Shaibani, Arjan Datt Law. (Trainee Presentation).
- 2020 Aug 29 Experience using Dual T-Cell depletion with ATG and PTCy for GVHD Prophylaxis in RIC alloHCT using in 10/10 Matched Related and Unrelated Donors. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Maria Queralt Salas, Eshetu G. Atenafu, Arjun Datt Law, Wilson Lam, Zeyad Al-Shaibani, Ivan Pasic, **Dennis Dong Hwan Kim**, Fotios V. Michelis, Armin Gerbitz, Jeffrey Howard Lipton, Jonas Mattsson, Rajat Kumar, Auro Viswabandya. (Trainee Presentation).
- 2020 Aug 29 The impact of allogeneic transplantation in AML and MDS with chromosome 3 abnormalities. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Maria Rhida Bautista, Shiyi Chen, Wilson Lam, , Fotios V. Michelis, Dennis (Dong Hwan) **Kim**, Jeffrey Howard Lipton, Auro Viswabandya, Rajat Kumar, Ivan Pasic, Armin Gerbitz, Jonas Mattson, Zeyad Al-Shaibani, Arjun Datt Law. (Trainee Presentation).
- 2020 Aug 29 Hypoalbuminemia prior alloHCT is a relevant negative predictor for survival. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Maria Queralt Salas, Eshetu G. Atenafu, Arjun Datt Law MD, Wilson Lam MD, Ivan Pasic MD, Dennis (Dong Hwan) Kim MD, Fotios V. Michelis MD, Zeyad-Al Shaibani MD, Armin Gerbitz MD, Auro Viswabandya MD, Jeffrey Howard Lipton MD, Jonas Mattsson MD, Rajat Kumar MD. (Trainee Presentation).
- 2020 Aug 29 Prospective Pilot Study on Frailty and Function Assessment during Clinics in Allogeneic Hematopoietic Cell Transplantation. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Maria Queralt Salas MD12, Eshetu G. Atenafu3, Arijit Nag12, Ora Bascom2, Leeann Wilson2, Wilson Lam MD12, Arjun Datt Law MD12, Ivan Pasic MD12, Dennis (Dong Hwan) Kim MD12, Fotios V. Michelis MD12, Zeyad-Al Shaibani MD12, Armin Gerbitz MD12, Auro Viswabandya MD12,

Jeffrey Howard Lipton MD¹², Jonas Mattsson MD¹², Shabbir M.H. Alibhai MD³, Rajat Kumar MD¹². (Trainee Presentation).

- 2020 Aug 29 Bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for acute myeloid leukemia in CR1. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Igor Novitzky-Basso^{1,2}, Shiyi Chen^{2,3}, Jeffrey H. Lipton^{1,2}, Dennis D. Kim^{1,2}, Auro Viswabandya^{1,2}, Rajat Kumar^{1,2}, Wilson Lam^{1,2}, Arjun Law^{1,2}, Zeyad Al-Shaibani^{1,2}, Armin Gerbitz^{1,2}, Ivan Pasic^{1,2}, Jonas Mattsson^{1,2}, Fotios V. Michelis^{1,2}. (Trainee Presentation).
- 2020 Aug 29 Comparison of the prognostic ability of the HCT-CI the modified EBMT and the EBMT-ADT pre-transplant risk scores for acute leukemias. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Eshrak Al-Shaibani¹, Shiyi Chen², Jeffrey H. Lipton¹, Dennis D. Kim¹, Auro Viswabandya¹, Rajat Kumar¹, Wilson Lam¹, Arjun Law¹, Zeyad Al-Shaibani¹, Armin Gerbitz¹, Ivan Pasic¹, Jonas Mattsson¹, Fotios V. Michelis¹ EBMT-Virtual, Virtual. (Trainee Presentation).
- 2020 Aug 29 Subcutaneous Immunoglobulin Replacement Therapy in Patients who Underwent Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Study to Measure Feasibility, Safety and Health Care Resource Use. 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT - Virtual). Ivan Pasic MD, PhD¹, Wael Alanazi MD¹, George Dranitsaris PhD², Lani Lieberman MD³, Auro Viswabandya MD¹, Dennis D. Kim MD, PhD¹, Jeffrey H. Lipton MD, PhD¹, Fotios V. Michelis MD, PhD¹. (Trainee Presentation).
- 2019 Dec 7 **Presenter.** No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft_Versus_Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): Poster presentation - Kyounga. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Dec 7 **Presenter.** High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): **Kim DH.** Poster presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Dec 7 **Presenter.** Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): **Kim DH.** Poster presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Dec 7 **Presenter.** The 17-Genes Leukemic Stemness Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): **Kim DH.** Poster presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Dec 7 **Presenter.** Risk Factors for Primary and Secondary Graft Failure in Allogeneic Hematopoietic Cell Transplantation: A Single Center Study. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): **Kim DH.** Poster presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Dec 7 **Presenter.** Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneic hematopoietic Cell Transplantation to Predict Outcomes. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): **Kim DH.** Oral presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.

- 2019 Dec 7 **Presenter.** Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. 61st Annual Meeting and Exposition of American Society of Hematology. Orlando, Florida, United States. Presenter(s): **Kim DH.** Poster presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Dec 7 **Presenter.** Reduced Intensity Conditioning and Dual T-Cell Modulation Improves GVHD Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): **Kim DH.** Poster presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Dec 7 **Presenter.** Patient Age and Donor HLA Matching Can Stratify Allogeneic Hematopoietic Cell Transplantation (HCT) Patients into Prognostic Groups: A Collaborative Study. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): **Kim DH.** Poster presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Dec 7 **Presenter.** Improved GVHD Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): **Kim DH.** Poster presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Dec 7 **Presenter.** BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): **Kim DH.** Poster presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Dec 7 **Presenter.** The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): **Kim DH.** Poster presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Dec 7 **Presenter.** Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt. 61st Annual Meeting and Exposition of American Society of Hematology (ASH). Orlando, Florida, United States. Presenter(s): **Kim DH.** Poster presentation. The American Society of Hematology (ASH) 61st annual meeting December 7-10, 2019.
- 2019 Sep 12 **Presenter.** Doubling time after first attempt of Imatinib discontinuation is helpful to identify the best candidate for the second attempt for treatment-free remission with dasatinib: Canadian TRAD trial. ESH-CML 2019. Bordeaux, France. Presenter(s): **Kim DH.** September 12-15.
- 2019 Sep 12 **Presenter.** Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt. ESH-CML 2019. Bordeaux, France. Presenter(s): **Kim DH.** September 12-15.
- 2019 Jun 13 **Presenter.** Allogeneic Hematopoietic cell transplantation can abrogate increasing risk of relapse from persistent mutations measured by targeted sequencing at remission in normal karyotype acute myeloid leukemia. 24th Congress of European Hematology Association. Amsterdam, Netherlands. Presenter(s): **Kim DH.** Oral presentation.
- 2019 Mar 14 **Presenter.** RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor AML. 2019 Korean Society of Hematology International Conference and 60th Annual Meeting. Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic Of. Presenter(s): **Kim DH.** Oral presentation.
- 2018 Sep 13 **Presenter.** Molecular milestones using the BCR-ABL1 qPCR level and doubling time (DT) after imatinib discontinuation to predict successful treatment-free remission: Treatment-free Remission Accomplished by Dasatinib (TRAD) trial. ESH-CML 2018. Miami, Florida, United States. Presenter(s): **Kim DH.**

Dennis Dong Hwan KIM

- 2018 Sep 13 **Presenter.** HMGCLL1 is a predictive germline biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. ESH-CML 2018. Miami, Florida, United States. Presenter(s): **Kim DH.**
- 2018 Jun 14 **Presenter.** The Value of BCR-ABL1 QPCR Level and Doubling Time (DT) to Predict Successful Treatment-Free Remission After Imatinib Discontinuation: Treatment-Free Remission Accomplished By Dasatinib (TRAD Trial. 23rd Congress of European Hematology Association (EHA). Stockholms län [SE-01], Sweden. Presenter(s): **Kim DH.**
- 2018 Jun 14 **Presenter.** Comparison of Mutation Dynamics in Higher Risk Myelodysplastic Syndrome Patients Treated with Azacitidine and Decitabine. 23rd Congress of European Hematology Association (EHA). Stockholms län [SE-01], Sweden. Presenter(s): **Kim DH.**
- 2018 Jun 14 **Presenter.** Longitudinal Genomic and Transcriptomic Tracking of Core Binding Factor Acute Myeloid Leukemia. 23rd Congress of European Hematology Association (EHA). Stockholms län [SE-01], Sweden. Presenter(s): **Kim DH.**
- 2018 Mar 29 **Presenter.** Comprehensive Genomic Analyses of Core-Binding Factor AML From Serial Samples. ICKSH International Conference of Korean Society of Hematology. Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic Of. Presenter(s): **Kim DH.**
- 2016 Sep 16 **Presenter.** Dynamic spectrum of somatic mutations in response to Dennis Dong Hwan Kim. 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy. Texas, United States. Presenter(s): **Kim DH.** (Trainee Presentation).
- 2014 Dec 8 **Presenter.** Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Dennis **D. Kim**, Isabelle Bence-Bruckler, Christopher M. Hillis, Irwin Walker, Suzanne Kamel-Reid, and Jeffrey H. Lipton. as a first author.
- 2013 Apr **Presenter.** Impact of NIH global scoring system of chronic graft-versus-host disease on relapse incidence. 33th Annual meeting of European Group of Bone Marrow Transplantation. Londong, United Kingdom. Presenter(s): Joon Ho Moon*, Sang Kyun Sohn, Jieun Uhm, Vikas Gupta, Jeffrey Lipton, Hans Messner, **Dennis Kim.** One of the prizes for the best poster presentations. (Trainee Presentation).
- 2011 Oct **Presenter.** Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype. European School of Hematology: Molecular in acute myeloid leukemia. Mandelieu, France. Presenter(s): **Kim DH.** [Poster presentation].
- 2011 Sep **Presenter.** Genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. 13th International Conference: Chronic myeloid leukemia. Estoril, Portugal. Presenter(s): **Kim DH.** [Poster presentation].
- 2010 Sep **Presenter.** Genome-wide single-nucleotide polymorphism-array based karyotyping detects clonal aberrations, and predicts the risk of imatinib failure in chronic myeloid leukemia. 12th International Conference: Chronic myeloid leukemia. Washington DC, District of Columbia, United States. Presenter(s): **Kim DH.** [Poster presentation].
- 2010 Sep **Presenter.** Multicenter retrospective study on the development of peripheral lymphocytosis during second-line dasatinib therapy for chronic myeloid leukemia. 12th International Conference: Chronic myeloid leukemia. Washington DC, District of Columbia, United States. Presenter(s): **Kim DH.** [Poster presentation].
- 2010 Sep **Speaker.** IFN- γ (interferon-gamma) genotype predict cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. 12th International Conference: Chronic myeloid leukemia. Washington DC, District of Columbia, United States. Presenter(s): **Kim DH.** [Brief oral presentation].
- 2009 Oct **Presenter.** Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Annual meeting of American Society of Human Genetics. Honolulu, Hawaii, United States. Presenter(s): **Kim DH.** [Poster presentation].

- 2009 Sep **Speaker.** Addition of hemoglobin level into the prognostic scoring system together with white blood cell and platelet count provides better prognostic stratification for treatment-related mortality and overall survival, but not for relapse risk in adult patients with acute promyelocytic leukemia. 5th International Symposium on Acute Promyelocytic Leukemia. Rome, Italy. Presenter(s): **Kim DH.** [Simultaneous communication].
- 2009 Sep **Presenter.** No impact of PML/RAR α isoform subtype on clinical outcomes following Idarubicin/all-trans-retinoic acid based combination chemotherapy for acute promyelocytic leukemia. 5th International Symposium on Acute Promyelocytic Leukemia. Rome, Italy. Presenter(s): **Kim DH.** [Poster presentation].
- 2009 Sep **Presenter.** Comprehensive evaluation of time-to-response parameter as a predictor of long-term outcomes following imatinib therapy in chronic phase chronic myeloid leukemia. 11th International Conference: Chronic Myeloid Leukemia: Biological Basis of Therapy. Bordeaux, France. Presenter(s): **Kim DH.** [Poster presentation].
- 2007 Nov **Speaker.** Vascular endothelial growth factor (VEGFA) gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: Preventive effect of VEGF on acute GVHD. European School of Hematology: Translational Research in Transplantation. Leiden, Netherlands. Presenter(s): **Kim DH.** [Simultaneous communication] Scholarship awarded.

Presented and Published Abstracts

- 2021 Dec 11 **Presenter.** Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults. 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Maria Queralt Salas, Eshetu G Atenafu, Eshrak Al-Shaibani, Ora Bascom, Leeann Wilson, Carol Chen, Ivan Pasic, Arjun Law, Wilson Lam, **Dennis Dong Hwan Kim**, Armin Gerbitz, Auro Viswabandya, Jeffrey H Lipton, Fotios Michelis, Jonas Mattsson, Shabbir Alibhai, Rajat Kumar. Oral Presentation #110, December 11-14, 2021.
- Publication Details:*
Salas MQ, Atenafu EG, Al-Shaibani E, Bascom O, Wilson L, Chen C, Pasic I, Law A, Lam W, **Kim DDH**, Gerbitz A, Viswabandya A, Lipton JH, Michelis F, Mattsson J, Alibhai S, Rajat Kumar R. Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults. Blood. 2021 Nov 23;138(Suppl 1):110. **Coauthor or Collaborator.**
- 2021 Dec 11 **Presenter.** Propensity Score Matching Analysis Comparing Ruxolitinib Vs Historical Controls in 2nd Line or Beyond Treatment for Chronic Gvhd after Therapy Failure. 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Igor Novitzky-Basso, Swe Mar Linn, Jennifer White, Mohamed Elemery, Anargyros Xenocostas, Nada Hamad, Sui Tan, Samantha Culos, Arjun Law, **Dennis Dong Hwan Kim.** Poster Presentation #1805, December 11-14, 2021.
- Publication Details:*
Novitzky-Basso I, Linn SM, White J, Elemery M, Xenocostas A, Hamad N, Tan S, Culos S, Law A, **Kim DDH.** Propensity Score Matching Analysis Comparing Ruxolitinib Vs Historical Controls in 2nd Line or Beyond Treatment for Chronic Gvhd after Therapy Failure. Blood. 2021 Nov 23;138(Suppl 1):1805. **Senior Responsible Author.**
- 2021 Dec 11 **Presenter.** Single Centre, Retrospective Analysis of Extracorporeal Photopheresis (ECP) Therapy in the Patients Who Are Heavily Pre-Treated for Steroid Resistant Chronic Graft-Versus-Host Disease (GVHD). 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Swe Mar Linn, Igor Novitzky-Basso, Christopher J. Patriquin, Ivan Pasic, Wilson Lam, Arjun Law, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey H Lipton, Rajat Kumar, Jonas Mattsson, David Barth, **Dennis Dong Hwan Kim.** Poster Presentation #1806, December 11-14, 2021.
- Publication Details:*
Linn SM, Novitzky-Basso I, Patriquin CJ, Pasic I, Lam W, Law A, Michelis F, Gerbitz A, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Barth D, **Kim DDH.** Single Centre, Retrospective Analysis of

Extracorporeal Photopheresis (ECP) Therapy in the Patients Who Are Heavily Pre-Treated for Steroid Resistant Chronic Graft-Versus-Host Disease (GVHD). *Blood*. 2021 Nov 23;138(Suppl 1):1806. **Senior Responsible Author.**

2021 Dec 11 **Presenter.** ATG and Post-Transplant Cyclophosphamide Predisposes to Inferior Outcome When Using Cryopreserved Stem Cell Grafts. 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Igor Novitzky-Basso, Mats Remberger, Carol Chen, Ivan Pasic, Wilson Lam, Arjun Law, Armin Gerbitz, Auro Viswabandya, Jeffrey H Lipton, **Dennis Dong Hwan Kim**, Rajat Kumar, Jonas Mattsson, Fotios Michelis. (Oral Presentation #479). December 11-14, 2021.

Publication Details:

Novitzky-Basso I, Remberger M, Chen C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, **Kim DDH**, Kumar R, Mattsson J, Michelis F. ATG and Post-Transplant Cyclophosphamide Predisposes to Inferior Outcome When Using Cryopreserved Stem Cell Grafts. *Blood*. 2021 Nov 23;138(Suppl 1):479. **Coauthor or Collaborator.**

2021 Dec 11 **Presenter.** Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival. 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Jennifer White, Mohamed Elemery, Swe Mar Linn, Igor Novitzky-Basso, Anargyros Xenocostas, Nada Hamad, Samantha Culos, Sui Tan, Arjun Law, Rajat Kumar, Jonas Mattsson, **Dennis Dong Hwan Kim**. Poster Presentation #3905, December 11-14, 2021.

Publication Details:

White J, Elemery M, Linn SM, Novitzky-Basso I, Xenocostas A, Hamad N, Culos S, Tan S, Law A, Kumar R, Mattsson J, **Kim DDH**. Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival. *Blood*. 2021 Nov 23;138(Suppl 1):3905. **Senior Responsible Author.**

2021 Dec 11 **Presenter.** Propensity Score Matching Analysis Comparing Extracorporeal Photopheresis (ECP) vs Best Available Therapy in Third Line or Later Treatment of Chronic Graft-Versus-Host Disease (cGVHD). 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Swe Mar Linn, Igor Novitzky-Basso, Elizabeth Shin, Christopher J. Patriquin, Ivan Pasic, Wilson Lam, Arjun Law, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey H Lipton, Rajat Kumar, Jonas Mattsson, David Barth, **Dennis Dong Hwan Kim**. Poster Presentation #3896, December 11-14, 2021.

Publication Details:

Linn SM, Novitzky-Basso I, Shin E, Patriquin CJ, Pasic I, Lam W, Law A, Michelis F, Gerbitz A, Viswabandya A, Lipton JH, Kumar R, Mattsson J, Barth D, **Kim DDH**. Propensity Score Matching Analysis Comparing Extracorporeal Photopheresis (ECP) vs Best Available Therapy in Third Line or Later Treatment of Chronic Graft-Versus-Host Disease (cGVHD). *Blood*. 2021 Nov 23;138(Suppl 1):3896. **Senior Responsible Author.**

2021 Dec 11 **Presenter.** Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience. 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Eshrak Al-Shaibani, Shiyi Chen, Wilson Lam, Arjun Law, Ivan Pasic, Fotios Michelis, Auro Viswabandya, **Dennis Dong Hwan Kim**, Armin Gerbitz, Jeffrey H Lipton, Jonas Mattsson, Rajat Kumar. Poster Presentation #4122, December 11-14, 2021.

Publication Details:

Al-Shaibani E, Chen S, Lam W, Law A, Pasic I, Michelis F, Viswabandya A, **Kim DDH**, Gerbitz A, Lipton JH, Mattsson J, Kumar R. Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience. *Blood*. 2021 Nov 23;138(Suppl 1):4122.

Coauthor or Collaborator.

2021 Dec 11 **Presenter.** Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥ 2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks. 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Michael J. Mauro, Yosuke Minami, Delphine Rea, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna G. Turkina, Dong-Wook Kim, Jane F Apperley, Jorge E. Cortes, Andre N.R. Abdo, Laura Fogliatto, **Dennis Dong Hwan Kim**, Philipp D le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín Garcia Gutierrez, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Carla Boquimpani. Oral Presentation #310, December 11-14, 2021.

Publication Details:

Mauro MJ, Minami Y, Rea D, Hochhaus A, Lomaia E, Voloshin S, Turkina AG, Kim DW, Apperley JF, Cortes JE, Abdo ANR, Fogliatto L, **Kim DH**, le Coutre PD, Saussele S, Annunziata M, Hughes TP, Chaudhri NA, Chee LCY, Garcia Gutierrez V, Sasaki K, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Boquimpani C. Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥ 2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks. Blood. 2021 Nov 23;138(Suppl 1):310. **Coauthor or Collaborator.**

2021 Dec 11 **Presenter.** Single-Cell Proteogenomic Sequencing Allows Early Detection of Relapse Clone with CN-LOH at FLT3-ITD Locus from Initial Diagnosis in AML. 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Taehyung Kim, Hyewon Lee, Jose-Mario Capo-Chichi, Myung Hee Chang, Young Seok Yoo, Gurbaksh Basi, Troy Ketela, Adam C. Smith, Anne Tierens, Mark D. Minden, Zhaolei Zhang, **Dennis Dong Hwan Kim**. Oral and Poster Abstracts #3428, December 11-14, 2021.

Publication Details:

Kim T, Lee H, Capo-Chichi JM, Chang MH, Yoo YS, Basi G, Ketela T, Smith AC, Tierens A, Minden MD, Zhang Z, **Kim DDH**. Single-Cell Proteogenomic Sequencing Allows Early Detection of Relapse Clone with CN-LOH at FLT3-ITD Locus from Initial Diagnosis in AML. Blood. 2021 Nov 23;138(Suppl 1):3428. **Senior Responsible Author.**

2021 Dec 11 **Presenter.** Variant Allele Frequency Status in Elderly Patients with Acute Myeloid Leukemia Can be Early Predictors of Responsiveness to Decitabine Treatment. 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Mihee Kim, Taehyung Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Ga-Young Song, Deok-Hwan Yang, Je-Jung Lee, Seunghyun Choi, MiYeon Kim, Jae-Sook Ahn, Hyeoung-Joon Kim, **Dennis Dong Hwan Kim**. Oral and Poster Abstracts #3450, December 11-14, 2021.

Publication Details:

Kim M, Kim T, Ahn SY, Jung SH, Song GY, Yang DH, Lee JJ, Choi S, Kim MY, Ahn JS, Kim HJ, **Kim DDH**. Variant Allele Frequency Status in Elderly Patients with Acute Myeloid Leukemia Can be Early Predictors of Responsiveness to Decitabine Treatment. Blood. 2021 Nov 23;138(Suppl 1):3450. **Senior Responsible Author.**

2021 Dec 11 **Presenter.** A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy. 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Fatima Khadadah, Anargyros Xenocostas, Lambert Busque, Kareem Jamani, Sonia Cerquozzi, Philip Kuruvilla, Brian Leber, Rayan Kaedbey, Sarit Assouline, **Dennis Dong Hwan Kim**. Oral and Poster Presentation #3610, December 11-14, 2021.

Publication Details:

Khadadah F, Xenocostas A, Busque L, Jamani K, Cerquozzi S, Kuruvilla P, Leber B, Kaedbey R, Assouline S, **Kim DDH**. A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy. Blood.

2021 Nov 23;138(Suppl 1):3610. **Senior Responsible Author.**

2021 Dec 11 **Presenter.** Myelodysplastic Syndromes: A More Global 5-Hydroxymethylcytosine Deficiency Disorder Than Suggested By the Presence of TET2 Mutations. 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Atlanta, Georgia, United States. Presenter(s): Carmelo Gurnari, Simona Pagliuca, Yihong Guan, Courtney E. Hershberger, Ying Ni, Jaymeson Gordon, Hetty E. Carraway, Richard A Padgett, Diego Coutinho, Ilana Zalcborg, Jae-Sook Ahn, Hyeoung-Joon Kim, **Dennis Dong Hwan Kim, Sr.**, Mark D. Minden, Joop H. Jansen, Babal K. Jha, Torsten Haferlach, Jaroslaw P. Maciejewski, Valeria Visconte. Oral and Poster Presentation #3665, December 11-14, 2021.

Publication Details:

Gurnari C, Pagliuca S, Guan Y, Hershberger CE, Ni Y, Gordon J, Carraway HE, Padgett RA, Coutinho D, Zalcborg I, Ahn JS, KimHJ, **Kim DDH**, Minden MD, Jansen JH, Jha BK, Haferlach T, Maciejewski JP, Visconte V. Myelodysplastic Syndromes: A More Global 5-Hydroxymethylcytosine Deficiency Disorder Than Suggested By the Presence of TET2 Mutations. Blood. 2021 Nov 23;138(Suppl 1):3665. **Coauthor or Collaborator.**

2021 Jun 9 **Presenter.** Relationship of HLA Alleles and the Risk of Cytomegalovirus (CMV) Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation (ALLO-HSCT). 26th Congress of the European Hematology Association. Netherlands. Presenter(s): Shruti Prem, Mats Remberger, Wilson Lam, Ahmad Alotaibi, Rajat Kumar, Auro Viswabandya, Arjun Law, Fotios Michelis, Jeffrey Lipton, Jonas Mattsson, **Dennis Kim**, Cynthia Ellison. Poster Presentation #EP1261, June 9-17, 2021. (Trainee Presentation)

Publication Details:

Prem S, Remberger M, Lam W, Alotaibi A, Kumar R, Viswabandya A, Law A, Michelis F, Lipton J, Mattsson J, **Kim D**, Ellison C. Relationship of HLA Alleles and the Risk of Cytomegalovirus (CMV) Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation (ALLO-HSCT). HemaSphere. 2021;5(Suppl 2):608-609. **Coauthor or Collaborator.**

2021 Mar 14 **Presenter.** Impact of Fluoroquinolone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation - EBMT (Virtual). Madrid, Spain. Presenter(s): Presenter(s): Eshrak Al-Shaibani, Zoe Evans, Kayla Madsen, Shiyi Chen, Carol Chen, Ivan Pasic, Wilson Lam, Arjun Law, Fotios V. Michelis, Armin Gerbitz, Dennis D. Kim, Rajat Kumar, Jeffrey H Lipton, Jonas Mattsson, Shahid Husain, Zeyad Al-Shaibani, Auro Viswabandya. The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation - EBMT (Virtual), March 14-27, 2021 (Oral Presentation #O088).

Publication Details:

Al-Shaibani E, Evans Z, Madsen K, Chen S, Chen C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, **Kim DD**, Kumar R, Lipton JH, Mattsson J, Husain S, Al-Shaibani Z, Viswabandya A. Impact of Fluoroquinolone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. Bone Marrow Transplantation. 56(21):183. Impact of Fluoroquinolone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. Abstr O088. **Coauthor or Collaborator.**

2021 Mar 14 **Presenter.** Outcome of Allogenic Stem Cell Transplantation in Elderly Patients: A Single Center Study. The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation - EBMT (Virtual). Madrid, Spain. Presenter(s): Presenter(s): Eshrak Al-Shaibani, Shiyi Chen, Wilson Lam, Arjun Law, Ivan Pasic, Fotios V. Michelis, Auro Viswabandya, Dennis D. Kim, Armin Gerbitz, Jeffrey H Lipton, Jonas Mattsson, Rajat Kumar. The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation - EBMT (Virtual), March 14-27, 2021 (Oral Presentation #P067).

Publication Details:

Al-Shaibani E, Chen S, Wilson W, Law A, Pasic I, Michelis FV, Viswabandya A, **Kim DD**, Gerbitz A, Lipton JH, Mattsson J, Kumar R. Outcome of Allogenic Stem Cell Transplantation in Elderly Patients: A Single Center Study. Bone Marrow Transplantation. 56(21):184-335. Outcome of Allogenic Stem Cell Transplantation in Elderly Patients: A Single Center Study. Abstr P067. <https://doi.org/10.1038/s41409-021-01343-5>. **Coauthor or Collaborator.**

2021 Feb 8 **Presenter.** Weight Loss after Allogeneic Stem Cell Transplantation is Associated with Increased Mortality. 2021 TCT Meetings Of ASTCT & CIBMTR (Online Program). Salt Lake, Utah, United States. Presenter(s): Katherine Lee, Kayla Madsen, Shiyi Chen, Arjun Datt Law, Armin Gerbitz, Rajat Kumar, Dennis D Kim, Wilson Lam, Fotios V Michelis, Ivan Pasic, Auro Viswabandya, Jeffrey H Lipton, Jonas Mattsson. (Poster Presentation #198). 2021 TCT Meetings of ASTCT and CIBMTR, February 8-12, 2021 (Virtual).

Publication Details:

Lee, K, Madsen K, Chen S, Law AD, Gerbitz A, Kumar R, **Kim DD**, Lam WL, Michelis FV, Pasic I, Viswabandya A, Lipton JH, Mattsson J. Weight Loss after Allogeneic Stem Cell Transplantation is Associated with Increased Mortality. Transplantation and Cellular Therapy. 27(3 (Suppl)):S181-S182. Weight Loss after Allogeneic Stem Cell Transplantation is Associated with Increased Mortality. Abstr 198. **Coauthor or Collaborator.**

2021 Feb 8 **Presenter.** Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid- Refractory or Dependent Chronic GVHD – a Multicentre Phase II Clinical Trial (CARE Trial). 2021 TCT Meetings Of ASTCT & CIBMTR (Online Program). Salt Lake, Utah, United States. Presenter(s): Imran Ahmad, Janetta Bijl, Sabine Ivison, Eshetu G. Atenafu, Tony Panzarella, Raewyn Broady, David Szwajcer, Irwin Walker, Dennis D Kim, Christopher Bredeson, Ronan Foley, Donna E. Hogge, David Allan, Jean-Sébastien Delisle, Kirk Schultz, Donna A. Wall, Megan Levings, Denis-Claude Roy. 2021 TCT Meetings of ASTCT and CIBMTR (Virtual), February 8-12, 2021. (Poster Presentation #338).

Publication Details:

Ahmad I, Bijl J, Ivison S, Atenafu EG, Panzarella T, Broady R, Szwajcer D, Walker I, **Kim DD**, Christopher C, Foley R, Hogge DE, Allan D, Delisle J-S, Schultz K, Wall DA, Levings M, Roy D-C. Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid- Refractory or Dependent Chronic GVHD – a Multicentre Phase II Clinical Trial (CARE Trial). Transplantation and Cellular Therapy. 27(3 (Suppl)):S285. Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid- Refractory or Dependent Chronic GVHD – a Multicentre Phase II Clinical Trial (CARE Trial). Abstr 338. **Coauthor or Collaborator.**

2020 Aug 3 CONTINUOUS ALLOREACTIVE T CELL DEPLETION AND REGULATORY T CELL EXPANSION FOR THE TREATMENT OF STEROID- REFRACTORY OR DEPENDENT CHRONIC GVHD - A MULTICENTRE PHASE II CLINICAL TRIAL (THE CARE TRIAL).

Publication Details:

Imran Ahmad¹, Janetta Bijl¹, Eshetu Atenafu², Tony Panzarella², Raewyn Broady³, David Szwajcer⁴, Irwin Walker⁵, Dennis Kim², Chris Bredeson⁶, Ronan Foley⁵, Donna Hogge³, David Allan⁶, Jean-Sébastien Delisle¹, Megan Levings³, Kirk Schultz³, Donna Wall², Denis-Claude Roy. CONTINUOUS ALLOREACTIVE T CELL DEPLETION AND REGULATORY T CELL EXPANSION FOR THE TREATMENT OF STEROID- REFRACTORY OR DEPENDENT CHRONIC GVHD - A MULTICENTRE PHASE II CLINICAL TRIAL (THE CARE TRIAL). CTTC. **Coauthor or Collaborator.**

2018 Dec 3 **Co-Presenter.** A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-Mutated AML. 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). San Diego, California, United States. Presenter(s): **Dennis Kim.** Co-Presenter, oral presentation
Disease site: Allo BMT.

Publication Details:

A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-Mutated AML.

2018 Dec 3 **Presenter.** Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature as a High Risk Profile for Leukemic Transformation. 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). San Diego, California, United States. Presenter(s): **Dennis Kim.** Poster presentation

Dennis Dong Hwan KIM

Disease site: Leukemia.

Publication Details:

Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature as a High Risk Profile for Leukemic Transformation. **Senior Responsible Author.**

2018 Dec 2 Early Prediction of Stable MR by Achievement of 2.8 Log Reduction in BCR-ABL1 qPCR Levels at 6 Months in Patients with Chronic Myeloid Leukemia Treated with Frontline Imatinib. 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). San Diego, California, United States. Presenter(s): Aisling Nee. Poster presentation
Disease site: Leukemia.

Publication Details:

Early Prediction of Stable MR by Achievement of 2.8 Log Reduction in BCR-ABL1 qPCR Levels at 6 Months in Patients with Chronic Myeloid Leukemia Treated with Frontline Imatinib. **Senior Responsible Author.**

2018 Dec 2 Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Nodel Provides Stratification of Patients According to Probability of SIS Discontinuation. 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). San Diego, California, United States. Presenter(s): Rhida Bautista. Poster presentation
Disease site: Allo BMT.

Publication Details:

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Nodel Provides Stratification of Patients According to Probability of SIS Discontinuation. **Senior Responsible Author.**

2018 Dec 2 RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML). 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). San Diego, California, United States. Presenter(s): TaeHyung **Kim**. Winner of ASH abstract achievement award. Poster presentation at the 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018) taking place on December 1-3, 2018, San Diego, CA
Disease site: Leukemia.

Publication Details:

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML). **Senior Responsible Author.**

2018 Dec 1 Residual Allelic Burden Measured by Nex-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML). 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). San Diego, California, United States. Presenter(s): TaeHyung **Kim**. Winner of ASH abstract achievement award. Poster presentation at the 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018) taking place on December 1-3, 2018
Disease site: Leukemia.

Publication Details:

Residual Allelic Burden Measured by Nex-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML). **Senior Responsible Author.**

2018 Dec 1 **Presenter.** Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished by Dasatinib (TRAD) Trial. 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). San Diego, California,

Dennis Dong Hwan KIM

United States. Presenter(s): **Dennis Kim**. Oral presentation at the 60th ASH Annual Meeting and Exposition (ASH 2018) taking place on December 1-3, 2018, San Diego, CA
Disease site: Leukemia.

Publication Details:

Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished by Dasatinib (TRAD) Trial.

2018 Dec 1 High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate Following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not. 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). San Diego, California, United States. Presenter(s): Warren Fingrut. Winner of ASH abstract achievement award
Disease site: Allo BMT
Poster presentation at the 60th American Society of Hematology Annual Meeting & Exposition (ASH 2018) taking place on December 1-3, 2018, San Diego, CA.

Publication Details:

High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate Following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not. **Senior Responsible Author**.

2018 Dec 1 Comparisons of the impact of pre-transplant co-morbidity scores on the allogeneic bone marrow transplant. 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). San Diego, California, United States. Presenter(s): Mohammed Marei. Poster presentation
Disease site: Allo BMT.

Publication Details:

Comparisons of the impact of pre-transplant co-morbidity scores on the allogeneic bone marrow transplant. **Senior Responsible Author**.

2018 Mar 18 High Risk of Relapse with High Mutation Burden at Day 21 Post-Transplant Can Be Overcome By Chronic GVHD in Patients with AML. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2018). Lisbon, Portugal. Presenter(s): Joon-Ho Moon. Poster presentation at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2018) taking place on March 18-21 2018, Lisbon, Portugal. (Trainee Presentation)

Publication Details:

High Risk of Relapse with High Mutation Burden at Day 21 Post-Transplant Can Be Overcome By Chronic GVHD in Patients with AML. **Senior Responsible Author**.

2018 Mar 18 Influence of FLT3-ITD and NPM1 Status on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Cytogenetically Normal AML. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2018). Lisbon, Portugal. Presenter(s): Ivan Pasic. Poster presentation at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2018) taking place on March 18-21 2018, Lisbon, Portugal. (Trainee Presentation)

Publication Details:

Influence of FLT3-ITD and NPM1 Status on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Cytogenetically Normal AML. **Coauthor or Collaborator**.

2018 Mar 18 The Prognostic Impact of Serum Ferritin Level at Time of Diagnosis of Chronic Graft-Versus-Host Disease on Survival and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2018). Lisbon, Portugal. Presenter(s): Warren Fingrut. Poster presentation at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2018) taking place on March 18-21 2018, Lisbon, Portugal. (Trainee Presentation)

Publication Details:

The Prognostic Impact of Serum Ferritin Level at Time of Diagnosis of Chronic Graft-Versus-Host Disease on Survival and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation. **Senior Responsible Author.**

2018 Mar 18 Reduced Intensity Conditioning and Dual T-Cell Suppression with Anti-Thymocyte Globulin and Post Transplant Cyclophosphamide for the Prophylaxis of Graft Versus Host Disease in Haploidentical Stem Cell Transplants for Hematological Malignancies. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2018). Lisbon, Portugal. Presenter(s): Queralt Salas Gay. Poster presentation at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2018) taking place on March 18-21 2018, Lisbon, Portugal. (Trainee Presentation)

Publication Details:

Reduced Intensity Conditioning and Dual T-Cell Suppression with Anti-Thymocyte Globulin and Post Transplant Cyclophosphamide for the Prophylaxis of Graft Versus Host Disease in Haploidentical Stem Cell Transplants for Hematological Malignancies. **Coauthor or Collaborator.**

2018 Mar 18 Low rates of acute and chronic GVHD using a combination of ATG and PTCy for GVHD prophylaxis in MUD transplants for hematological malignancies-a single centre experience. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2018). Lisbon, Portugal. Presenter(s): Shruti P. Poster presentation at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2018) taking place on March 18-21 2018, Lisbon, Portugal. (Trainee Presentation)

Publication Details:

Low rates of acute and chronic GVHD using a combination of ATG and PTCy for GVHD prophylaxis in MUD transplants for hematological malignancies-a single centre experience. **Coauthor or Collaborator.**

2017 Dec 11 Clinical and genetic relevance of somatic mutations in core binding factor (CBF) acute myeloid leukemia (AML) patients using serial sequencing. 59th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): **Kim**, Taehyung. (Presenter - Poster). Dec 8-12 ASH.

Publication Details:

Taehyung **Kim**, Joon Ho Moon, Jae-Sook Ahn, Marc S. Tyndel, Yeo-Kyeong Kim, Seung-Shin Lee, Seo-Yeon Ahn, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Seunghyun Choi, Yoojin Lee, Sang Kyun Sohn, Yoo Hong Min, June-Won Cheong, Hyeong-Joon Kim, Zhaolei Zhang, and Dennis (Dong-Hwang) Kim. Clinical and genetic relevance of somatic mutations in core binding factor (CBF) acute myeloid leukemia (AML) patients using serial sequencing. Blood. 2017;130(Suppl 1):3955. **Senior Responsible Author.**

2017 Dec 10 Dasatinib induced reversible nephrotic range proteinuria occurs more frequently compared to other tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. 59th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Alahmari, Ali. (Presenter - Poster). Dec 8-12 ASH.

Publication Details:

Ali Alahmari, Jeffrey H. Lipton, and **Dennis Kim**. Dasatinib induced reversible nephrotic range proteinuria occurs more frequently compared to other tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Blood. 2017;130(Suppl 1):2880. **Senior Responsible Author.**

2017 Dec 9 Next generation sequencing (NGS)-based post-transplant monitoring in acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation (HCT). 59th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): **Kim**, Taehyung. (Presenter - Oral). Dec 8-12 ASH.

Publication Details:

Taehyung **Kim**, Joon Ho Moon, Jae-Sook Ahn, Marc S. Tyndel, Yeo-Kyeong Kim, Seung-Shin Lee, Seo-Yeon Ahn, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Seunghyun Choi, Myung-Geun Shin, Hoon Kook, Sun-Hee Kim, Seong Kyu Park, Hyeong-Joon Kim, Zhaolei Zhang, and Dennis (Dong-Hwang) Kim. Next generation sequencing (NGS)-based post-transplant monitoring in acute myeloid leukemia

patients receiving allogeneic hematopoietic stem cell transplantation (HCT). Blood. 130(Suppl 1):271. **Senior Responsible Author.**

2017 Dec 9 Pre-transplant pulmonary function test parameters of FEF50% (Forced expiratory flow at 50% of forced vital capacity) and RV (residual volume) in combination can predict the risk for development of chronic graft-versus-host disease after allogeneic stem cell transplantation. 59th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Lam, Wilson. (Presenter - Poster). Dec 8-12 ASH.

Publication Details:

Wilson Lam, Arjun Datt Law, Fotios V. Michelis, Santhosh Thyagu, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, Theodore Marras, Shikha Mittoo, and **Dennis Kim**. Pre-transplant pulmonary function test parameters of FEF50% (Forced expiratory flow at 50% of forced vital capacity) and RV (residual volume) in combination can predict the risk for development of chronic graft-versus-host disease after allogeneic stem cell transplantation. Blood. 2017;130(Suppl 1):1973. **Senior Responsible Author.**

2017 Dec 9 Dynamics of genome wide methylation profiling in response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. 59th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Liao, Shun. (Presenter - Poster). Dec 8-12 ASH.

Publication Details:

Shun Liao, Taehyung Kim, Hyeoung-Joon Kim, Jae-Sook Ahn, Jaehyuk Choi, Yeo-Kyeong Kim, Yoon-Sang Kim, Seung-Shin Lee, Zhaolei Zhang, and **Dennis Kim**. Dynamics of genome wide methylation profiling in response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood. 2017;130(Suppl 1):1599. **Senior Responsible Author.**

2017 Oct 5 Clinical significance of secondary-type mutations in myelodysplastic syndrome and acute myeloid leukemia treated with Decitabine. ESH - 4th International Conference on Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment. Estoril, Portugal. Presenter(s): **Kim**, Taehyung. (Presenter - Poster #1). Oct 5-7 ESH-AML.

Publication Details:

Clinical significance of secondary-type mutations in myelodysplastic syndrome and acute myeloid leukemia treated with Decitabine. **Senior Responsible Author.**

2017 Oct 5 Comprehensive genomic analyses of core-binding factor (CBF) AML using serial sequencing elucidate hierarchy of mutation acquisition order. ESH - 4th International Conference on Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment. Estoril, Portugal. Presenter(s): **Kim**, Taehyung. (Presenter - Poster #2). Oct 5-7 ESH-AML.

Publication Details:

Comprehensive genomic analyses of core-binding factor (CBF) AML using serial sequencing elucidate hierarchy of mutation acquisition order. **Senior Responsible Author.**

2017 Jun 24 Serial sequencing reveals clonal origins and strategies for early detection of post-allogeneic hematopoietic stem cell transplantation (HCT) relapse in acute myeloid leukemia (AML). 21st Congress of the European Hematology Association. Madrid, Spain. Presenter(s): Taehyung **Kim**. (Trainee Presentation)

Publication Details:

Serial sequencing reveals clonal origins and strategies for early detection of post-allogeneic hematopoietic stem cell transplantation (HCT) relapse in acute myeloid leukemia (AML). **Senior Responsible Author.**

2017 Mar 26 **Presenter.** Mutational pathway and dynamics may not be prognostic in patients with myelodysplastic syndrome receiving hypomethylating agent pre-treatment for allogeneic stem cell transplantation. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2017). Marseille, France. Presenter(s): JS Ahn. (Trainee Presentation)

Publication Details:

Mutational pathway and dynamics may not be prognostic in patients with myelodysplastic syndrome receiving hypomethylating agent pre-treatment for allogeneic stem cell transplantation.

2017 Mar 26 **Presenter.** Outcome following second allogeneic hematopoietic cell transplantation: a single centre experience. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2017). Marseille, France. Presenter(s): F Michelis. (Trainee Presentation)

Publication Details:

Outcome following second allogeneic hematopoietic cell transplantation: a single centre experience.

2016 Dec 5 **Presenter.** The Clonal Origins of Leukemic Progression of Myelodysplasia. 58th Annual Meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Taehyung Kim. (Trainee Presentation)

Publication Details:

Taehyung Kim, Marc Tyndel, Hyeoung Joon Kim, Jae-Sook Ahn, Seung Hyun Choi, Hee Jeong Park, Yeo-Kyeoung Kim, Deok-Hwan Yang, Je-Jung Lee, Sung-Hoon Jung, Soo Young Kim, Yoo-Hong Min, June-Won Cheong, Sang Kyun Sohn, Joon Ho Moon, Murim Choi, Moses Lee, Zhaolei Zhang, **Dennis Dong Hwan Kim.** The Clonal Origins of Leukemic Progression of Myelodysplasia. Blood. 2015 Dec:#4307. **Senior Responsible Author.**

2016 Dec 5 **Presenter.** Aside from the Allelic Burden of JAK2-V617F, Acquisition of Mutations in Myeloid Gene Panel Is Associated with the Transformation of Myeloproliferative Neoplasm into Secondary AML. 58th Annual Meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Meong Hi Son. (Trainee Presentation)

Publication Details:

Meong Hi Son, Taehyung Kim, Jae-Sook Ahn, Marc Tyndel, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Seung-Shin Lee, Seo-Yeon Ahn, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Hee Jeong Park, Seung Hyun Choi, Zhaolei Zhang, **Dennis Dong Hwan Kim.** Aside from the Allelic Burden of JAK2-V617F, Acquisition of Mutations in Myeloid Gene Panel Is Associated with the Transformation of Myeloproliferative Neoplasm into Secondary AML. Blood. 2015 Dec:#4281. **Senior Responsible Author.**

2016 Dec 5 **Presenter.** Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. 58th Annual Meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Silvia Park.

Publication Details:

Silvia Park, Choi Hangseok, Hee-Je Kim, Jae-Sook Ahn, Hyeoung Joon Kim, Sung-Hyun Kim⁶, Yeung-Chul Mun, Chul Won Jung, Dong Hwan Kim. Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. Blood. 2015 Dec:#1623. **Principal Author.**

2016 Dec 5 **Presenter.** Fludarabine/Busulfan Plus Low Dose TBI As Reduced Intensity Conditioning in Older Patients undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies. 58th Annual Meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Manar Khalil. (Trainee Presentation)

Publication Details:

Hans A. Messner, Jeffrey H. Lipton, **Dennis Dong Hwan Kim,** Auro Viswabandya, Santhosh Thyagu, Uday Deotare, Fotios V. Michelis. Fludarabine/Busulfan Plus Low Dose TBI As Reduced Intensity Conditioning in Older Patients undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies. Blood. 2015 Dec:#4652. **Coauthor or Collaborator.**

2016 Dec 4 **Presenter.** Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants. 58th Annual

Meeting of American Society of Hematology. San Diego, California, United States. (Trainee Presentation)

Publication Details:

Uday Deotare, David Loach, Fotios V. Michelis, Dennis D. Kim, Santhosh Thyagu, Jeffrey H. Lipton, Hans A. Messner, Auro Viswabandya. Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants. Blood. 2015 Dec:#3430. **Coauthor or Collaborator.**

2016 Dec 4 **Presenter.** Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype. 58th Annual Meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Taehyung **Kim.**

Publication Details:

TaeHyung Kim, Jae-Sook Ahn, Marc S Tyndel, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Seung-Shin Lee, Seo-Yeon Ahn, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Hee Jeong Park, Seung Hyun Choi, Chul Won Jung, Jun Ho Jang, Heeje Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Sung-Hyun Kim, Zhaolei Zhang, **Dennis Dong Hwan Kim.** Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype. Blood. 2015 Dec:#2876. **Senior Responsible Author.**

2016 Dec 3 **Presenter.** Failure to Achieve Early Molecular Milestone within 3 Months is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase inhibitor Failure. 58th Annual Meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): **Dennis Kim.**

Publication Details:

Dennis (Dong Hwan) **Kim,** Isabelle Bence-Bruckler, Donna Forrest, Lynn Savoie, Stephen Couban, Lambert Busque, Robert Delage, Pierre Laneuville, Elena Liew, Anargyros Xenocostas, Kristjan Paulson, Suzanne Kamel-Reid, Jeffrey H. Lipton, Brian Leber13. Failure to Achieve Early Molecular Milestone within 3 Months is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase inhibitor Failure. Blood. 2015 Dec:#1922. **Principal Author.**

2016 Dec 3 **Presenter.** Comprehensive Analysis of Pre-Transplant Pulmonary Function Test Parameters Including FEV1, FVC, DLco, FEF50%/75%, Frc, RV and TLC As Prognostic Factors for Long-Term Outcomes after Allogeneic Transplantation. 58th Annual Meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Wilson Lam. (Trainee Presentation)

Publication Details:

Wilson Lam, Uday Deotare, Jeffrey H. Lipton, Theodore Marras, Hans A. Messner, Fotios V. Michelis, Shikha Mittoo, Santhosh Thyagu, Auro Viswabandya, **Dennis Dong Hwan Kim.** Comprehensive Analysis of Pre-Transplant Pulmonary Function Test Parameters Including FEV1, FVC, DLco, FEF50%/75%, Frc, RV and TLC As Prognostic Factors for Long-Term Outcomes after Allogeneic Transplantation. Blood. 2015 Dec:#2253. **Senior Responsible Author.**

2016 Dec 3 **Presenter.** Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. 58th Annual Meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Dennis (Dong Hwan) **Kim.**

Publication Details:

Dennis Dong Hwan Kim, Isabelle BenceBruckler, Donna L. Forrest, Mary Lynn Savoie, Stephen Couban, Lambert Busque, Robert Delage, Pierre Laneuville, Elena Liew, Anargyros Xenocostas, Kristjan Paulson, Suzanne KamelReid, Jeff H. Lipton, Brian Leber. Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. Blood. 2015 Dec:#1907. **Principal Author.**

2016 Dec 3 **Presenter.** Refined hepatic grading system including bilirubin and ALP levels at the onset of chronic GVHD, but not AST/ALT levels, improves risk stratification of long-term outcomes in the patients

developing chronic GVHD. 58th Annual Meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Saud AlHayfi. (Trainee Presentation)

Publication Details:

Saud Alhayli, Elizabeth Shin, Wilson Lam, Uday Deotare, Fotios V. Michelis, Santhosh Thyagu, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, **Dennis Dong Hwan Kim**. Refined hepatic grading system including bilirubin and ALP levels at the onset of chronic GVHD, but not AST/ALT levels, improves risk stratification of long-term outcomes in the patients developing chronic GVHD. Blood. 2015 Dec:#2235. **Senior Responsible Author**.

2016 Dec 3 **Speaker**. Longitudinal Tracking of MDS Patients Using Next Generation Sequencing Provides a Predictive Measure for Azacitidine Response and AML Progression. 58th Annual Meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Taehyung **Kim**. (Trainee Presentation)

Publication Details:

Taehyung Kim, Joon Ho Moon, Yoo Jin Lee, Marc Tyndel, Jae-Sook Ahn, Hyeoung-Joon Kim, Yeo-Kyeong Kim, Seung-Shin Lee, Seo-Yeon Ahn, Sung-Hoon Jung, Deok-Hwan Yang, Je-Jung Lee, Hee Jeong Park, Seung Hyun Choi, Chul Won Jung, Jun Ho Jang, Heeje Kim, Sang Kyun Sohn, Jong-Ho Won, Sung-Hyun Kim, Zhaolei Zhang, **Dennis Dong Hwan Kim**. Longitudinal Tracking of MDS Patients Using Next Generation Sequencing Provides a Predictive Measure for Azacitidine Response and AML Progression. Blood. 2015 Dec:#52. **Senior Responsible Author**.

2016 Jun 11 **Speaker**. Dynamics of Somatic Mutations Commonly detected in other myeloid neoplasms beyond the BCR-ABL gene rearrangement in response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. EHA Meeting. Denmark. Presenter(s): **Kim**, Taehyung. (Trainee Presentation)

Publication Details:

TaeHyung Kim, Marc S. Tyndel, Hyeoung Joon Kim, Jae-Sook Ahn, Seung Hyun Choi, Hee Jeong Park, Yeo-Kyeong Kim, Soo Young Kim, Seung-Shin Lee, Hoon Gook, Jeffrey H. Lipton, Zhaolei Zhang, **Dennis Dong Hwan Kim**. Dynamics of Somatic Mutations Commonly detected in other myeloid neoplasms beyond the BCR-ABL gene rearrangement in response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Haematologica. 2016 Jun:#2875. **Senior Responsible Author**.

2016 Apr 3 **Co-Author**. Cohesin complex mutation may not influence the result of allogeneic stem cell transplantation in normal karyotype. 42nd EBMT 2016 Annual Meeting. Valencia, Spain. Presenter(s): Jae-Sook Ahn* 1, Hyeoung-Joon Kim1, Yeo-Kyeong Kim1, Sung-Hoon Jung1, Seung-Shin Lee1, Deok-Hwan Yang1, Je-Jung Lee1, Seung Hyun Choi2, Chul Won Jung3, Jun-Ho Jang3, Hee Je Kim4, Joon Ho Moon5, Sang Kyun Sohn5, Jong Ho Won6, Sung-Hyun Kim7, TaeHyung Kim8, **Dennis Dong Hwan Kim**.

Publication Details:

Cohesin complex mutation may not influence the result of allogeneic stem cell transplantation in normal karyotype.

2015 Dec 14 **Presenter**. The double-negative NPM1/FLT3-ITD mutation shows long term outcomes after allogeneic transplant similar to those of the 'favourable' risk group according to the ELN risk classification, distinct from other intermediate-I risk in normal-karyotype AML. 42nd EBMT 2016 Annual Meeting. Valencia, Spain. Presenter(s): Jae-Sook Ahn, Hyeoung-Joon Kim, Yeo-Kyeong Kim, Sung-Hoon Jung, Seung-Shin Lee, Deok-Hwan Yang, Je-Jung Lee, Seung Hyun Choi2, Chul Won Jung, Jun-Ho Jang, Hee Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong Ho Won, Sung-Hyun Kim, TaeHyung Kim, **Dennis Dong Hwan Kim**.

Publication Details:

The double-negative NPM1/FLT3-ITD mutation shows long term outcomes after allogeneic transplant similar to those of the 'favourable' risk group according to the ELN risk classification, distinct from other intermediate-I risk in normal-karyotype AML.

2015 Dec 6 **Moderator**. Clinical Allogeneic Transplantation - Results: New Insights Into the Biology of Allogeneic Transplantation. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): **Kim DH**. Oral session
Session Name: 732. Clinical Allogeneic Transplantation: Results: New Insights Into the Biology of Allogeneic Transplantation
Session Date: Sunday, December 6, 2015
Session Time: 4:30 PM - 6:00 PM
Room: Orange County Convention Center, Tangerine 3 (WF3-4).

Publication Details:

Clinical Allogeneic Transplantation - Results: New Insights Into the Biology of Allogeneic Transplantation.

2015 Dec Propensity Score Matching Analysis Demonstrates the Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy Regardless of Other Clinical Features Including Age of the Patients. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): **Dennis Dong Hwan Kim**, Feras Alfraih, Tanya Adityan, Jeffrey H. Lipton.

Publication Details:

Dennis Dong Hwan Kim, Feras Alfraih, Tanya Adityan, Jeffrey H. Lipton. Propensity Score Matching Analysis Demonstrates the Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy Regardless of Other Clinical Features Including Age of the Patients. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Dec Whole Exome Sequencing Reveals That DNMT3A and ASXL1 Mutation Are Involved in the Development of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia Patients without ABL1 Tyrosine Kinase Domain Mutation. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Taehyung Simon Kim, Zhaolei Zhang, Marc Tyndel, Jae-Sook Ahn, Seunghyun Choi, Hyeoung Joon Kim, Jeffrey H. Lipton, **Dennis Dong Hwan Kim**.

Publication Details:

Taehyung Simon Kim, Zhaolei Zhang, Marc Tyndel, Jae-Sook Ahn, Seunghyun Choi, Hyeoung Joon Kim, Jeffrey H. Lipton, **Dennis Dong Hwan Kim**. Whole Exome Sequencing Reveals That DNMT3A and ASXL1 Mutation Are Involved in the Development of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia Patients without ABL1 Tyrosine Kinase Domain Mutation. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Dec Whole Exome Sequencing Reveals the Landscape of Clonal Evolution from MDS to AML Progression. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Taehyung Simon Kim, Zhaolei Zhang, Marc Tyndel, Jae-Sook Ahn, Yeo-Kyeoung Kim, Seung Hyun Choi, Hyeoung-Joon Kim, Moses Lee, Murim Choi, Jeffrey H. Lipton, **Dennis Dong Hwan Kim**. (Continuing Education)

Publication Details:

Taehyung Simon Kim, Zhaolei Zhang, Marc Tyndel, Jae-Sook Ahn, Yeo-Kyeoung Kim, Seung Hyun Choi, Hyeoung-Joon Kim, Moses Lee, Murim Choi, Jeffrey H. Lipton, **Dennis Dong Hwan Kim**. Whole Exome Sequencing Reveals the Landscape of Clonal Evolution from MDS to AML Progression. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Dec Prolonged Duration of Systemic Immunosuppression after Allogeneic Hematopoietic Cell Transplantation Associates with the Use of Peripheral Blood Stem Cells, Severe Grade of Chronic Gvhd, Progressive Type Onset of Chronic Gvhd, Grade 2-4 Acute Gvhd and Older Age, but Not with T-Cell Depletion or Conditioning Regimen. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Sita D. Bhella, Elizabeth Shin, Marc Poch Martell, Jieun Uhm, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, **Dennis Dong Hwan Kim**. (Continuing Education)

Publication Details:

Sita D. Bhella, Elizabeth Shin, Marc Poch Martell, Jieun Uhm, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, **Dennis Dong Hwan Kim**. Prolonged Duration of Systemic Immunosuppression after Allogeneic Hematopoietic Cell Transplantation Associates with the Use of Peripheral Blood Stem Cells, Severe Grade of Chronic Gvhd, Progressive Type Onset of Chronic Gvhd, Grade 2-4 Acute Gvhd and Older Age, but Not with T-Cell Depletion or Conditioning Regimen. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Dec Incidence and Risk Factors for VzV Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of Cgvhd By NIH Consensus Criteria, and No T-Cell Depletion. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Sita D. Bhella, Elizabeth Shin, Marc Poch Martell, Jieun Uhm, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, **Dennis Dong Hwan Kim**. (Continuing Education)

Publication Details:

Sita D. Bhella, Elizabeth Shin, Marc Poch Martell, Jieun Uhm, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, **Dennis Dong Hwan Kim**. Incidence and Risk Factors for VzV Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of Cgvhd By NIH Consensus Criteria, and No T-Cell Depletion. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Dec Incidence and Risk Factors for Nontuberculous Mycobacteria Infection after Allogeneic Hematopoietic Cell Transplantation. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Jennifer M. Beswick, Elizabeth Shin, Jieun Uhm, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, Theodore Marras, **Dennis Dong Hwan Kim**. (Continuing Education)

Publication Details:

Jennifer M. Beswick, Elizabeth Shin, Jieun Uhm, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, Theodore Marras, **Dennis Dong Hwan Kim**. Incidence and Risk Factors for Nontuberculous Mycobacteria Infection after Allogeneic Hematopoietic Cell Transplantation. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Dec Propensity Score Matching Analysis Comparing Azathioprine Plus Prednisone Vs Prednisone Alone Regimens As First-Line Treatment in Chronic Graft-Versus-Host Disease. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. (Continuing Education)

Publication Details:

Propensity Score Matching Analysis Comparing Azathioprine Plus Prednisone Vs Prednisone Alone Regimens As First-Line Treatment in Chronic Graft-Versus-Host Disease. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Dec Donor Type, Chronic Gvhd Subtype , and the Severity of Chronic Gvhd at the Time of Initiation of Chronic Gvhd Treatment Affect Failure-Free Survival in the Patients with Chronic Gvhd. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Jieun Uhm, Elizabeth Shin, Marc Poch Martell, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, **Dennis Dong Hwan Kim**. (Continuing Education)

Publication Details:

Jieun Uhm, Elizabeth Shin, Marc Poch Martell, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, **Dennis Dong Hwan Kim**. Donor Type, Chronic Gvhd Subtype , and the Severity of Chronic Gvhd at the Time of Initiation of Chronic Gvhd Treatment Affect Failure-Free Survival in the Patients with Chronic Gvhd. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Dec Risk Factor Analysis for the Development of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation: Randomized Stratification and Propensity Score Analysis. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Marc Poch Martell, Elizabeth Shin, Jieun Uhm, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, **Dennis Dong Hwan Kim**. (Continuing Education)

Publication Details:

Marc Poch Martell, Elizabeth Shin, Jieun Uhm, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, **Dennis Dong Hwan Kim**. Risk Factor Analysis for the Development of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation: Randomized Stratification and Propensity Score Analysis. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Dec Influence of Matched Sibling Donor's Availability and Stem Cell Transplantation on Treatment Outcome for Acute Lymphoblastic Leukemia; Study on 294 Patients. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Feras Alfraih, Wahiba Chebbo, **Dennis Dong Hwan Kim**, Ghuzayel Aldawsari, Fahad Z. Alsharif, Hazza A Alzahrani, Said Y Mohamed, Walid Rasheed, Amr Hanbali, Syed Osman Ahmed, Marwan Shaheen, Naeem A. Chaudhri, Fahad Al Mohareb, Mahmoud Aljurf. (Continuing Education)

Publication Details:

Feras Alfraih, Wahiba Chebbo, **Dennis Dong Hwan Kim**, Ghuzayel Aldawsari, Fahad Z. Alsharif, Hazza A Alzahrani, Said Y Mohamed, Walid Rasheed, Amr Hanbali, Syed Osman Ahmed, Marwan Shaheen, Naeem A. Chaudhri, Fahad Al Mohareb, Mahmoud Aljurf. Influence of Matched Sibling Donor's Availability and Stem Cell Transplantation on Treatment Outcome for Acute Lymphoblastic Leukemia; Study on 294 Patients. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Dec Fertility Recovery Following Allogeneic Bone Marrow Transplantation in Aplastic Anemia; A Study of 157 Patients. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Feras Alfraih, Shad Ahmed, **Dennis Dong Hwan Kim**, Walid Rasheed, Ghuzayel Aldawsari, Fahad Alsharif, Said Y Mohamed, Amr Hanbali, Syed Osman Ahmed, Marwan Shaheen, Naeem A. Chaudhri, Fahad Al Mohareb, Mahmoud Al-Jurf, Hazza A Alzahrani. (Continuing Education)

Publication Details:

Feras Alfraih, Shad Ahmed, **Dennis Dong Hwan Kim**, Walid Rasheed, Ghuzayel Aldawsari, Fahad Alsharif, Said Y Mohamed, Amr Hanbali, Syed Osman Ahmed, Marwan Shaheen, Naeem A. Chaudhri, Fahad Al Mohareb, Mahmoud Al-Jurf, Hazza A Alzahrani. Fertility Recovery Following Allogeneic Bone Marrow Transplantation in Aplastic Anemia; A Study of 157 Patients. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Dec Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation. 57th Annual Meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Samantha J Mayo, Hans A. Messner, Sean B. Rourke, Doris Howell, J. Charles Victor, John Kuruvilla, Jeffrey H. Lipton, Vikas Gupta, **Dennis Dong Hwan Kim**, Laura McGillis, Jieun Uhm, Fotios V. Michelis, Naheed Alam, Anna Lambie, Dawn Breen, David Loach, Christine Piescic, Kelly Metcalfe. (Continuing Education)

Publication Details:

Samantha J Mayo, Hans A. Messner, Sean B. Rourke, Doris Howell, J. Charles Victor, John Kuruvilla, Jeffrey H. Lipton, Vikas Gupta, **Dennis Dong Hwan Kim**, Laura McGillis, Jieun Uhm, Fotios V. Michelis, Naheed Alam, Anna Lambie, Dawn Breen, David Loach, Christine Piescic, Kelly Metcalfe. Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 2015 Dec. **Coauthor or Collaborator**.

2015 Jun 11 **Presenter**. SINGLE NUCLEOTIDE POLYMORPHISMS IN APOPTOSIS PATHWAY ARE ASSOCIATED WITH RESPONSE TO IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA. 20th Congress of the European Hematology Association. Istanbul, Austria. Presenter(s): Uhm J, Zheng Q, Cao J, Hamad N, Kim HJ, Moon HJ, Sohn SK, Jung CW, Lipton JH, **Kim D**. (Trainee Presentation)

Publication Details:

SINGLE NUCLEOTIDE POLYMORPHISMS IN APOPTOSIS PATHWAY ARE ASSOCIATED WITH RESPONSE TO IMATINIB THERAPY IN CHRONIC MYELOID LEUKEMIA.

2015 Jun 11 **Presenter**. THE DNMT3A R882 MUTATION WITH FLT3-ITD POSITIVITY IS AN EXTREMELY POOR

PROGNOSTIC FACTOR IN PATIENTS WITH NORMAL KARYOTYPE AML AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION. 20th Congress of the European Hematology Association. Istanbul, Austria. Presenter(s): Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, **Kim D.**

Publication Details:

THE DNMT3A R882 MUTATION WITH FLT3-ITD POSITIVITY IS AN EXTREMELY POOR PROGNOSTIC FACTOR IN PATIENTS WITH NORMAL KARYOTYPE AML AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION.

2015 Mar 22 **Presenter.** The double-negative NPM1/FLT3-ITD mutation shows long term outcomes after allogeneic transplant similar to those of the 'favourable' risk group according to the ELN risk classification, distinct from other intermediate-I risk in normal-karyotype AML. 41st Annual meeting of the European Society for Blood and Marrow Transplantation. Istanbul, Turkey. Presenter(s): Ahn JS, Kim HJ, Kim YK, Jung SH, Yang DH, Lee JJ, Kim NK, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, **Kim DH.**

Publication Details:

The double-negative NPM1/FLT3-ITD mutation shows long term outcomes after allogeneic transplant similar to those of the 'favourable' risk group according to the ELN risk classification, distinct from other intermediate-I risk in normal-karyotype AML.

2015 Feb 12 **Presenter.** Moderate/Severe Grade of Chronic Graft Versus Host Disease and Younger Age (Less Than 45 Years Old) Are Risk Factors for Avascular Necrosis in Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. CIBMTR/ASBMT. San Diego, California, United States. Presenter(s): Sita Bhella. Oral presentation, I worked as a supervisor. (Trainee Presentation)

Publication Details:

Moderate/Severe Grade of Chronic Graft Versus Host Disease and Younger Age (Less Than 45 Years Old) Are Risk Factors for Avascular Necrosis in Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

2014 Dec 8 **Presenter.** HCT-CI Has Prognostic Value in Acute, but Not Chronic Gvhd Specific Survival. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Marc Poch Martell, Nada Hamad, Fotios V. Michelis, Jieun Uhm, Feras Alfraih, Mohamed Shanavas, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Matthew D. Seftel and **Dennis Kim.** (Trainee Presentation)

Publication Details:

Marc Poch Martell, Nada Hamad, Fotios V. Michelis, Jieun Uhm, Feras Alfraih, Mohamed Shanavas, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Matthew D. Seftel and **Dennis Kim.** HCT-CI Has Prognostic Value in Acute, but Not Chronic Gvhd Specific Survival. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):3915. **Senior Responsible Author.**

2014 Dec 8 **Presenter.** Validation of Favourable Impact of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Marc Poch Martell, Uhm J, Alam N, Gupta V, Jeffrey H. Lipton, John Kuruvilla, Matthew D. Seftel, Hans A. Messner and **Dennis Kim.** (Trainee Presentation)

Publication Details:

Marc Poch Martell, Uhm J, Alam N, Gupta V, Jeffrey H. Lipton, John Kuruvilla, Matthew D. Seftel, Hans A. Messner and **Dennis Kim.** Validation of Favourable Impact of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):3936. **Senior Responsible Author.**

2014 Dec 8 **Presenter.** Propensity Score Matching Analysis Comparing Reduced Intensity Versus Myeloablative Conditioning in AML/MDS Patients Transplanted with Fludarabine-Busulfan-Low Dose Total Body Irradiation Based Regimen. 56th Annual Meeting of American Society of Hematology. San Francisco,

California, United States. Presenter(s): Hassan Sibai, Fotios V. Michelis, Nada Hamad, Jieun Uhm, Vikas Gupta, John G. Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Matthew D. Seftel, and Dennis **D. Kim**. (Trainee Presentation)

Publication Details:

Hassan Sibai, Fotios V. Michelis, Nada Hamad, Jieun Uhm, Vikas Gupta, John G. Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Matthew D. Seftel, and Dennis **D. Kim**. Propensity Score Matching Analysis Comparing Reduced Intensity Versus Myeloablative Conditioning in AML/MDS Patients Transplanted with Fludarabine-Busulfan-Low Dose Total Body Irradiation Based Regimen. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):3870. **Senior Responsible Author**.

2014 Dec 8 **Presenter**. A Risk Score to Predict CMV Viremia within the First 100 Days after Allogeneic Stem Cell Transplantation Based on Pre-Transplant Parameters. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Feras Alfraih, John Kuruvilla, Naheed Alam, Anna Lambie, Vikas Gupta, Dennis D. Kim, Matthew D. Seftel, Jieun Uhm, David Loach, Eshetu G Atenafu, Jeffrey H. Lipton, and Hans A. Messner. (Trainee Presentation)

Publication Details:

Feras Alfraih, John Kuruvilla, Naheed Alam, Anna Lambie, Vikas Gupta, Dennis D. Kim, Matthew D. Seftel, Jieun Uhm, David Loach, Eshetu G Atenafu, Jeffrey H. Lipton, and Hans A. Messner. A Risk Score to Predict CMV Viremia within the First 100 Days after Allogeneic Stem Cell Transplantation Based on Pre-Transplant Parameters. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):3877.

Coauthor or Collaborator.

2014 Dec 8 **Presenter**. Clinical Characteristics, Risk Factors and Outcomes of CMV Disease after Allogeneic Stem Cell Transplantation. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Feras Alfraih, Naheed Alam, Anna Lambie, Vikas Gupta, Dennis D. Kim, John Kuruvilla, Jeffrey H. Lipton, Matthew D. Seftel, Jieun Uhm, David Loach, and Hans A. Messner. (Trainee Presentation)

Publication Details:

Feras Alfraih, Naheed Alam, Anna Lambie, Vikas Gupta, Dennis D. Kim, John Kuruvilla, Jeffrey H. Lipton, Matthew D. Seftel, Jieun Uhm, David Loach, and Hans A. Messner. Clinical Characteristics, Risk Factors and Outcomes of CMV Disease after Allogeneic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):3879. **Coauthor or Collaborator**.

2014 Dec 8 **Presenter**. The NIH Chronic Gvhd Global Score and the CIBMTR Risk Score Correlate Well with Failure Free Survival Following Frontline Systemic Corticosteroid Therapy for Chronic Gvhd. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Jieun Uhm, Nada Hamad, Elizabeth M Shin, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Matthew Seftel, and Dennis **D. Kim**. (Trainee Presentation)

Publication Details:

Jieun Uhm, Nada Hamad, Elizabeth M Shin, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Matthew Seftel, and Dennis **D. Kim**. The NIH Chronic Gvhd Global Score and the CIBMTR Risk Score Correlate Well with Failure Free Survival Following Frontline Systemic Corticosteroid Therapy for Chronic Gvhd. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):3925. **Senior Responsible Author**.

2014 Dec 8 **Presenter**. The Risk Factors for IgG Hypogammaglobulinemia after Allogeneic Hematopoietic Stem Cell Transplantation and Its Impact on Transplant Outcomes. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Jieun Uhm, Nada Hamad, Vikas Gupta, John Kuruvilla, Hans A. Messner, Matthew Seftel, Jeffrey H. Lipton, and Dennis **D. Kim**. (Trainee Presentation)

Publication Details:

Jieun Uhm, Nada Hamad, Vikas Gupta, John Kuruvilla, Hans A. Messner, Matthew Seftel, Jeffrey H. Lipton, and Dennis **D. Kim**. The Risk Factors for IgG Hypogammaglobulinemia after Allogeneic

Hematopoietic Stem Cell Transplantation and Its Impact on Transplant Outcomes. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):3928. **Senior Responsible Author.**

2014 Dec 8 **Presenter.** Multiple CMV Reactivations Are Associated with Lower Risk of Relapse Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Feras Alfraih, Naheed Alam, Vikas Gupta, Dennis D. Kim, John Kuruvilla, Jeffrey H. Lipton, David Loach, Matthew D. Seftel, Jieun Uhm, Anna Lambie and Hans A. Messner. (Trainee Presentation)

Publication Details:

Feras Alfraih, Naheed Alam, Vikas Gupta, Dennis D. Kim, John Kuruvilla, Jeffrey H. Lipton, David Loach, Matthew D. Seftel, Jieun Uhm, Anna Lambie and Hans A. Messner. Multiple CMV Reactivations Are Associated with Lower Risk of Relapse Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):3955. **Coauthor or Collaborator.**

2014 Dec 7 **Presenter.** Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Fotios V. Michelis, Hans A Messner, Jieun Uhm, Naheed Alam, David Loach, Laura McGillis, Anna Lambie, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Matthew D. Seftel, Dennis D. Kim. (Trainee Presentation)

Publication Details:

Fotios V. Michelis, Hans A Messner, Jieun Uhm, Naheed Alam, David Loach, Laura McGillis, Anna Lambie, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Matthew D. Seftel, Dennis D. Kim. Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):2529. **Senior Responsible Author.**

2014 Dec 6 **Presenter.** An Adverse Prognostic Effect of Homozygous TET2 Mutational Status on the Relapse Risk of Acute Myeloid Leukemia Patients of Normal Karyotype. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Jae-Sook Ahn, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Il-Kwon Lee, Nan Young Kim, Mark D Minden, Chul Won Jung, Jun-Ho Jang, Hee-Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Sung-Hyun Kim, Namshin Kim, Kenichi Yoshida, Seishi Ogawa, and **Dennis Kim.** (Trainee Presentation)

Publication Details:

Jae-Sook Ahn, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Il-Kwon Lee, Nan Young Kim, Mark D Minden, Chul Won Jung, Jun-Ho Jang, Hee-Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Sung-Hyun Kim, Namshin Kim, Kenichi Yoshida, Seishi Ogawa, and Dennis **D. Kim.** An Adverse Prognostic Effect of Homozygous TET2 Mutational Status on the Relapse Risk of Acute Myeloid Leukemia Patients of Normal Karyotype. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):1052. **Senior Responsible Author.**

2014 Dec 6 **Presenter.** Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Fotios V. Michelis, Rouslan Kotchetkov, Rebecca M. Grunwald, Aamir Azeem, Jieun Uhm, Naheed Alam, Laura McGillis, Anna Lambie, David Loach, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Dennis D. Kim, Matthew D. Seftel and Hans A. Messner. (Trainee Presentation)

Publication Details:

Fotios V. Michelis, Rouslan Kotchetkov, Rebecca M. Grunwald, Aamir Azeem, Jieun Uhm, Naheed Alam, Laura McGillis, Anna Lambie, David Loach, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Dennis D. Kim, Matthew D. Seftel and Hans A. Messner. Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):1179. **Coauthor or Collaborator.**

2014 Dec 6 **Presenter.** Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Fotios V. Michelis, Rouslan Kotchetkov, Aamir Azeem, Rebecca M. Grunwald, Jieun Uhm, Naheed Alam, Anna Lambie, Laura McGillis, David Loach, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Dennis D. Kim, Matthew D. Seftel and Hans A. Messner. (Trainee Presentation)

Publication Details:

Fotios V. Michelis, Rouslan Kotchetkov, Aamir Azeem, Rebecca M. Grunwald, Jieun Uhm, Naheed Alam, Anna Lambie, Laura McGillis, David Loach, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Dennis D. Kim, Matthew D. Seftel and Hans A. Messner. Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):1237. **Coauthor or Collaborator.**

2014 Dec 6 **Presenter.** The Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy. 56th Annual Meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Dennis **D. Kim**, Feras Alfraih, Honggi Lee, Jeffrey H. Lipton.

Publication Details:

Dennis **D. Kim**, Feras Alfraih, Honggi Lee, Jeffrey H. Lipton. The Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy. Blood (ASH Annual Meeting Abstracts). 2014 Nov 15;124(21):1804. **Principal Author.**

2014 Feb 26 **Presenter.** Preliminary data from a multi-center study of Clofarabine/Busulfan conditioning for acute myeloid leukemia not in remission at allogeneic transplantation. CIBMTR/ASBMT. Grapevine, Texas, United States. Presenter(s): Magenau J, Westervelt P, cGuirk JP, Khaled SK, Becker PS, Jagasia MH, Rowley S, **Kim D**, Frey NV, Parameswaran H, Lieland S, Braun T, Schechter-Finkelstein T, Parkin B, Harriw AC, Scott BL, DiPersio JF, Forma SJ, Mineishi S.

Publication Details:

Magenau J, Westervelt P, cGuirk JP, Khaled SK, Becker PS, Jagasia MH, Rowley S, **Kim D**, Frey NV, Parameswaran H, Lieland S, Braun T, Schechter-Finkelstein T, Parkin B, Harriw AC, Scott BL, DiPersio JF, Forma SJ, Mineishi S. Preliminary data from a multi-center study of Clofarabine/Busulfan conditioning for acute myeloid leukemia not in remission at allogeneic transplantation. Biol Blood Marrow Transplant (Supplement). 2014 Feb;20(2 Suppl 1):s155-156 (#220). **Coauthor or Collaborator.**

2014 Feb 26 **Presenter.** Alemtuzumab as therapy for steroid refractory acute GVHD: Promising efficacy but higher rate of infectious complications based on observational study. CIBMTR/ASBMT. Grapevine, Texas, United States. Presenter(s): Alam N, Atenafu E, Gupta V, Kuruvilla J, Lipton JH, Messner H, Seftel M, **Kim D**. (Trainee Presentation)

Publication Details:

Alam N, Atenafu EG, Gupta V, Kuruvilla J, Lipton JH, Messner H, Seftel M, **Kim D**. Alemtuzumab as therapy for steroid refractory acute GVHD: Promising efficacy but higher rate of infectious complications based on observational study. Biol Blood Marrow Transplant. 2014 Feb;20(2 Suppl 1):s260 (abstract 403). **Senior Responsible Author.**

2013 Dec 9 **Presenter.** Risk Factors For Chronic Eye and Mouth GVHD In Unrelated Hematopoietic Cell Transplantation: T Cell Depletion Is The Only Risk Factor Identified and Appears To Be Favorable. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Shanavas M, Hamad N, Michelis F, Uhm J, Gupta V, Kuruvilla J, Lipton JH, Messner HA, **Kim D**. (Trainee Presentation)

Publication Details:

Mohamed Shanavas, Nada Hamad, Fotios V. Michelis, Jieun Uhm, Vikas Gupta, John Kuruvilla, Hans A. Messner, Jeffrey H. Lipton, **Dennis Dong Hwan Kim**. Risk Factors For Chronic Eye and Mouth GVHD In

Unrelated Hematopoietic Cell Transplantation: T Cell Depletion Is The Only Risk Factor Identified and Appears To Be Favorable. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):4601. **Senior Responsible Author.**

2013 Dec 9 **Presenter.** Risk Model Incorporating Donor IL6 and ifng Genotype and Gut Gvhd Can Discriminate High Risk Patients For Steroid Refractory Acute Gvhd. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Alam N, Atenafu EG, Xu W, Uhm J, Gupta V, Kuruvilla J, Messner HA, Lipton JH, **Kim D.** (Trainee Presentation)

Publication Details:

Naheed Alam, Eshetu G Atenafu, Wei Xu, Jieun Uhm, Vikas Gupta, John Kuruvilla, Hans A. Messner, Jeffrey H. Lipton, **Dennis Kim.** Risk Model Incorporating Donor IL6 and ifng Genotype and Gut Gvhd Can Discriminate High Risk Patients For Steroid Refractory Acute Gvhd. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):2044. **Senior Responsible Author.**

2013 Dec 9 **Presenter.** A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Mohamed Shanavas, Hans A. Messner, Suzanne Kamel-Reid, Eshetu G Atenafu, Vikas Gupta, John Kuruvilla, **Dennis Dong Hwan Kim,** Jieun Uhm, Anna Lambie, Laura Ellis, Jeffrey H. Lipton. (Trainee Presentation)

Publication Details:

Mohamed Shanavas, Hans A. Messner, Suzanne Kamel-Reid, Eshetu G Atenafu, Vikas Gupta, John Kuruvilla, **Dennis Dong Hwan Kim,** Jieun Uhm, Anna Lambie, Laura Ellis, Jeffrey H. Lipton. A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):5501. **Coauthor or Collaborator.**

2013 Dec 9 **Presenter.** Outcomes of Allogeneic Hematopoietic Cell Transplantation In Aplastic Anemia Using Intermediate Dose Alemtuzumab Based-Conditioning. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Nada Hamad, Ryan Del Bel, Hans A. Messner, **Dennis Kim,** John Kuruvilla, Jeffrey H. Lipton, Jieun Uhm, Wei Xu, Vikas Gupta. (Trainee Presentation)

Publication Details:

Nada Hamad, Ryan Del Bel, Hans A. Messner, **Dennis Kim,** John Kuruvilla, Jeffrey H. Lipton, Jieun Uhm, Wei Xu, Vikas Gupta. Outcomes of Allogeneic Hematopoietic Cell Transplantation In Aplastic Anemia Using Intermediate Dose Alemtuzumab Based-Conditioning. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):2044. **Coauthor or Collaborator.**

2013 Dec 9 **Presenter.** The Benefit of Allogeneic Hematopoietic Cell Transplantation in Older Patients with Acute Myeloid Leukemia Is Restricted to Those in First Complete Remission At the Time of Transplantation. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Fotios V. Michelis, Hans A. Messner, Eshetu G Atenafu, **Dennis Dong Hwan Kim,** John Kuruvilla, Jeffrey H. Lipton, Jieun Uhm, David Loach, Vikas Gupta. (Trainee Presentation)

Publication Details:

Fotios V. Michelis, Hans A. Messner, Eshetu G Atenafu, **Dennis Dong Hwan Kim,** John Kuruvilla, Jeffrey H. Lipton, Jieun Uhm, David Loach, Vikas Gupta. The Benefit of Allogeneic Hematopoietic Cell Transplantation in Older Patients with Acute Myeloid Leukemia Is Restricted to Those in First Complete Remission At the Time of Transplantation. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):3097. **Coauthor or Collaborator.**

2013 Dec 9 **Presenter.** Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Moon JH, Sohn SK, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, **Kim D.** (Trainee Presentation)

Publication Details:

Moon JH, Sohn SK, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, **Kim D.** Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):4184. **Senior Responsible Author.**

2013 Dec 9 **Presenter.** Independent Validation of Chronic Graft-Versus-Host Disease (GVHD) Grading System Proposed by the NIH Consensus Criteria in Terms of Prognostic Stratification of the Patients Developed Chronic Gvhd. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Moon JH, Sohn SK, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, **Kim D.** (Trainee Presentation)

Publication Details:

Moon JH, Sohn SK, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, **Kim D.** Independent Validation of Chronic Graft-Versus-Host Disease (GVHD) Grading System Proposed by the NIH Consensus Criteria in Terms of Prognostic Stratification of the Patients Developed Chronic Gvhd. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):1946. **Senior Responsible Author.**

2013 Dec 9 **Presenter.** The Risk of Organ Specific Graft-Versus-Host Disease Can Be Predicted by the Multiple Single Nucleotide Polymorphism Based Predictive Models. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): **Kim D,** Won HH, Xu W, Uhm J, Gupta V, Kuruvilla J, Messner HA, Lipton JH.

Publication Details:

Kim D, Won HH, Xu W, Uhm J, Gupta V, Kuruvilla J, Messner HA, Lipton JH. The Risk of Organ Specific Graft-Versus-Host Disease Can Be Predicted by the Multiple Single Nucleotide Polymorphism Based Predictive Models. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):3056. **Principal Author.**

2013 Dec 8 **Presenter.** The Risk Of BK Virus Haemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation Is Increased With Myeloablative Conditioning, CMV Viremia and Acute GVHD. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Uhm J, Hamad N, Shanavas M, Michelis F, Gupta V, Kuruvilla J, Messner HA, Lipton JH, **Kim DH.** (Trainee Presentation)

Publication Details:

Uhm J, Hamad N, Shanavas M, Michelis F, Gupta V, Kuruvilla J, Messner HA, Lipton JH, **Kim DH.** The Risk Of BK Virus Haemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation Is Increased With Myeloablative Conditioning, CMV Viremia and Acute GVHD. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):3289. **Senior Responsible Author.**

2013 Dec 8 **Presenter.** Mycophenolate Compared to Methotrexate As Part of Cyclosporine Based-GVHD Prophylaxis Does Not Affect Transplant Outcomes, Reduces Organ Specific Acute And Chronic GVHD, but Increases The Risk of CMV Viremia In Matched Related Donor Peripheral Blood Stem Cell Transplantation. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Nada Hamad, Mohamed Shanavas, Fotios V. Michelis, Jieun Uhm, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, **Dennis Kim.** (Trainee Presentation)

Publication Details:

Nada Hamad, Mohamed Shanavas, Fotios V. Michelis, Jieun Uhm, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, **Dennis Kim.** Mycophenolate Compared to Methotrexate As Part of Cyclosporine Based-GVHD Prophylaxis Does Not Affect Transplant Outcomes, Reduces Organ Specific Acute And Chronic GVHD, but Increases The Risk of CMV Viremia In Matched Related Donor Peripheral Blood Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):3303. **Senior Responsible Author.**

2013 Dec 8 **Presenter.** Incidence, Risk Factors and Allogeneic Stem Cell Transplant Outcomes In Chronic Sclerotic Gvhd: T-Cell Depletion Is Preventive and Peripheral Blood Stem Cellis a Risk Factor, But Not HLA-

Mismatch With No Adverse Impact On Transplant Outcomes. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Uhm J, Hamad N, Shanavas M, Michelis F, Gupta V, Kuruvilla J, Messner HA, Lipton JH, **Kim D**. Dr J Uhm attained ASH abstract achievement award 2013 and I supervised her project as a senior author. (Trainee Presentation)

Publication Details:

Uhm J, Hamad N, Shanavas M, Michelis F, Gupta V, Kuruvilla J, Messner HA, Lipton JH, **Kim D**. Incidence, Risk Factors and Allogeneic Stem Cell Transplant Outcomes In Chronic Sclerotic Gvhd: T-Cell Depletion Is Preventive and Peripheral Blood Stem Cells a Risk Factor, But Not HLA-Mismatch With No Adverse Impact On Transplant Outcomes. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):3293. **Senior Responsible Author**.

2013 Dec 8 **Presenter**. Early Recovery Of Absolute Lymphocyte Counts $\geq 0.2 \times 10^9/L$ At Day 21 Can Predict Reduced Risk Of Relapse In Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Alfraih F, Gupta V, Kuruvilla J, Lipton JH, Messner HA, **Kim D**. (Trainee Presentation)

Publication Details:

Feras Abdulaziz Alfraih, John Kuruvilla, Hans A. Messner, Jeffrey H. Lipton, Vikas Gupta, **Dennis Dong Hwan Kim**. Early Recovery Of Absolute Lymphocyte Counts $\geq 0.2 \times 10^9/L$ At Day 21 Can Predict Reduced Risk Of Relapse In Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):3392. **Senior Responsible Author**.

2013 Dec 8 **Presenter**. Lymphocyte Recovery At Day 28 Post-Transplant Is Predictive Of Relapse In Patients With Acute Myeloid Leukemia Transplanted With Peripheral Blood Stem Cell Grafts. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Michelis F, Messner HA, Uhm J, Gupta V, Kuruvilla J, Lipton JH, **Kim D**. (Trainee Presentation)

Publication Details:

Fotios V. Michelis, Hans A. Messner, Jieun Uhm, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, **Dennis Dong Hwan Kim**. Lymphocyte Recovery At Day 28 Post-Transplant Is Predictive Of Relapse In Patients With Acute Myeloid Leukemia Transplanted With Peripheral Blood Stem Cell Grafts. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):3393. **Senior Responsible Author**.

2013 Dec 7 **Presenter**. Steroid Failure At Day 28 After Acute Graft-Versus-Host Disease Treatment and Long-Term Outcomes Following Allogeneic Transplantation: Adverse Impact On Survival and Non-Relapse Mortality But No Increasing Risk Of Relapse. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Moon JH, Sohn SK, Alam N, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, **Kim D**. (Trainee Presentation)

Publication Details:

Moon JH, Sohn SK, Alam N, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, **Kim D**. Steroid Failure At Day 28 After Acute Graft-Versus-Host Disease Treatment and Long-Term Outcomes Following Allogeneic Transplantation: Adverse Impact On Survival and Non-Relapse Mortality But No Increasing Risk Of Relapse. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):2066. **Senior Responsible Author**.

2013 Dec 7 **Presenter**. The Modified Pre-Transplant EBMT Risk Score Is Superior To The HCT-CI Score In Predicting Overall Survival and Non-Relapse Mortality After Allogeneic Hematopoietic Cell Transplantation In Patients With Acute Myeloid Leukemia. 55th Annual Meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Michelis F, Messner HA, Uhm J, Lambie A, McGillis L, Gupta V, Kuruvilla J, Lipton JH, **Kim D**. (Trainee Presentation)

Publication Details:

Michelis F, Messner HA, Uhm J, Lambie A, McGillis L, Gupta V, Kuruvilla J, Lipton JH, **Kim D**. The Modified Pre-Transplant EBMT Risk Score Is Superior To The HCT-CI Score In Predicting Overall Survival and Non-Relapse Mortality After Allogeneic Hematopoietic Cell Transplantation In Patients With Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts). 2013 Nov 15;122(21):2153. **Senior**

Responsible Author.

- 2012 Dec 10 **Presenter.** BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib. 54th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 2777).
- Publication Details:*
Kim DH, Lee HG, Kamel-Reid S, Lipton JH. BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib. Blood (ASH Annual Meeting Abstracts). 2012 Nov;120:2777.
Principal Author.
- 2012 Dec 10 **Presenter.** Independent Validation of Chronic Graft-Versus-Host Disease (GVHD) Grading System Proposed by the NIH Consensus Criteria in Terms of Prognostic Stratification of the Patients Developed Chronic Gvhd. 54th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Moon JH. [Poster presentation] (Abstract 1946). (Trainee Presentation)
- Publication Details:*
Moon JH, Sohn SK, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, **Kim DH.** Independent Validation of Chronic Graft-Versus-Host Disease (GVHD) Grading System Proposed by the NIH Consensus Criteria in Terms of Prognostic Stratification of the Patients Developed Chronic Gvhd. Blood (ASH Annual Meeting Abstracts). 2012 Nov;120:1946. **Senior Responsible Author.**
- 2012 Dec 10 **Presenter.** The Risk of Organ Specific Graft-Versus-Host Disease Can Be Predicted by the Multiple Single Nucleotide Polymorphism Based Predictive Models. 54th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 3056).
- Publication Details:*
Kim DH, Won HH, Xu W, Uhm J, Gupta V, Kuruvilla J, Messner HA, Lipton JH. The Risk of Organ Specific Graft-Versus-Host Disease Can Be Predicted by the Multiple Single Nucleotide Polymorphism Based Predictive Models. Blood (ASH Annual Meeting Abstracts). 2012 Nov;120:3056. **Principal Author.**
- 2012 Dec 9 **Presenter.** The Benefit of Allogeneic Hematopoietic Cell Transplantation in Older Patients with Acute Myeloid Leukemia Is Restricted to Those in First Complete Remission At the Time of Transplantation. 54th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Michelis F. [Poster presentation] (Abstract 3097). (Trainee Presentation)
- Publication Details:*
Michelis FV, Messner HA, Atenafu EG, **Kim DH,** Kuruvilla J, Lipton JH, Uhm J, Loach D, Gupta V. The Benefit of Allogeneic Hematopoietic Cell Transplantation in Older Patients with Acute Myeloid Leukemia Is Restricted to Those in First Complete Remission At the Time of Transplantation. Blood (ASH Annual Meeting Abstracts). 2012 Nov;120:3097. **Coauthor or Collaborator.**
- 2012 Dec 9 **Presenter.** Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd. 54th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Moon JH. [Poster presentation] (Abstract 4184). (Trainee Presentation)
- Publication Details:*
Moon JH, Sohn SK, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, **Kim DH.** Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd. Blood (ASH Annual Meeting Abstracts). 2012 Nov;120:4184. **Senior Responsible Author.**
- 2012 Dec 9 **Presenter.** Different Characteristics Identified by Single Nucleotide Polymorphism Array Analysis in Leukemia Suggest the Need for Different Application Strategies Depending On Disease Category. 54th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Huh

JW. [Poster presentation] (Abstract 2490). (Trainee Presentation)

Publication Details:

Huh JW, Jung CW, Kim HJ, Kim YK, Moon JH, Sohn SK, Kim HJ, Min WS, **Kim DH**. Different Characteristics Identified by Single Nucleotide Polymorphism Array Analysis in Leukemia Suggest the Need for Different Application Strategies Depending On Disease Category. Blood (ASH Annual Meeting Abstracts). 2012 Nov;120:2490. **Senior Responsible Author**.

2012 Dec 9 **Presenter**. Genome-Wide Genotype-Based Risk Model for Survival in Acute Myeloid Leukemia Patients with Normal Karyotype. 54th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 2526).

Publication Details:

Kim HJ, Choi HS, Kim YK, Sohn SK, Moon JH, Kim TH, Zhang Z, **Kim DH**. Genome-Wide Genotype-Based Risk Model for Survival in Acute Myeloid Leukemia Patients with Normal Karyotype. Blood (ASH Annual Meeting Abstracts). 2012 Nov;120:2526. **Senior Responsible Author**.

2012 Dec **Presenter**. Whole Exome Sequencing Analysis in AML with Normal Karyotype Not Harboring FLT3/ITD Mutation Reveals Novel Genetic Alterations. 54th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Lee IK. [Poster presentation] (Abstract 2593).

Publication Details:

Lee IK, Kim N, Kim YK, **Kim DH**, Trinh Q, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Huh JW, Kim NY, Yu L, Lee YG, Chung SH, Ahn JS, Yang DH, Lee JJ, Kim HJ. Whole Exome Sequencing Analysis in AML with Normal Karyotype Not Harboring FLT3/ITD Mutation Reveals Novel Genetic Alterations. Blood (ASH Annual Meeting Abstracts). 2012 Nov;120:2593. **Coauthor or Collaborator**.

2012 Dec **Presenter**. NPM1, IDH1/2 and DNAAH11 Gene Mutations Can Improve a Prognostic Stratification of Acute Myeloid Leukemia Patients with Normal Karyotype but Not Harboring FLT3/ITD Mutation. 54th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Kim YK. [Poster presentation] (Abstract 2534).

Publication Details:

Kim YK, Lee IK, **Kim DH**, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Huh JW, Kim N, Lee YG, Jung SH, Lee JJ, Kim HJ. NPM1, IDH1/2 and DNAAH11 Gene Mutations Can Improve a Prognostic Stratification of Acute Myeloid Leukemia Patients with Normal Karyotype but Not Harboring FLT3/ITD Mutation. Blood (ASH Annual Meeting Abstracts). 2012 Nov;120:2534. **Coauthor or Collaborator**.

2012 Dec **Speaker**. CMV Reactivations and Their Impact On Outcomes in Patients After Hematopoietic Cell Transplantation. 54th Annual Meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Alam N. [Poster presentation] (Abstract 4501). (Trainee Presentation)

Publication Details:

Alam N, Lambie A, Yunes YN, Alfraih F, Atenafu EG, **Kim DH**, Gupta V, Kuruvilla J, Lipton JH, Messner HA. CMV Reactivations and Their Impact On Outcomes in Patients After Hematopoietic Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2012 Nov;120:4501. **Coauthor or Collaborator**.

2011 Dec **Presenter**. Genome-Wide Single-Nucleotide Polymorphism-Array Can Improve Prognostic Stratification of Core Binding Factor Acute Myeloid Leukemia, Especially in the Subgroup with Inv(16)/t(16;16) or without D816 C-KIT Mutation. 53rd Annual meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Huh JW. [Poster presentation] (Abstract 3515). (Trainee Presentation)

Publication Details:

Huh J, Kim HJ, Min WS, Jung CW, Kim HJ, Kim SH, Kim YK, Kim HJ, Moon JH, Sohn SK, Kim SH, Lee WS, Won JH, Mun YC, Kim H, Park J, **Kim DH**. Genome-Wide Single-Nucleotide Polymorphism-Array

Can Improve Prognostic Stratification of Core Binding Factor Acute Myeloid Leukemia, Especially in the Subgroup with Inv(16)/t(16;16) or without D816 C-KIT Mutation. Blood (ASH Annual Meeting Abstracts). 2011 Nov;118:3515. **Senior Responsible Author.**

2011 Dec **Presenter.** Allogeneic Stem Cell Transplantation Is Associated with Long Term Disease Control in Chemo Sensitive Follicular Lymphoma Patients. 53rd Annual meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Viswabandya A. [Poster presentation] (Abstract 2024).

Publication Details:

Viswabandya A, Panzarella T, **Kim DH**, Gupta V, Lipton JH, Messner HA, Kuruvilla J. Allogeneic Stem Cell Transplantation Is Associated with Long Term Disease Control in Chemo Sensitive Follicular Lymphoma Patients. Blood (ASH Annual Meeting Abstracts). 2011 Nov;118:2024. **Coauthor or Collaborator.**

2011 Dec **Presenter.** Incidence, Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation. 53rd Annual meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Wong KM. [Poster presentation] (Abstract 1951).

Publication Details:

Wong KM, Atenafu EG, **Kim DH**, Kuruvilla J, Lipton JH, Messner HA, Gupta V. Incidence, Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2011 Nov;118:1951. **Coauthor or Collaborator.**

2011 Dec **Presenter.** Allogeneic Stem Cell Transplantation Is Associated with Prolonged Disease Control in Chemosensitive Aggressive Histology Lymphoma Patients When Done Early. 53rd Annual meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): Viswabandya A.

Publication Details:

Viswabandya A, Panzarella T, **Kim DH**, Gupta V, Lipton JH, Messner HA, Kuruvilla J. Allogeneic Stem Cell Transplantation Is Associated with Prolonged Disease Control in Chemosensitive Aggressive Histology Lymphoma Patients When Done Early. Blood (ASH Annual Meeting Abstracts). 2011 Nov;118:4525. **Coauthor or Collaborator.**

2011 Feb **Speaker.** Cotransplantation of third party umbilical cord blood mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood. BMT tandem meetings of IBMTR/ASBMT. Honolulu, Hawaii, United States. Presenter(s): Lee SH. [Oral presentation] (Abstract 48).

Publication Details:

Lee SH, Cheuh HW, Yoo KH, Sung KW, Koo HH, **Kim DH**, Jung CW, Choi SJ, Oh W, Yang YS. Cotransplantation of third party umbilical cord blood mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood. Biol Blood Marrow Transplant. 2011 Feb;17(2 Suppl):S169-S170 (Abstract 48). **Coauthor or Collaborator.**

2011 Feb **Speaker.** Single nucleotide polymorphism (SNP)-based predictive models for graft-versus-host disease (GVHD) identify high risk patients for overall and organ specific GVHD following allogeneic hematopoietic stem cell transplantation. BMT tandem meetings of IBMTR/ASBMT. Honolulu, Hawaii, United States. Presenter(s): **Kim DH**. [Oral presentation] (Abstract 36).

Publication Details:

Kim DH, Jung CW, Yun J, Won HH, Cheng L, Xu W, Gupta V, Kuruvilla J, Messner HA, Lipton JH. Single nucleotide polymorphism (SNP)-based predictive models for graft-versus-host disease (GVHD) identify high risk patients for overall and organ specific GVHD following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Feb;17(2 Suppl):s165 (Abstract 36). **Principal Author.**

2011 Feb **Presenter.** Decitabine as a Bridging Therapy Before Allogeneic Stem Cell Transplantation for

Myelodysplastic Syndrome. BMT tandem meetings of IBMTR/ASBMT. Honolulu, Hawaii, United States. Presenter(s): Jang JH. [Poster presentation] (Abstract 459).

Publication Details:

Jang JH, Kim DY, **Kim DH**, Kim K, Lee JH, Lee KH, Jung CW, Lee JH. Decitabine as a Bridging Therapy Before Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2011;17(2 Suppl):s319 (Abstract 459). **Coauthor or Collaborator**.

2010 Dec **Presenter**. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced progression after high-dose chemotherapy with autologous stem cell transplantation. 36th Annual meeting of European Group for Bone Marrow Transplantation. Vienna, Austria. Presenter(s): Kim JW. [Poster presentation] (Abstract 839) (co-author).

Publication Details:

Kim JW, Kim BS, Bang SM, Kim I, **Kim DH**, Kim WS, Yang DH, Lee JJ, Lee JH, Kwak JY, Kim JS, Sohn SK, Yoon SS, Lee JS, Han KS, Park MH, Park S, Kim BK. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced progression after high-dose chemotherapy with autologous stem cell transplantation. Bone Marrow Transplant. 2010;45(Suppl 2s):s256. **Coauthor or Collaborator**.

2010 Dec **Presenter**. Allogeneic Stem Cell Transplantation (alloSCT) and Donor Lymphocyte Infusion (DLI) In Patients with Non-Hodgkin Lymphoma (NHL) Who Experienced Relapse or Progression After Autologous Stem Cell Transplantation (autoSCT): Retrospective Analysis From the Korean Society of Blood and Marrow Transplantation. 52nd Annual meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Kim JW. [Poster presentation] (Abstract 3536).

Publication Details:

Kim JW, Kim BS, Bang SM, Kim I, **Kim DH**, Kim WS, Yang DH, Lee JJ, Lee JH, Kim JS, Sohn SK, Yhim HY, Kwak JY, Yoon SS, Lee JS, Park S, Kim BK. Allogeneic Stem Cell Transplantation (alloSCT) and Donor Lymphocyte Infusion (DLI) In Patients with Non-Hodgkin Lymphoma (NHL) Who Experienced Relapse or Progression After Autologous Stem Cell Transplantation (autoSCT): Retrospective Analysis From the Korean Society of Blood and Marrow Transplantation. Blood (ASH Annual Meeting Abstracts). 2010 Nov;116:3536. **Coauthor or Collaborator**.

2010 Dec **Presenter**. Multicenter retrospective study on the development of peripheral lymphocytosis during second-line dasatinib therapy for chronic myeloid leukemia. 52nd Annual meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Lee HY. [Poster presentation] (Abstract 2275). (Trainee Presentation)

Publication Details:

Lee HY, Lee SJ, Han B, Yi JH, Jung CW, Kim DY, Lee JH, Lee KH, Sohn SK, Kim SH, Lee WS, Park JS, Yhim HY, Kwak JY, Kim HY, Kim YK, Kim I, Park SY, **Kim DH**. Multicenter retrospective study on the development of peripheral lymphocytosis during second-line dasatinib therapy for chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2010 Nov;116:2275. **Senior Responsible Author**.

2010 Dec **Presenter**. Genome-wide single-nucleotide polymorphism-array based karyotyping detects clonal aberrations, and predicts the risk of imatinib failure in chronic myeloid leukemia. 52nd Annual meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Han BR. [Poster presentation] (Abstract 3387). (Trainee Presentation)

Publication Details:

Han B, Huh JW, Yi JH, Lee HY, Kim JW, Kim HJ, Kim YK, Kim HJ, Moon JH, Sohn SK, Jung CW, **Kim DH**. Genome-wide single-nucleotide polymorphism-array based karyotyping detects clonal aberrations, and predicts the risk of imatinib failure in chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2010 Nov;116:3387. **Senior Responsible Author**.

2010 Dec **Presenter**. Genome-wide single-nucleotide polymorphism-array based karyotyping detects clonal aberrations including uniparental disomy (UPD), gain or loss which were unfavorable prognostic factor in acute myeloid leukemia with normal karyotype. 52nd Annual meeting of American Society of Hematology.

Orlando, Florida, United States. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 1669).

Publication Details:

Kim DH, Huh JW, Han B, Lee HY, Yi JH, Jang JH, Kim K, Kim HJ, Kim YK, Sohn SK, Moon JH, Kim SH, Jung CW. Genome-wide single-nucleotide polymorphism-array based karyotyping detects clonal aberrations including uniparental disomy (UPD), gain or loss which were unfavorable prognostic factor in acute myeloid leukemia with normal karyotype. Blood (ASH Annual Meeting Abstracts). 2010 Nov;116:1669. **Principal Author**.

2010 Dec **Presenter**. Secondary Acute Myeloid Leukemia (AML), Including Therapy-Related AML, Associates with Worse Treatment Outcomes, Than De Novo AML Even After Hematopoietic Stem Cell Transplantation, and Its Unfavorable Behavior Does Not Associated with Functional Activity of p-Glycoprotein, MDR1. 52nd Annual meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Han BR. [Poster presentation] (Abstract 2157). (Trainee Presentation)

Publication Details:

Han B, Lee HY, Yi JH, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW, **Kim DH**. Secondary Acute Myeloid Leukemia (AML), Including Therapy-Related AML, Associates with Worse Treatment Outcomes, Than De Novo AML Even After Hematopoietic Stem Cell Transplantation, and Its Unfavorable Behavior Does Not Associated with Functional Activity of p-Glycoprotein, MDR1. Blood (ASH Annual Meeting Abstracts). 2010 Nov;116:2157. **Senior Responsible Author**.

2010 Dec **Presenter**. Pharmacogenomics-based drug response prediction model for acute myeloid leukemia with normal karyotype. 52nd Annual meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 2698).

Publication Details:

Kim DH, Han B, Lee K, Ahn TJ, Son SD, Sohn I, Jung SH, Park KH, Jang JH, Kim K, Kim HJ, Sohn SK, Moon JH, Kim JG, Huh N, Jung CW. Pharmacogenomics-based drug response prediction model for acute myeloid leukemia with normal karyotype. Blood (ASH Annual Meeting Abstracts). 2010 Nov;116:2698. **Principal Author**.

2010 Dec **Presenter**. Addition of Hemoglobin Level Into the Prognostic Scoring System Together with White Blood Cell and Platelet Count Provides Better Prognostic Stratification for Treatment-Related Mortality and Overall Survival, but Not for Relapse Risk In Adult Patients with Acute Promyelocytic Leukemia. 52nd Annual meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Yi JH. (Trainee Presentation)

Publication Details:

Yi JH, Jung CW, Han B, Lee HY, Jang JH, Kim K, Kim HJ, Kim YK, Lee WS, Joo YD, Kim MK, Hyun MS, Kim H, Park JH, **Kim DH**. Addition of Hemoglobin Level Into the Prognostic Scoring System Together with White Blood Cell and Platelet Count Provides Better Prognostic Stratification for Treatment-Related Mortality and Overall Survival, but Not for Relapse Risk In Adult Patients with Acute Promyelocytic Leukemia. Blood (ASH Annual Meeting Abstracts). 2010 Nov;116:4371. **Senior Responsible Author**.

2010 Dec **Presenter**. Dasatinib for Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib In Korean Patients. 52nd Annual meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Lee HY. (Trainee Presentation)

Publication Details:

Lee HY, Chang MH, Jung CW, **Kim DH**, Kim WS, Kim SJ, Kim K, Jang JH, Yoon SS, Lee KH, Kim HJ, Chung JS, Sohn SK. Dasatinib for Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib In Korean Patients. Blood (ASH Annual Meeting Abstracts). 2010 Nov;116:4494. **Coauthor or Collaborator**.

2010 Dec **Presenter**. A 2-Year Single Center Experience of Decitabine Treatment for the Patients with MDS and CMML. 52nd Annual meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): Yi JH. (Trainee Presentation)

Publication Details:

Yi JH, Jung CW, **Kim DH**, Kim K, Jang JH. A 2-Year Single Center Experience of Decitabine Treatment for the Patients with MDS and CMML. Blood (ASH Annual Meeting Abstracts). 2010 Nov;116:4952.

Coauthor or Collaborator.

2010 Jun **Presenter.** Monosomy karyotype in acute myeloid leukemia predicts adverse treatment outcome with low complete remission rate and worse event-free and overall survival, and associates with high functional activity of p-glycoprotein, MDR1. European Hematology Association: 15th Annual Congress. Barcelona, Spain. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 655).

Publication Details:

Kim DH, Ahn HK, Won YW, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW. Monosomy karyotype in acute myeloid leukemia predicts adverse treatment outcome with low complete remission rate and worse event-free and overall survival, and associates with high functional activity of p-glycoprotein, MDR1. Haematologica. 2010;95(Suppl 2):274, abs. 0655. **Principal Author.**

2010 Jun **Presenter.** Effectiveness of Decitabine in chronic myelomonocytic leukemia patients: International Cooperative Multi-center Study. European Hematology Association: 15th Annual Congress. Barcelona, Spain. Presenter(s): Jang JH. [Poster presentation] (Abstract 1375).

Publication Details:

Jang JH, Iastrebner M, Taborda G, Arbelbide J, Sackmann F, Klein G, Bernard H, Jozami C, Kim K, **Kim DH**, Jung CW. Effectiveness of Decitabine in chronic myelomonocytic leukemia patients: International Cooperative Multi-center Study. Haematologica. 2010;95(Suppl 2):553, abs. 1375. **Coauthor or Collaborator.**

2010 Jun **Presenter.** Hematopoietic stem cell transplantation from a related donor infected with swine-origin H1N1 influenza virus. European Hematology Association: 15th Annual Congress. Barcelona, Spain. Presenter(s): Lee SH. [Poster presentation] (Abstract 873) (co-author).

Publication Details:

Lee SH, Chueh H, Sung KW, Koo HH, **Kim DH**, Kim SJ, Jang JH, Kim K, Jung CW. Hematopoietic stem cell transplantation from a related donor infected with swine-origin H1N1 influenza virus. Haematologica. 2010;95(Suppl 2):363, abs. 0873. **Coauthor or Collaborator.**

2010 Mar **Presenter.** Candidate pathway approach of the single nucleotide polymorphisms (SNPs) involved in cytokine, NFkB, PDGF or Transforming Growth Factor-beta (TGF-β) pathway could predict the risk of acute / chronic graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HSCT). 36th Annual meeting of European Group for Bone Marrow Transplantation. Vienna, Austria. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 517).

Publication Details:

Kim DH, Jung CW, Park S, Park JH, Jun HJ, Xu W, Galal A, Gupta V, Kuruvilla J, Messner H, Lipton J. Candidate pathway approach of the single nucleotide polymorphisms (SNPs) involved in cytokine, NFkB, PDGF or Transforming Growth Factor-beta (TGF-β) pathway could predict the risk of acute / chronic graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2010;45(Suppl 2s):s128. **Principal Author.**

2010 Mar **Presenter.** Multicentre retrospective analysis of second allogeneic HSCT outcomes for haematologic malignancies in Korea. 36th Annual meeting of European Group for Bone Marrow Transplantation. Vienna, Austria. Presenter(s): Kim KH. [Poster presentation] (Abstract 480). (Trainee Presentation)

Publication Details:

Kim KH, Jung CW, Jang JH, Kim K, Ahn HK, Won JH, Hong DS, Moon JH, Sohn SK, Kim YK, Yang DH, Lee JJ, Kim HJ, Kim JS, Min YH, Kim DY, Lee JH, Lee JH, Lee KH, Kim I, Yoon SS, Park S, Lee SM, Joo YD, Jun HJ, **Kim DH**. Multicentre retrospective analysis of second allogeneic HSCT outcomes for haematologic malignancies in Korea. Bone Marrow Transplant. 2010;45(Suppl 2s):s114. **Senior Responsible Author.**

- 2010 Mar **Presenter.** Allogeneic haematopoietic stem cell transplantation for adult patients with acquired aplastic anaemia: multivariate analysis and propensity score matching. 36th Annual meeting of European Group for Bone Marrow Transplantation. Vienna, Austria. Presenter(s): **Kim H.** [Poster presentation] (Abstract 624).
- Publication Details:*
Kim H, Park JH, Kim BS, **Kim DH**, Hyun MS, Kim SH, Bae SH, Choi JH, Sohn SK, Shin HJ, Won JH, Yoon SS, Jo DY, Joo YD, Lee KH. Allogeneic haematopoietic stem cell transplantation for adult patients with acquired aplastic anaemia: multivariate analysis and propensity score matching. Bone Marrow Transplant. 2010;45(Suppl 2s):s169. **Coauthor or Collaborator.**
- 2010 Mar **Presenter.** Allogeneic haematopoietic stem cell transplantation outcomes in imatinib-treated chronic myeloid leukaemia patients. 36th Annual meeting of European Group for Bone Marrow Transplantation. Vienna, Austria. Presenter(s): Ahn HK. [Poster presentation] (Abstract 812). (Trainee Presentation)
- Publication Details:*
Ahn HK, Jung CW, Kim K, Jang JH, **Kim DH**, Yoon SS, Kim IH, Sohn SK, Moon JH, Lee JH, Lee KH, Won JH, Lee NS. Allogeneic haematopoietic stem cell transplantation outcomes in imatinib-treated chronic myeloid leukaemia patients. Bone Marrow Transplant. 2010;45(Suppl 2s):s244. **Coauthor or Collaborator.**
- 2010 Feb **Presenter.** Clinical relevance of large granular lymphocyte expansion following allogeneic hematopoietic stem cell transplantation with HLA identical sibling donors. 2010 BMT tandem meetings of IBMTR/ASBMT. Orlando, Florida, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 283).
- Publication Details:*
Kim DH, Al-Dawsari G, Jung CW, Hong C, Kamel-Reid S, Galal A, Gupta V, Kuruvilla J, Lipton JH, Messner HA. Clinical relevance of large granular lymphocyte expansion following allogeneic hematopoietic stem cell transplantation with HLA identical sibling donors. Biol Blood Marrow Transplant. 2010;16(Suppl 2):s225. **Principal Author.**
- 2009 Dec **Presenter.** Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia. 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 1110).
- Publication Details:*
Kim DH, Kim JA, Yun J, Sriharsha L, Jang JH, Kim K, Jung CW, Kamel-Reid S, Radich J, Lipton JH. Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:1110. **Principal Author.**
- 2009 Dec **Presenter.** IFN- γ (interferon-gamma) Genotype Predict Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia. 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 2178).
- Publication Details:*
Kim DH, Kong JH, Park S, Jung CW, Sriharsha L, Xu W, Kamel-Reid S, Kim YK, Kim HJ, Lipton JH. IFN- γ (interferon-gamma) Genotype Predict Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:2178. **Principal Author.**
- 2009 Dec **Presenter.** Single Nucleotide Polymorphism (SNP) Approach of Multiple Candidate Pathways Predicting the Risk of Acute / Chronic Graft-Versus-Host Disease or Transplant Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: Potential Involvement of Nuclear Factor Kappa-B (NFKB), Platelet-Derived Growth Factor (PDGF) and Transforming Growth Factor-Beta (TGF- β) Pathway with Chronic Graft-Versus-Host Disease Graft-Versus-Host Disease. 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): **Kim DH.** [Poster presentation]

(Abstract 2221).

Publication Details:

Kim DH, Yun J, Kong JH, Jung CW, Galal A, Gupta V, Kuruville J, Messner HA, Lipton JH. Single Nucleotide Polymorphism (SNP) Approach of Multiple Candidate Pathways Predicting the Risk of Acute / Chronic Graft-Versus-Host Disease or Transplant Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: Potential Involvement of Nuclear Factor Kappa-B (NFkB), Platelet-Derived Growth Factor (PDGF) and Transforming Growth Factor-Beta (TGF- β) Pathway with Chronic Graft-Versus-Host Disease Graft-Versus-Host Disease. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:2221.

Principal Author.

2009 Dec **Presenter.** Expansion of Large Granular Lymphocytes Following Allogeneic Stem Cell Transplantation: Its Association with Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect. 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 2253).

Publication Details:

Kim DH, Al-Dawsari G, Jung CW, Hong C, Kamel-Reid S, Wright J, Galal A, Gupta V, Kuruville J, Lipton JH, Messner HA. Expansion of Large Granular Lymphocytes Following Allogeneic Stem Cell Transplantation: Its Association with Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:2253. **Principal Author.**

2009 Dec **Presenter.** Monosomy Karyotype in Acute Myeloid Leukemia Predicts Adverse Treatment Outcome with Low Complete Remission Rate and Worse Event-Free and Overall Survival, and Associates with High Functional Activity of Multidrug Resistance (MDR). 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Ahn HK. [Poster presentation] (Abstract 3112). (Trainee Presentation)

Publication Details:

Ahn HK, **Kim DH**, Park S, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW. Monosomy Karyotype in Acute Myeloid Leukemia Predicts Adverse Treatment Outcome with Low Complete Remission Rate and Worse Event-Free and Overall Survival, and Associates with High Functional Activity of Multidrug Resistance (MDR). Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:3112. **Co-Principal Author.**

2009 Dec **Presenter.** Candidate Pathway Approach of Single Nucleotide Polymorphism On Imatinib Transport/Metabolism Pathway and DNA Repair Enzyme Pathway Associated with Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia. 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Kim JA. [Poster presentation] (Abstract 3284). (Trainee Presentation)

Publication Details:

Kim JA, **Kim DH**, Won YW, Park S, Kim HJ, Kim SH, Jang JH, Kim K, Kim YK, Lee JJ, Kim HJ, Moon JH, Sohn SK, Jung CW. Candidate Pathway Approach of Single Nucleotide Polymorphism On Imatinib Transport/Metabolism Pathway and DNA Repair Enzyme Pathway Associated with Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:3284. **Co-Principal Author.**

2009 Dec **Presenter.** Decitabine Activity in Myelodysplastic Syndromes. International Cooperative Multi-Center Study. 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Iastrebner M. [Poster presentation] (Abstract 3804).

Publication Details:

Iastrebner M, Jang JH, Nucifora E, Kim K, Sackmann F, **Kim DH**, Orlando S, Jung CW, Basquiera A, Bengio R, Quiroga L, Klein G, Garcia J, Arbelbide J, Pavlovsky A, Prates MV. Decitabine Activity in Myelodysplastic Syndromes. International Cooperative Multi-Center Study. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:3804. **Coauthor or Collaborator.**

2009 Dec **Presenter.** Effectiveness of Decitabine in Chronic Myelomonocytic Leukemia Patients. International

Dennis Dong Hwan KIM

Cooperative Multi-Center Study. 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Iastrebnner M. [Poster presentation].

Publication Details:

Iastrebnner M, Jang JH, Fernandez I, Kim K, Garay G, **Kim DH**, Saba S, Jung CW, Santini F, Bernard H, Salvatierra L, Korin J, Taborda G, Giuliani RA, Flores G, Flores A. Effectiveness of Decitabine in Chronic Myelomonocytic Leukemia Patients. International Cooperative Multi-Center Study. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:3809. **Coauthor or Collaborator**.

2009 Dec **Presenter**. Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea. 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Kim KH. (Trainee Presentation)

Publication Details:

Kim KH, **Kim DH**, Jang JH, Kim K, Jung CW, Won JH, Moon JH, Sohn SK, Kim YK, Yang DH, Lee JJ, Kim HJ, Kim JS, Min YH, Kim DY, Lee JH, Lee JH, Lee KH, Kim I, Yoon SS, Park S, Lee SM, Joo YD. Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:4298. **Co-Principal Author**.

2009 Dec **Presenter**. Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases. 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Park JS.

Publication Details:

Park JS, **Kim DH**, Choi CW, Jeong SH, Choi JH, Kim K, Kim SJ, Jung CW, Yang DH, Kim HC, Jang^[SEP] JH. Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:4661. **Coauthor or Collaborator**.

2009 Dec **Presenter**. Validation of Updated Cytogenetic Risk Classification in Patients with Myelodysplastic Syndrome: Retrospective Study at Single Institution. 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. Presenter(s): Yun J.

Publication Details:

Yun J, Kong JH, Kim JA, **Kim DH**, Jang JH, Kim K, Jung CW. Validation of Updated Cytogenetic Risk Classification in Patients with Myelodysplastic Syndrome: Retrospective Study at Single Institution. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:4837. **Coauthor or Collaborator**.

2009 Dec **Presenter**. Multicenter Retrospective Analysis of High Dose Chemotherapy and Autologous PBSCT for Ovarian Cancer. 51st Annual meeting of American Society of Hematology. New Orleans, Louisiana, United States. (Trainee Presentation)

Publication Details:

Kim KH, Won JH, Park HS, Jeong SH, Lee HW, Park JS, Cho SG, Lee JM, Park CW, **Kim DH**, Jang JH, Lee WS, Lee JL, Mun YC, Seong CM, Kim HJ. Multicenter Retrospective Analysis of High Dose Chemotherapy and Autologous PBSCT for Ovarian Cancer. Blood (ASH Annual Meeting Abstracts). 2009 Nov;114:4365. **Coauthor or Collaborator**.

2009 Mar **Presenter**. Vascular endothelial growth factor (VEGFA) gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: Preventive effect of VEGF on acute GVHD. 35th Annual meeting of European Group for Bone Marrow Transplantation. Goteborg, Sweden. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 545).

Publication Details:

Kim DH, Lee NY, Lee MH, Sohn SK, Jang JH, Kim K, Kim SJ, Kim WS, Jung CW. Vascular endothelial growth factor (VEGFA) gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: Preventive effect of VEGF on acute GVHD. Bone Marrow Transplant. 2009;44(Suppl 2s):s129. **Principal Author**.

2009 Mar **Presenter.** The use of intravenous busulfan combined with cyclophosphamide (ivBuCy) reduces early hepatic toxicity and non-relapse mortality following allogeneic hematopoietic stem cell transplantation compared to oral busulfan containing regimen (poBuCy). 35th Annual meeting of European Group for Bone Marrow Transplantation. Goteborg, Sweden. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 657). (Trainee Presentation)

Publication Details:

Jun HJ, Kim KH, Chang MH, Yi SY, Kim SJ, Jang JH, Kim K, Kim WS, **Kim DH**, Kim SJ, Kim WS, Jung CW. The use of intravenous busulfan combined with cyclophosphamide (ivBuCy) reduces early hepatic toxicity and non-relapse mortality following allogeneic hematopoietic stem cell transplantation compared to oral busulfan containing regimen (poBuCy). Bone Marrow Transplant. 2009;44(Suppl 2s):s171.

Coauthor or Collaborator.

2009 Feb **Presenter.** Vascular endothelial growth factor (VEGFA) gene polymorphisms may predict the risk of acute GVHD following allogeneic transplantation: Preventive effect of VEGF on acute GVHD. 2009 BMT tandem meetings of IBMTR/ASBMT. Tampa, Florida, United States. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 283).

Publication Details:

Kim DH, Lee NY, Lee MH, Sohn SK, Jang JH, Kim K, Jung CW. Vascular endothelial growth factor (VEGFA) gene polymorphisms may predict the risk of acute GVHD following allogeneic transplantation: Preventive effect of VEGF on acute GVHD. Biol Blood Marrow Transplant. 2009;15(Suppl 2):103 (Abstract 283). **Principal Author.**

2008 Dec **Presenter.** Clinical relevance of Vascular Endothelial Growth Factor (VEGFA) and VEGF receptor (VEGFR2) gene single nucleotide polymorphism on the treatment outcomes following imatinib mesylate therapy. 50th Annual meeting of American Society of Hematology. San Fransisco, California, United States. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 1110).

Publication Details:

Kim DH, Ahn HK, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Lipton JH. Clinical relevance of Vascular Endothelial Growth Factor (VEGFA) and VEGF receptor (VEGFR2) gene single nucleotide polymorphism on the treatment outcomes following imatinib mesylate therapy. Blood (ASH Annual Meeting Abstracts). 2008 Nov;112:1110. **Principal Author.**

2008 Dec **Presenter.** Natural killer (NK) or NK/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. 50th Annual meeting of American Society of Hematology. San Fransisco, California, United States. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 933).

Publication Details:

Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH. Natural killer (NK) or NK/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Blood (ASH Annual Meeting Abstracts). 2008 Nov;112:933. **Principal Author.**

2008 Dec **Presenter.** Genetic Variants in the Candidate Genes of the Apoptosis Pathway and Susceptibility to Chronic Myeloid Leukemia. 50th Annual meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): **Kim DH**.

Publication Details:

Kim DH, Kim KH, Chang MH, Xu W, Ma C, Liu X, Siminovitch K, Messner HA, Lipton JH. Genetic Variants in the Candidate Genes of the Apoptosis Pathway and Susceptibility to Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts). 2008 Nov;112:3973. **Principal Author.**

2008 Dec **Presenter.** BCL2 Gene Polymorphism Could Predict the Treatment Outcomes in Patients with De Novo Acute Myeloid Leukemia. 50th Annual meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Kim KH. (Trainee Presentation)

Publication Details:

Kim KH, **Kim DH**, Lee SJ, Moon JH, Chang MH, Lee MH, Jung CW, Sohn SK. BCL2 Gene Polymorphism Could Predict the Treatment Outcomes in Patients with De Novo Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts). 2008 Nov;112:3973. **Co-Principal Author.**

2008 Dec **Presenter.** Neutrophil Counts Could Predict the Response to Immunosuppressive Treatment with Antithymocyte Globulin and Cyclosporine in the Patients with Severe Aplastic Anemia. 50th Annual meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Chang MH. (Trainee Presentation)

Publication Details:

Chang MH, **Kim DH**, Kim KH, Ahn HK, Lee SJ, Jang JH, Kim K, Jung CW. Neutrophil Counts Could Predict the Response to Immunosuppressive Treatment with Antithymocyte Globulin and Cyclosporine in the Patients with Severe Aplastic Anemia. Blood (ASH Annual Meeting Abstracts). 2008 Nov;112:4109. **Co-Principal Author.**

2008 Dec **Presenter.** Do Microenvironmental Factors Play Important Role in Supporting the Maintenance of Leukemic Stem Cells of Chronic Myelogenous Leukemia? 50th Annual meeting of American Society of Hematology. San Francisco, California, United States. Presenter(s): Cho YH.

Publication Details:

Cho YH, **Kim DH**, Jang JH, Kim SJ, Kim K, Kim WS, Jung CW. Do Microenvironmental Factors Play Important Role in Supporting the Maintenance of Leukemic Stem Cells of Chronic Myelogenous Leukemia? Blood (ASH Annual Meeting Abstracts). 2008 Nov;112:4219. **Coauthor or Collaborator.**

2007 Dec **Speaker.** Clinical relevance of a pharmacogenetic approach using multiple candidate gene polymorphisms to predict response and resistance to imatinib mesylate therapy in chronic myeloid leukemia. 49th Annual meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): **Kim DH**. [Simultaneous presentation] (Abstract 737).

Publication Details:

Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitich K, Messner HA, Lipton JH. Clinical relevance of a pharmacogenetic approach using multiple candidate gene polymorphisms to predict response and resistance to imatinib mesylate therapy in chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:737. **Principal Author.**

2007 Dec **Presenter.** Late Onset Eosinophilia (beyond Day 100), Rather Than Early Onset Eosinophilia, Has a Significant Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT). 49th Annual meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 1062).

Publication Details:

Kim DH, Popradi G, Kuruvilla J, Gupta V, Minden M, Messner HA, Lipton JH. Late Onset Eosinophilia (beyond Day 100), Rather Than Early Onset Eosinophilia, Has a Significant Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT). Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:1062. **Principal Author.**

2007 Dec **Presenter.** No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. 49th Annual meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): **Kim DH**. [Poster presentation] (Abstract 1950).

Publication Details:

Kim DH, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:1950. **Principal Author.**

- 2007 Dec **Presenter.** Impact of Myeloablative Versus Reduced Intensity Conditioning Regimens on Early Lymphocyte Recovery and Its Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients with Hematologic Malignancies. 49th Annual meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): **Kim DH.**
- Publication Details:*
Kim DH, Popradi G, Kuruvilla J, Gupta V, Minden M, Lipton JH, Messner HA. Impact of Myeloablative Versus Reduced Intensity Conditioning Regimens on Early Lymphocyte Recovery and Its Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients with Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:5039. **Principal Author.**
- 2007 Dec **Presenter.** Early Recovery of Absolute Lymphocyte Count (ALC) Is a Predictor of Long-Term Outcome Following Related Allogeneic Peripheral Blood Stem Cell Transplantation in Adults with AML/MDS. 49th Annual meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Popradi G.
- Publication Details:*
Popradi G, **Kim DH,** Kuruvilla J, Gupta V, Minden M, Lipton JH, Messner HA. Early Recovery of Absolute Lymphocyte Count (ALC) Is a Predictor of Long-Term Outcome Following Related Allogeneic Peripheral Blood Stem Cell Transplantation in Adults with AML/MDS. Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:1102. **Coauthor or Collaborator.**
- 2007 Jun **Presenter.** Use of absolute lymphocyte counts to predict response to chemotherapy and survival in diffuse large B-cell lymphoma. 43rd Annual Meeting of American Society of Clinical Oncology meetings. Chicago, Illinois, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 8082).
- Publication Details:*
Kim DH, Chae Y, Baek J, Kim J, Kim Y, Park Y, Do Y, Chung J, Kim M, Song H. Use of absolute lymphocyte counts to predict response to chemotherapy and survival in diffuse large B-cell lymphoma. ASCO Annual Meeting Proceedings Part 1. 2007 Jun 20;25(Suppl 18S):8082. **Principal Author.**
- 2007 Apr **Presenter.** Vascular endothelial growth factor gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. 98th Annual Meeting of the American Association of Cancer Research meetings. Los Angeles, California, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 4632).
- Publication Details:*
Kim DH, Park JY, Sohn SK, Kim JG, Do YR, Song HS, Lipton JH, Messner HA. Vascular endothelial growth factor gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; 2007 Apr 14-18; Los Angeles. Philadelphia (PA): AACR. 2007:4632. **Principal Author.**
- 2007 Mar **Presenter.** Comparative analysis of BCR/ABL mRNA transcript clearance using quantitative PCR after allogeneic stem cell transplantation between imatinib resistant and imatinib-naïve/responsive/intolerant patients with chronic myeloid leukemia. 33rd Annual meeting of European Group for Bone Marrow Transplantation. Lyon, France. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 442).
- Publication Details:*
Kim D, Messner H, Minden M, Gupta V, Kuruvilla J, Lipton J. Comparative analysis of BCR/ABL mRNA transcript clearance using quantitative PCR after allogeneic stem cell transplantation between imatinib resistant and imatinib-naïve/responsive/intolerant patients with chronic myeloid leukemia. Bone Marrow Transplant. 2007;39(Suppl 1s):S67. **Principal Author.**
- 2007 Mar **Presenter.** Cryopreservation of allogeneic peripheral blood stem cells does not influence the recovery of lymphocyte counts after allogeneic transplantation. 33rd Annual meeting of European Group for Bone Marrow Transplantation. Lyon, France. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 622).

Publication Details:

Kim D, Jamal N, Saragosa R, Lipton J, Minden M, Gupta V, Kuruvilla J, Messner H. Cryopreservation of allogeneic peripheral blood stem cells does not influence the recovery of lymphocyte counts after allogeneic transplantation. *Bone Marrow Transplant.* 2007;39(Suppl 1s):S133. **Principal Author.**

2007 Feb **Presenter.** Evidence of successful allogeneic transplantation using cryopreserved peripheral blood stem cells from healthy donors. 2007 BMT tandem meetings of IBMTR/ASBMT. Keystone, Colorado, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 107).

Publication Details:

Evidence of successful allogeneic transplantation using cryopreserved peripheral blood stem cells from healthy donors. *Biol Blood Marrow Transplant.* 2007;13(2 Suppl):42 (Abstract 107). **Principal Author.**

2007 Feb **Presenter.** Clinical efficacy of long-term low dose acyclovir for VZV infection prophylaxis after allogeneic peripheral blood stem cell transplantation. 2007 BMT tandem meetings of IBMTR/ASBMT. Keystone, Colorado, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 350).

Publication Details:

Kim DH, Messner HA, Gupta V, Kuruvilla J, Chae YS, Sohn SK, Lipton JH. Clinical efficacy of long-term low dose acyclovir for VZV infection prophylaxis after allogeneic peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant.* 2007;13(2 Suppl):127 (Abstract 350). **Principal Author.**

2006 Dec **Presenter.** Single Nucleotide Polymorphism of CC Chemokine Ligand 5 Promoter Gene in Recipient May Affect on the Development of Chronic Graft-Versus-Host Disease and Its Severity after Allogeneic Transplantation. 48th Annual meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 2878).

Publication Details:

Kim DH, Sohn SK, Kuruvilla J, Gupta V, Lipton J, Messner H. Single Nucleotide Polymorphism of CC Chemokine Ligand 5 Promoter Gene in Recipient May Affect on the Development of Chronic Graft-Versus-Host Disease and Its Severity after Allogeneic Transplantation. *Blood (ASH Annual Meeting Abstracts).* 2006 Nov;108:2878. **Principal Author.**

2006 Dec **Presenter.** FCGR3A Gene Polymorphisms May Correlate with Response to Frontline R-CHOP Therapy for Diffuse Large B-Cell Lymphoma. 48th Annual meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract 2457).

Publication Details:

Kim DH, Jung HD, Sohn SK, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Hyun MS. FCGR3A Gene Polymorphisms May Correlate with Response to Frontline R-CHOP Therapy for Diffuse Large B-Cell Lymphoma. *Blood (ASH Annual Meeting Abstracts).* 2006 Nov;108:2457. **Principal Author.**

2006 Dec **Presenter.** Factors Influencing Varicella-Zoster Virus (VZV) Infection after Allogeneic Peripheral Blood Stem Cell Transplantation: Low-Dose Acyclovir Prophylaxis and Pre-Transplant Diagnosis of Lymphoproliferative Disorders. 48th Annual meeting of American Society of Hematology. Orlando, Florida, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract #3373).

Publication Details:

Kim DH, Messner H, Gupta V, Kuruvilla J, Wright J, Lipton J. Factors Influencing Varicella-Zoster Virus (VZV) Infection after Allogeneic Peripheral Blood Stem Cell Transplantation: Low-Dose Acyclovir Prophylaxis and Pre-Transplant Diagnosis of Lymphoproliferative Disorders. *Blood (ASH Annual Meeting Abstracts).* 2006 Nov;108:3373. **Principal Author.**

2006 Mar **Presenter.** Application of cryopreservation to allogeneic peripheral blood haematopoietic stem cell transplantation: evaluation of its safety and its influence on engraftment and clinical outcomes. 32nd Annual meeting of European Group for Bone Marrow Transplantation. Hamburg, Germany. Presenter(s): **Kim DH.** [Poster discussion] (Poster 812).

Publication Details:

Kim DH, Saragosa R, Jamal N, Panzerella T, Gupta V, Lipton J, Messner H. Application of cryopreservation to allogeneic peripheral blood haematopoietic stem cell transplantation: evaluation of its safety and its influence on engraftment and clinical outcomes. Bone Marrow Transplantation. 2006;37:s217. **Principal Author**.

2006 Mar **Presenter**. Time to first acute exacerbation can stratify the patients according to their prognosis during clinical course of chronic GvHD: evaluation of new end-point for chronic GvHD. 32nd Annual meeting of European Group for Bone Marrow Transplantation. Hamburg, Germany. Presenter(s): **Kim DH**. [Poster discussion] (Poster 439).

Publication Details:

Sohn SK, **Kim DH**, Lee KB, Lee KH, Lee JH, Choi SJ, Lee JH. Time to first acute exacerbation can stratify the patients according to their prognosis during clinical course of chronic GvHD: evaluation of new end-point for chronic GvHD. Bone Marrow Transplantation. 2006;37:s82. **Co-Principal Author**.

2006 Mar **Presenter**. Disparity of variable number of tandem repeats between donor and recipient has a potential to predict the outcomes of allogeneic HLA-identical stem cell transplantation. 32nd Annual meeting of European Group for Bone Marrow Transplantation. Hamburg, Germany. Presenter(s): **Kim DH**. [Poster discussion] (Poster 434).

Publication Details:

Kim DH, Jung HD, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS, Lee KB. Disparity of variable number of tandem repeats between donor and recipient has a potential to predict the outcomes of allogeneic HLA-identical stem cell transplantation. Bone Marrow Transplantation. 2006;37:s80. **Principal Author**.

2006 Mar **Presenter**. Contribution of transplant dose of non-CD34+ cells, especially CD8+ cytotoxic T-cell and CD56+ natural killer cell, on engraftment kinetics after allogeneic peripheral stem cell transplantation. 32nd Annual meeting of European Group for Bone Marrow Transplantation. Hamburg, Germany. Presenter(s): **Kim DH**. [Poster discussion] (poster 649).

Publication Details:

Kim DH, Won DI, Lee NY, Sohn SK, Suh JS, Lee KB. Contribution of transplant dose of non-CD34+ cells, especially CD8+ cytotoxic T-cell and CD56+ natural killer cell, on engraftment kinetics after allogeneic peripheral stem cell transplantation. Bone Marrow Transplantation. 2006;37:s158. **Principal Author**.

2006 Mar **Presenter**. Survival benefit of asymptomatic cytomegalovirus reactivation and early lymphocyte recovery after HLA-identical allogeneic peripheral blood stem cell transplantation. 32nd Annual meeting of European Group for Bone Marrow Transplantation. Hamburg, Germany. Presenter(s): **Kim DH**. [Poster discussion] (Poster 684).

Publication Details:

Kim DH, Sohn SK, Lee NY, Suh JS, Lee KB. Survival benefit of asymptomatic cytomegalovirus reactivation and early lymphocyte recovery after HLA-identical allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation. 2006;37:s171. **Principal Author**.

2006 Mar **Presenter**. Risk factor analysis for predicting progressive or quiescent-type chronic graft-versus-host disease in patient cohort with history of acute graft-versus-host disease after allogeneic stem cell transplantation. 32nd Annual meeting of European Group for Bone Marrow Transplantation. Hamburg, Germany. Presenter(s): Sohn SK.

Publication Details:

Sohn SK, **Kim DH**, Baek JH, Kim JG, Lee KB, Lee KH, Lee JH, Choi SJ, Lee JH, Shin IH. Risk factor analysis for predicting progressive or quiescent-type chronic graft-versus-host disease in patient cohort with history of acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplantation. 2006;37:s82. **Coauthor or Collaborator**.

2006 Mar **Presenter**. New staging systems are useful for predicting prognosis of multiple myeloma patients who

underwent autologous peripheral blood haematopoietic stem cell transplantation as an up-front therapy. 32nd Annual meeting of European Group for Bone Marrow Transplantation. Hamburg, Germany. Presenter(s): **Kim H.**

Publication Details:

Kim H, Suh C, Park JH, Sohn HJ, Kim S, Kim SH, Lee JH, Bang SM, **Kim DH**, Sohn SK, Lee JJ. New staging systems are useful for predicting prognosis of multiple myeloma patients who underwent autologous peripheral blood haematopoietic stem cell transplantation as an up-front therapy. Bone Marrow Transplantation. 2006;37:s139. **Coauthor or Collaborator.**

2005 Dec **Presenter.** Rapid Helper T-Cell Recovery at 3 Months Correlates to Successful Transplant Outcomes after Allogeneic Stem Cell Transplantation. 47th Annual meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Moon JH.

Publication Details:

Moon JH, Baek JH, **Kim DH**, Sohn SK, Kim JG, Lee KB, Suh JS. Rapid Helper T-Cell Recovery at 3 Months Correlates to Successful Transplant Outcomes after Allogeneic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2005 Nov;106:5201. **Principal Author.**

2005 Dec **Presenter.** A Comparison of 3 Staging Systems for the Outcome Following Autologous Stem Cell Transplantation (ASCT) in Patients with Multiple Myeloma (MM). 47th Annual meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Sohn HJ.

Publication Details:

Sohn HJ, Kim K, Lee JH, Bang SM, **Kim DH**, Lee JJ, Suh CW. A Comparison of 3 Staging Systems for the Outcome Following Autologous Stem Cell Transplantation (ASCT) in Patients with Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts). 2005 Nov;106:5479. **Coauthor or Collaborator.**

2005 Dec **Presenter.** Risk Factor Analysis for Predicting Chronic Graft-Versus-Host Disease of Progressive or Quiescent Type in a Cohort of Patients with a History of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation. 47th Annual meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): Sohn SK.

Publication Details:

Sohn SK, **Kim DH**, Baek JH, Kim JG, Lee KB, Lee KH, Lee JH, Choi SJ, Lee JH. Risk Factor Analysis for Predicting Chronic Graft-Versus-Host Disease of Progressive or Quiescent Type in a Cohort of Patients with a History of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2005 Nov;106:5337. **Coauthor or Collaborator.**

2005 Dec **Presenter.** Multidrug Resistance-1 Gene Polymorphism Associated with the Outcomes after Allogeneic HLA-Identical Stem Cell Transplantation. 47th Annual meeting of American Society of Hematology. Atlanta, Georgia, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract #1757).

Publication Details:

Kim DH, Jeon SB, Baek JH, Lee NY, Kim JG, Sohn SK, Suh SJ, Do YR, Kwon KK. Multidrug Resistance-1 Gene Polymorphism Associated with the Outcomes after Allogeneic HLA-Identical Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2005 Nov;106:1757. **Principal Author.**

2005 May **Presenter.** Multidrug resistance-1 gene polymorphism associated with the treatment outcomes in de novo acute myeloid leukemia. 41st Annual meeting of American Society of Clinical Oncology. Chicago, Illinois, United States. Presenter(s): **Kim DH.** [Poster discussion] (Abstract #6550), ASCO merit award.

Publication Details:

Kim DH. Multidrug resistance-1 gene polymorphism associated with the treatment outcomes in de novo acute myeloid leukemia. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005;23(16S, Part I of II (June 1 Supplement)):6550. **Principal Author.**

2005 Mar **Presenter.** Prognostic factors for patients with non-Hodgkin's lymphoma who underwent high-dose

chemotherapy followed by autologous stem cell transplantation. 31st Annual meeting of European Group for Bone Marrow Transplantation. Prague, Czech Republic. Presenter(s): Kim YK.

Publication Details:

Kim YK, Lee JJ, Yang DH, Lee NS, Won JH, Hong DS, Park HS, **Kim DH**, Kim JG, Sohn SK, Kim HJ. Prognostic factors for patients with non-Hodgkin's lymphoma who underwent high-dose chemotherapy followed by autologous stem cell transplantation. Bone Marrow Transplant. 2005;35(S2):S245. **Coauthor or Collaborator.**

2004 Dec **Speaker.** IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. 46th Annual meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): **Kim DH.** [Simultaneous presentation] (Abstract #422), ASH travel award.

Publication Details:

Kim DH, Lee NY, Sohn SK, Baek JH, Kim JG, Lee JL, Suh JS, Lee KS, Lee KB. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts). 2004 Nov;104:422. **Principal Author.**

2004 Dec **Speaker.** Transplantation with Higher Dose of Natural Killer Cells Associated with Better Outcomes in Terms of Non-Relapse Mortality and Infectious Events after Allogeneic Peripheral Blood Stem Cell Transplantation from HLA-Matched Sibling Donors. 46th Annual meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): **Kim DH.** [Simultaneous presentation] (Abstract #733).

Publication Details:

Sohn SK, **Kim DH**, Lee NY, Baek JH, Kim JG, Suh JS, Lee KS, Lee KB, Shin HJ, Chung JS. Transplantation with Higher Dose of Natural Killer Cells Associated with Better Outcomes in Terms of Non-Relapse Mortality and Infectious Events after Allogeneic Peripheral Blood Stem Cell Transplantation from HLA-Matched Sibling Donors. Blood (ASH Annual Meeting Abstracts). 2004 Nov;104:733. **Coauthor or Collaborator.**

2004 Dec **Presenter.** Bcl-2 Mediated Apoptosis Interacts with p53-Dependent Pathway in Progression of Peripheral T-Cell Lymphoma. 46th Annual meeting of American Society of Hematology. San Diego, California, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract #4548).

Publication Details:

Kim DH, Jung JT, Kwak EK, Do YR, Kim JG, Park TI, Sohn SK, Kwon KW, Song HS, Lee KB. Bcl-2 Mediated Apoptosis Interacts with p53-Dependent Pathway in Progression of Peripheral T-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts). 2004 Nov;104:4548. **Principal Author.**

2004 Jun **Presenter.** Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: Donor lymphocyte infusion and previous history of early CMV infection. 40th Annual meeting of American Society of Clinical Oncology. New Orleans, Louisiana, United States. Presenter(s): **Kim DH.** [poster presentation] (Abstract #6648).

Publication Details:

Kim DH. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: Donor lymphocyte infusion and previous history of early CMV infection. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings. 2004;22(14S (July 15 Supplement)):6648. **Principal Author.**

2004 Jun **Presenter.** Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. 40th Annual meeting of American Society of Clinical Oncology. New Orleans, Louisiana, United States. Presenter(s): **Kim DH.** [Poster presentation] (Abstract #6632).

Dennis Dong Hwan KIM

Publication Details:

Kim DH. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings. 2004;22(14S (July 15 Supplement)):6632. **Principal Author.**

CIBMTR Study proposal

2015 Feb 12 **Speaker.** in vivo T cell depletion on transplant outcomes in CMV seropositive and seronegative recipients with acute myeloid leukemia. Center for International Blood and Marrow Transplant Registry. San Diego, California, United States. Presenter(s): Mohamed Shanavas, **Dennis Kim.** Study proposal for registry study in BMT area. (Trainee Presentation).

Poster Presentation

2016 Feb 18 **Co-Author.** Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL). 2016 BMT Tandem Meetings. Honolulu, Hawaii, United States. Presenter(s): Hamilton B.

Other Presentations

2016 Sep **Contributor.** 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy. ESH European School of Haematology. Houston, Texas, United States.

2. NATIONAL

Invited Lectures and Presentations

- 2021 Oct 29 **Invited Lecturer.** Across the Horizon in CML 2021: The Present and Future. Princess Margaret Cancer Centre - Leukemia Update 2021. Canada. Presenter(s): **Kim DH.** Via Zoom Live Webinar (approx. 500 ppl).
- 2021 Sep 9 **Invited Lecturer.** Case Discussion of Steroid Refractory Acute/Chronic GVHD. GvHD National Virtual Program. Canada. Presenter(s): **Kim DH.** Via Zoom Live Webinar (approx. 100 ppl).
- 2021 Feb 25 **Invited Lecturer.** Update in GVHD Treatment 2021: Focusing on JAK1/2 Inhibitor. Queen Elizabeth II Health Sciences Center. Halifax, Nova Scotia, Canada. Presenter(s): **Kim DH.** Hematology Round, Via Zoom Live Webinar (approx. 500 ppl).
- 2021 Feb 4 **Invited Speaker.** Next-Generation Sequencing in Leukemia 2021. CSMLS (Canadian Society for Medical Laboratory Science). Canada. Presenter(s): **Kim DH.** Hematology Virtual Symposium February 3–4, 2021 via ZOOM (approx. 150 ppl).
- 2019 Nov 22 **Invited Speaker.** Precision Medicine in CML Management. St. John's, Newfoundland and Labrador, Canada. Presenter(s): **Kim DH.** Hematology Grand Round.
- 2019 Nov 21 **Invited Speaker.** Treatment-free remission with the 2nd generation TKI therapy. St. John's, Newfoundland and Labrador, Canada. Presenter(s): **Kim DH.**
- 2019 Sep 20 **Invited Speaker.** Update on the management in MDS patients: Genomics/HCT and new drug. Canadian Hematology Conference Autumn Meeting (CHC). Toronto, Ontario, Canada. Presenter(s): **Kim DH.**
- 2018 Oct 18 **Invited Speaker.** How Do I Treat CML Patients in 2018? Round Table. Newfoundland and Labrador, Canada. Presenter(s): **DH Kim.** Round Table.
- 2018 Oct 17 **Invited Speaker.** An Open discussion on TFR for CML Patients. Round Table. Newfoundland and

Dennis Dong Hwan KIM

Labrador, Canada. Presenter(s): **DH Kim**. Round Table.

- 2018 Sep 27 **Invited Speaker**. Is CML a Single Hit Disorder? - Future CML Management in Precision Medicine Age. Vancouver General Hospital. Vancouver, British Columbia, Canada. Hematology Round Table.
- 2018 Sep 27 **Invited Speaker**. Navigating the Landscape of CML - Management, Goal and Milestone in 2018. Vancouver General Hospital. Vancouver, British Columbia, Canada. Hematology Round Table.
- 2018 Apr 25 **Invited Speaker**. TFR ion CML (Treat-Free Remission): Three Clinical Scenarios. Round Table. Saskatoon, Saskatchewan, Canada. Presenter(s): **DH Kim**. Round Table.
- 2018 Apr 25 **Invited Speaker**. Personalized Mangement in CML considering Efficacy and CVE Risk. Round Table. Edmonton, Alberta, Canada. Presenter(s): **DH Kim**. Round Table.
- 2018 Apr 24 **Invited Speaker**. Personalized Mangement in CML considering Efficacy and CVE Risk. Round Table. Calgary, Alberta, Canada. Presenter(s): **DH Kim**. Round Table.
- 2017 Sep 14 **Invited Speaker**. 2017 EHA Highlights - CML and AML sessions (webcast). European Hematology Association Review. Presenter(s): **Kim DH**. Webcast.
- 2017 Feb 17 **Invited Speaker**. Update: TRAD trial - Treatment free Remission Accomplished with Dasatinib. BMS Advisory Board Meeting. Toronto, Ontario, Canada. Presenter(s): **Kim DH**.
- 2016 Sep 22 **Invited Speaker**. BMT: Current and novel research initiatives. CCRU Health Canada Preceptorship / Health Canada. Toronto, Ontario, Canada. Presenter(s): **Kim, Dennis**.
- 2016 Jun 16 **Invited Speaker**. Breaking News: How to maximize the use of TKI in the context of allogeneic HCT in CML. Canadian Blood and Marrow Transplant Group. Toronto, Ontario, Canada. Presenter(s): **Kim DH**.
- 2016 Apr 8 **Invited Speaker**. Update: TRAD trial - Treatment free Remission Accomplished with Dasatinib. BMS Advisory Board Meeting. Toronto, Ontario, Canada. Presenter(s): **Kim DH**.
- 2015 Aug 19 **Invited Speaker**. Chronic Myeloid Leukemia: GOLS & EHA update 2015. Edmonton, Alberta, Canada. Presenter(s): **Kim DH**. Round table - around 15 hematologists.
- 2015 Apr 17 **Invited Speaker**. Updated: TRAD trial (Treatment-free Remission Accomplished iwth Dasatinib). BMS National Advisory Board. Toronto, Ontario, Canada. Presenter(s): **Kim DH**.
- 2014 Aug 11 **Invited Speaker**. Recent Advances of Genomics in Leukemias. Department of Hemato-Oncology, Chonnam National University. Hwasun, Korea, Republic Of. Presenter(s): **Kim DH**.
- 2014 Apr 16 **Invited Speaker**. Updates on CML management: To be or not to be with frontline 2GTKI. Montreal. Montreal, Quebec, Canada. Presenter(s): **Kim DH**.
- 2014 Apr 15 **Invited Speaker**. Updates on CML management: To be or not to be with frontline 2GTKI. Hopital Trois-Rivierres. Trois-Rivierres, Quebec, Canada. Presenter(s): **Kim DH**.
- 2014 Apr 14 **Invited Speaker**. Updates on CML management: To be or not to be with frontline 2GTKI. Cote de Palais. Cote de Palais, Quebec, Canada. Presenter(s): **Kim DH**.
- 2014 Apr 14 **Invited Speaker**. Updates on CML management: To be or not to be with frontline 2GTKI. Maguire. Maguire, Quebec, Canada. Presenter(s): **Kim DH**.
- 2012 Apr 12 **Chair**. Chronic Graft-versus-Host Disease. The 12th Canadian Blood and Marrow Transplantation Group meeting. Toronto, Ontario, Canada. Presenter(s): Dr. Irwin Walker.
- 2011 Jul 16 **Invited Speaker**. Large granular lymphocytosis following dasatinib therapy in CML 2011. BMS Canada Advisory board meeting. Montreal, Quebec, Canada. Presenter(s): **Kim DH**. (Continuing Education).
- 2010 Oct 24 **Invited Speaker**. Large granular lymphocytosis following dasatinib therapy for chronic myeloid leukemia: Caveat or Blessing? Hematology Symposium. Tokyo, Japan. Presenter(s): **Kim DH**.

Dennis Dong Hwan KIM

- 2010 Oct 22 **Invited Speaker.** Large granular lymphocytosis following dasatinib therapy for chronic myeloid leukemia: Caveat or Blessing? Scientific Seminar. Saga, Japan. Presenter(s): **Kim DH.** (Continuing Education).
- 2010 Feb 20 **Speaker.** ASH 2009 update - Predictor of response to 2nd line dasatinib therapy and large granular lymphocytosis. Korean Society of Hematology Chronic Myeloid Leukemia Working Party. Muju Resort, Korea, Republic Of.
- 2010 Jan 30 **Speaker.** ASH 2009 update - In vitro and in vivo sensitivity : IC50 and blood level concentration. Korean Society of Hematology Chronic Myeloid Leukemia Working Party. Seoul, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2010 Jan 8 **Speaker.** Evaluation of antifungal prophylaxis against invasive fungal infections during corticosteroid containing GVHD therapy following allo-HSCT (ITRAconazole in GVHD; ITRAG trial). Keumkang Forum. Jeju, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2009 Feb 28 **Invited Speaker.** Pharmacogenetics in Hematopoietic Stem Cell Transplantation. The 13th Winter Korean Society of Blood and Marrow Transplantation, Plenary Session. Busan, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2009 Feb 21 **Invited Speaker.** Cancer Biomarker : Single Nucleotide Polymorphism. Korean Cancer Association, The 1st Winter Workshop of molecular medicine. Seoul, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2009 Jan 10 **Speaker.** Pharmacokinetics & Pharmacodynamics of Itraconazole. Keumkang Forum. Jeju, Korea, Republic Of. Presenter(s): **Kim DH.**

Presented Abstracts

- 2014 Jun 11 **Presenter.** Interactions between Alemtuzumab and Cytomegalovirus Serostatus of Recipient in Unrelated Donor Transplant for Myeloid Malignancies. The 14th Canadian Blood and Marrow Transplantation Group Meeting. Halifax, Nova Scotia, Canada. Presenter(s): Mohamed Shanavas, Naheed Alam, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Mathew Seftel, Jieun Uhm, and **Dennis Kim.** [Poster presentation].
- 2014 Jun 11 **Presenter.** Serum Albumin Level < 32 g/l on Day 30 Can Predict Higher Risk of Non-Relapse Mortality in Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation. The 14th Canadian Blood and Marrow Transplantation Group Meeting. Halifax, Nova Scotia, Canada. Presenter(s): Feras Alfraih, Jieun Uhm, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Matthew Seftel and **Dennis Kim.** Dr. Feras Alfraih, the clinical fellow, present this as a poster.
- 2014 Jun 11 **Presenter.** Validation of Favourable Impact of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation. The 14th Canadian Blood and Marrow Transplantation Group Meeting. Halifax, Nova Scotia, Canada. Presenter(s): M Poch Martell, J Uhm, N Alam, V Gupta, J Kuruvilla, JH Lipton, M Seftel, HA Messner and **D Kim.** Dr. Marc Poch Martell, the clinical fellow, presented this as a poster.
- 2013 Apr **Speaker.** The risk of steroid refractory acute graft-versus-host disease can be predicted by the risk model using donor IL6 and IFNG genotype along with gut GVHD. The 13th Canadian Blood and Marrow Transplantation Group Meeting. Winnipeg, Manitoba, Canada. Presenter(s): Alam N, Atenafu EG, Xu W, Uhm J, Gupta V, Kuruvilla J, Messner HA, Lipton JH, **Kim D.** Selected among the top 8 abstracts for Oral Presentations at the 13th Canadian Blood and Marrow Transplantation Group Meeting, Winnipeg, Canada. (Trainee Presentation).
- 2013 Apr **Presenter.** Chronic GVHD risk score model by CIBMTR can provide better prognostic stratification of chronic GVHD patients by adding absolute lymphocyte counts and eosinophil counts at chronic GVHD onset. The 13th Canadian Blood and Marrow Transplantation Group Meeting. Winnipeg, Manitoba, Canada. Presenter(s): **Kim DH,** Lambie A, Ellis L, Loach D, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J.
- 2012 Apr 20 **Presenter.** The risk of each organ specific graft-versus-host disease can be predicted by the multiple

- single nucleotide polymorphisms based predictive models. The 12th Canadian Blood and Marrow Transplantation Group Meeting. Toronto, Ontario, Canada. Presenter(s): **Kim DH**. [Poster presentation].
- 2012 Apr **Presenter**. Independent validation of chronic graft-versus-host disease grading system by the NIH consensus criteria. The 12th Canadian Blood and Marrow Transplantation Group Meeting. Toronto, Ontario, Canada. Presenter(s): **Kim DH**. [Poster presentation].
- 2012 Apr **Speaker**. Peripheral blood stem cell transplant increases the risk of chronic graft-versus-host disease of lung compared to bone marrow transplantation. The 12th Canadian Blood and Marrow Transplantation Group Meeting. Toronto, Ontario, Canada. Presenter(s): Alam N. Selected among the top 8 abstracts for Oral Presentatino at he 13th Canadian Blood and Marrow Transplantation Group Meeting, Winnipeg, Canada. (Trainee Presentation).
- 2010 Apr **Presenter**. Large granular lymphocyte expansion following allogeneic stem cell transplantation: its association with graft-versus-host disease and graft-versus-leukemia effect. 12th Biennial Conference of Canadian Bone Marrow Transplantation Group. Vancouver, British Columbia, Canada. Presenter(s): **Kim DH**. [Poster presentation].
- 2009 May **Speaker**. Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Korean Society of Hematology, Spring meeting. Seoul, Korea, Republic Of. Presenter(s): **Kim DH**. [Oral presentation].
- 2009 May **Speaker**. Clinical relevance of short-term response parameters such as cytogenetic or molecular response as predictor for interim or long-term treatment outcomes of imatinib therapy in chronic phase chronic myeloid leukemia: landmark analysis, time-dependent Cox's proportional hazard model and receiver-operational characteristics method based approach. Korean Society of Hematology, Spring meeting. Seoul, Korea, Republic Of. Presenter(s): **Kim DH**. [Oral presentation].
- 2009 Feb **Speaker**. Multicenter Retrospective Analysis of Second Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Outcomes for Hematologic Malignancies in Korea. Korean Society of Hematopoietic Stem Cell Transplantation, Winter meeting. Korea, Republic Of. Presenter(s): **Kim DH**. [Oral presentation].
- 2008 Apr **Presenter**. The favorable impact of late onset eosinophilia on allogeneic transplant outcomes may be derived of lower grade of chronic GVHD, frequent expression of autoantibody and rapid lymphocyte recovery. 11th Biennial Conference of Canadian Bone Marrow Transplantation Group. Montreal, Quebec, Canada. Presenter(s): **Kim DH**. [Poster presentation].
- 2006 Apr **Speaker**. Age (> 50 years) has a significant adverse impact on the outcome of myeloablative transplantation for myelofibrosis: Data from the Princess Margaret Hospital. 10th Biennial Conference of Canadian Bone Marrow Transplantation Group. Edmonton, Alberta, Canada. Presenter(s): **Kim DH**. [Simultaneous presentation].
- 2006 Apr **Presenter**. Application of cryopreservation to allogeneic peripheral blood hematopoietic stem cell transplantation from HLA-identical sibling donors: evaluation of its safety and its influence on engraftment and clinical outcomes. 10th Biennial Conference of Canadian Bone Marrow Transplantation Group. Edmonton, Alberta, Canada. Presenter(s): **Kim DH**. [Poster presentation].

3. PROVINCIAL / REGIONAL

Invited Lectures and Presentations

- 2021 Nov 1 **Invited Lecturer**. Across the Horizon in CML 2021: The Present and Future. Sunnybrook Health Sciences Center. Brampton, Ontario, Canada. Presenter(s): **Kim DH**. Sunnybrook Grand Round, Via Zoom Live Webinar (approx. 50 ppl).
- 2021 Apr 15 **Invited Lecturer**. Improving CML Outcomes in 2021. Humber River Hospital. Brampton, Ontario, Canada. Presenter(s): **Kim DH**. Oncology Round, Via Zoom Live Webinar (approx. 15 ppl).

- 2021 Apr 14 **Invited Lecturer.** William Osler Health System. Brampton Civic Hospital. Brampton, Ontario, Canada. Presenter(s): **Kim DH.** Oncology Round, Via Zoom Live Webinar (approx. 20 ppl).
- 2021 Mar 4 **Invited Lecturer.** Grand River Hospital. Improving CML Outcomes in 2021. Kitchener, Ontario, Canada. Presenter(s): **Kim DH.** Oncology Round, Via Zoom Live Webinar (approx. 20 ppl).
- 2021 Jan 14 **Invited Lecturer.** Improving CML Outcomes in 2021. Windsor Regional Cancer Program. Windsor, Ontario, Canada. Presenter(s): **Kim DH.** Oncology Round, Via Zoom Live Webinar (approx. 15 ppl).
- 2020 Oct 30 **Invited Speaker.** What's New in the Drug Development of CML in 2020? Princess Margaret Cancer Centre - Leukemia Update 2020. Digital Symposium. Audience 400.
- 2020 Sep 22 **Chair.** Detection of Actionable BCR-ABL1 KD Mutations in CML Patients: NGS and ddPCR. Charing session. Grand Round. Speaker – Simona Soverini. Audience 100.
- 2020 Sep 21 **Invited Speaker.** CML 2020: Improving CML outcomes in 2020 and beyond. Virtual. Education Round. Audience 10.
- 2020 Aug 7 **Invited Speaker.** Pre and post-transplant MRD monitoring in AML. Hans Messner Education Round, Princess Margaret Cancer Center. Toronto, Ontario, Canada. Audience 70.
- 2020 Feb 27 **Invited Speaker.** Recent Advances in CML Management. South Lake Hospital. New Market, Ontario, Canada. Presenter(s): **Kim DH.** Grand Round.
- 2020 Feb 5 **Invited Speaker.** Recent Advances in CML Management. Brampton Civic Hospital. Brampton, Ontario, Canada. Presenter(s): **Kim DH.** Grand Round.
- 2020 Jan 7 **Invited Speaker.** Recent Advances in CML Management. Toronto East General Hospital. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** Grand Round.
- 2019 Jun 28 **Invited Speaker.** Precision Medicine in CML: Is CML a single-hit disorder? Sudbury Regional Cancer Centre. Sudbury, Ontario, Canada. Presenter(s): **Kim DH.** Grand Round.
- 2019 May 27 **Invited Speaker.** TFR-Oriented Management in CML Patients. Humber River Hospital. North York, Ontario, Canada. Presenter(s): **Kim DH.** Grand Round - Humber River Hospital.
- 2019 May 14 **Invited Speaker.** TFR-Oriented Management in CML Patients. Royal Victoria Hospital. Barrie, Ontario, Canada. Presenter(s): **Kim DH.** Round Table.
- 2019 Apr 8 **Invited Speaker.** TFR-Oriented Management in CML Patients. Brampton Civic Hospital. Brampton, Ontario, Canada. Presenter(s): **Kim DH.** Grand Round.
- 2019 Feb 27 **Invited Speaker.** Next Step to Implement Precision Medicine in Leukemia/BMT. Vancouver General Hospital, Leukemia/BMT Program. Vancouver, British Columbia, Canada. Presenter(s): **Kim DH.** Medical Round February 27-28.
- 2019 Feb 13 **Invited Speaker.** ASH Update 2018 & TFR-oriented CML Management. Alberta, Canada. Presenter(s): **Kim DH.** Round Table.
- 2019 Feb 12 **Invited Speaker.** ASH Update 2018 & TFR-oriented CML Management. Edmonton, Alberta, Canada. Presenter(s): **Kim DH.** Round Table.
- 2019 Jan 31 **Invited Speaker.** TFR-Oriented Management in CML Patients. South Lake Hospital, Regional Cancer Centre. New Market, Ontario, Canada. Presenter(s): **Kim DH.** Grand Round.
- 2017 Jun 2 **Invited Speaker.** Cardiovascular events and CML therapy. Novartis Regional Advisory Board Meeting. Toronto, Ontario, Canada. Presenter(s): **Kim DH.**
- 2017 Jun 2 **Invited Speaker.** Treatment free remission - Data updates 2017. Novartis Regional Advisory Board Meeting. Toronto, Ontario, Canada. Presenter(s): **Kim DH.**

- 2017 May 19 **Invited Speaker.** Should TFR be the new goal of therapy? From survival to operational cure. Novartis Regional Advisory Board Meeting, Western Canada. Vancouver, British Columbia, Canada. Presenter(s): **Kim DH.**
- 2017 May 18 **Invited Speaker.** Treatment free remission - Data updates 2017. Novartis Regional Advisory Board Meeting, Western Canada. Vancouver, British Columbia, Canada. Presenter(s): **Kim DH.**
- 2017 May 12 **Invited Speaker.** Recent advances in CML management 2017: From survival to operational cure. New Brunswick Hematology Day 2017. St. John, New Brunswick, Canada. Presenter(s): **Kim DH.**
- 2017 May 11 **Invited Speaker.** Recent Advances in CML Management 2017: From survival to operational cure. Novartis Advisory Board Meeting. St. John, New Brunswick, Canada. Presenter(s): **Kim DH.**
- 2017 May 8 **Invited Speaker.** Management of Ph+ALL/advanced CML in the context of Allogeneic HCT & TKI. Sunnybrook Hematology Rounds. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** Invitation to speak at the Hematology Rounds at Sunnybrook Hospital.
- 2017 Apr 7 **Invited Speaker.** How To Manage Your CML Patients in the context of treatment free remission. Princess Margaret Cancer Centre Leukemia Update Program. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** Princess Margaret Leukemia Update 2017 - attendees around 200 ppl.
- 2016 Oct 6 **Invited Speaker.** Treatment free remission approach in the management of CML 2016. Novartis. Vancouver, British Columbia, Canada. Presenter(s): **Kim Dennis.** Seminar.
- 2016 Oct 5 **Invited Speaker.** CML - Treatment & Management & Update from EHA. Novartis. Kelowna, British Columbia, Canada. Presenter(s): **Kim Dennis.** Seminar.
- 2016 Apr 26 **Invited Speaker.** Breaking News Update in CML. Novartis Symposium. Vancouver, British Columbia, Canada. Presenter(s): **Kim DH.**
- 2016 Apr 15 **Invited Speaker.** Switch of TKI: When? How? and to What? Princess Margaret Cancer Centre Leukemia program. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** Princess Margaret Leukemia Update 2016 - attendees around 200 ppl.
- 2015 Aug 19 **Invited Speaker.** Chronic Myeloid Leukemia: GOLS & EHA update 2015. Novartis. Calgary, Alberta, Canada. Presenter(s): **Kim DH.** Round table - 30 hematologists.
- 2015 Mar 27 **Invited Speaker.** Do we have to kill the last CML cell? : Treatment free remission. Princess Margaret Cancer Centre Leukemia program. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** Princess Margaret Leukemia Update 2015 - attendees around 200 ppl.
- 2015 Feb 5 **Invited Speaker.** Recent advances in CML management: Focusing on TKI discontinuation. Round Table. Sudbury, Ontario, Canada. Presenter(s): **Kim, D.** Round Table - around 10 Hematologists.
- 2015 Jan 30 **Invited Speaker.** Recent advances in CML management: Focusing on TKI discontinuation. Best of Hematology Conference. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** Best of Hematology Conference, around 50 hematologists held at Sunnybrook Hospital.
- 2014 Aug 13 **Invited Speaker.** Medical Grand Round: Genomics in Leukemia. Department of Internal Medicine, Kyungpook National University. Daegu, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2014 Mar 28 **Invited Speaker.** Updates on CML management: To be or not to be with frontline 2GTKI. Leukemia program at the PMH. Toronto, Ontario, Canada. Presenter(s): **Kim DH.**
- 2013 Mar **Invited Speaker.** Recent Advances in Chronic Myeloid Leukemia. Leukemia program at the PMH. Toronto, Ontario, Canada. Presenter(s): **Kim DH.**
- 2012 Feb 3 **Invited Speaker.** Updates on Chronic Myeloid Leukemia. Leukemia program at the PMH. Toronto, Ontario, Canada. Presenter(s): **Kim DH.**
- 2010 Oct 23 **Invited Speaker.** Large granular lymphocytosis following dasatinib therapy for chronic myeloid leukemia:

Caveat or Blessing? Scientific Symposium. Saitama, Japan. Presenter(s): **Kim DH.** (Continuing Education).

Presented Abstracts

2014 Apr 2 **Presenter.** INTERACTIONS BETWEEN ALEMTUZUMAB AND CYTOMEGALOVIRUS SEROSTATUS OF RECIPIENT IN UNRELATED DONOR TRANSPLANT FOR MYELOID MALIGNANCIES. Department of Hematology, University of Toronto. Toronto, Ontario, Canada. Presenter(s): Shanavas M, Alam N, Gupta V, Uhm J, Seftel M, Kuruville J, Lipton JH, Messner H, **Kim D.** (Trainee Presentation).

Presented and Published Abstracts

2020 Jul 24 Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion For the Treatment Of Steroid-Refractory Or Dependent Chronic GVHD - A Multicentre Phase II Clinical Trial (The Care Trial). Cell Therapy Transplant Canada (CTTC). Alberta, Canada. Meeting cancelled due to COVID-19.

Publication Details:

Ahmad I, Bijl J, Atenafu E, Panzarella T, Broady R, Szwajcer D, Walker I, **Kim D**, Bredeson C, Foley R, Hogge D, Allan D, Delisle JS, Levings M, Schultz K, Wall D, Roy DC. Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion For the Treatment Of Steroid-Refractory Or Dependent Chronic GVHD - A Multicentre Phase II Clinical Trial (The Care Trial). 2020 Jul 24. **Coauthor or Collaborator.**

4. LOCAL

Invited Lectures and Presentations

- 2021 Nov 15 **Lecturer.** Identification of a Relapse-Fated FLT3-ITD AML Subclone Using Single Cell Sequencing. Leukemia Multidisciplinary Cancer Conference (MCC). Ontario, Canada. Round, via MS Teams– Leukemia Staff, Fellows and Hematology PGY4/5 Academic Presentations.
- 2021 Jun 3 **Chair.** Clonal Evolution in CML. Princess Margaret Cancer Center. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** DMOH Grand Rounds, Speaker - Dr. Thomas Ernst, Jena University, Jena, Germany.
- 2019 Oct 3 **Chair.** Treatment optimization in CML. Princess Margaret Hospital. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** Grand Round at Princess Margaret Hospital.
- 2019 May 3 **Invited Speaker.** Precision Medicine in CML. Princess Margaret Leukemia Update. Toronto, Ontario, Canada. Presenter(s): **Kim DH.**
- 2019 Feb 8 **Invited Speaker.** Novel Effective Therapy in Acute Leukemia & Allogeneic HCT. CARE - Ontario Winter Hematology Update Conference. Toronto, Ontario, Canada. Presenter(s): **Kim DH.**
- 2018 Dec 10 **Lecturer.** Post ASH Update on CML Research. Leukemia Academic Rounds. Toronto, Ontario, Canada. Presenter(s): **Kim DH.**
- 2018 Nov 27 **Invited Speaker.** Chimeric Antigen Receptor (CAR) T-cells in CML: CML HSCs Expressing IL-1RAP May be Targets of CAR-engineered T-cells. Novartis Pharmaceuticals Canada Inc - Post-ESH Update 2018. Toronto, Ontario, Canada. Round Table Discussion.
- 2018 Nov 12 **Chair.** Clonal Hematopoiesis. Leukemia Academic Rounds. Toronto, Ontario, Canada. Presenter(s): Lambert Busque.
- 2018 Oct 2 **Chair.** Molecular Monitoring in CML: What you need to know for optimal patient care. Leukemia Academic Rounds. Toronto, Ontario, Canada. Presenter(s): Susan Branford.

- 2018 Sep 28 **Invited Speaker.** Chronic Myeloid Leukemia: Recent Advances in CML Research 2018. Canadian Hematology Conference (CHC 2018). Toronto, Ontario, Canada. Presenter(s): **Dennis Kim.** Myeloproliferative Neoplasms (MPNs) and Leukemia / Chair: Dr. Dennis Kim
Practical Issues in CML in 2018.
- 2018 Apr 26 **Invited Speaker.** TFR in CML (Treatment-Free Remission): Three Clinical Scenarios. Princess Margaret Cancer Centre Leukemia Update Program. Toronto, Ontario, Canada. Presenter(s): **Kim DH.**
- 2018 Feb 23 **Invited Speaker.** Post ASH Update - Myeloid Leukemias and Transplant. CARE at ASH 2018. Toronto, Ontario, Canada. Presenter(s): **DH Kim.**
- 2017 Dec 18 **Lecturer.** Post ASH Update - Minimal residual disease detection using next-generation sequencing technology in AML with/without receiving allogeneic HCT. Leukemia Academic Rounds. Toronto, Ontario, Canada. Presenter(s): **Kim DH.**
- 2017 Nov 24 **Invited Speaker.** Treatment Free Remission. Bristol Myers Squibb. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** Provided BMS with speaker services in connection with the Sprycel National Advisory Board.
- 2017 Nov 13 **Invited Speaker.** The Changing Landscape in CML Therapy: New Treatment Goals and Choices. Novartis Pharmaceuticals Canada Inc. Toronto, Ontario, Canada. Presenter(s): Dr. **Dennis Kim,** Professor Timothy Hughes. Speaker Tour (Virtual) Presentation.
- 2017 Feb 27 **Invited Speaker.** Dynamics of Somatic Mutation Profile in Chronic Myeloid Leukemia. Leukemia Academic Rounds. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** Invitation to speak at the Leukemia Academic Rounds 12-1, Princess Margaret Cancer Center, 7th Floor, Classroom 7-605.
- 2016 Jun 6 **Invited Speaker.** Path to enhance TFR success in CML. Sunnybrook Grand Rounds. Toronto, Ontario, Canada. Presenter(s): **Kim, Dennis.** Invitation to speak at the Grand Round at Sunnybrook Hospital.
- 2016 Jan 29 **Invited Speaker.** HLA Typing and Beyond. Joint Allo/Auto Transplant Rounds. Toronto, Ontario, Canada. Presenter(s): **Kim, Dennis,** McCarthy, Douglas. Invitation to speak at the Joint Allo/Auto Transplant Rounds from 8-9, 7th Floor, Classroom 7-605.
- 2016 Jan 21 **Invited Speaker.** Do we have to kill the last CML cell? - Treatment free remission. Bristol-Myer-Squibb. Kingston, Ontario, Canada. Presenter(s): **Kim DH.** Round table.
- 2015 Sep 15 **Chair.** Practical Guidance for the Contemporary Management of CML. Toronto, Ontario, Canada. Presenter(s): Professor Giuseppe Saglio. Broadcasting.
- 2015 Feb 6 **Invited Speaker.** Recent advances in CML management: Focusing on TKI discontinuation. Grand Rounds. Sudbury, Ontario, Canada. Presenter(s): **Kim, D.** Grand Round - around 30.
- 2013 Oct 1 **Invited Speaker.** Updates on CML: Optimal CML management. Novartis Canada. Toronto, Ontario, Canada. Presenter(s): **Kim DH** and Lim P.
- 2013 Aug 14 **Invited Speaker.** Updates on CML management: Focused on new ELN recommendation 2013. BMS Korea. Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea, Republic Of. Presenter(s): **Kim DH.**
- 2012 Nov 6 **Invited Speaker.** Evolving Paradigm in CML. Novartis Canada. Thunder Bay, Ontario, Canada. Presenter(s): **Kim DH.**
- 2012 Oct 2 **Lecturer.** Graft-versus-host disease. DMOH, Princess Margaret Hospital. Toronto, Ontario, Canada. Presenter(s): **Kim DH.**
- 2012 Jun 26 **Invited Speaker.** Evolving Paradigm in CML. Novartis Canada. Newmarket, Ontario, Canada. Presenter(s): **Kim DH.**
- 2012 Jun 12 **Invited Speaker.** SNPs and Genomics in Leukemia. Department of hematology, University of Western Ontario. London, Ontario, Canada. Presenter(s): **Kim DH.**

Dennis Dong Hwan KIM

- 2012 May 17 **Speaker.** Genomics in Leukemia. DMOH, PMH. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** Grand Round.
- 2012 May 7 **Invited Speaker.** Evolving Paradigm in CML. Novartis Canada. Barrie, Ontario, Canada. Presenter(s): **Kim DH.**
- 2009 Nov 19 **Invited Speaker.** Clinical application of human genetic variants in the prediction of the response following treatment for hematologic disease and transplantation. Grand Round, Department of Medical Oncology and Hematology Princess Margaret Hospital. Toronto, Ontario, Canada. Presenter(s): **Kim DH.** Grand Round. (Continuing Education).
- 2009 Jul 29 **Speaker.** Management of chronic GVHD. Hematopoietic Stem Cell Transplantation Program, Samsung Medical Center, Research Seminar. Seoul, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2009 May 27 **Lecturer.** Pharmacogenetics in Hematologic diseases. Seoul National University School of Medicine, Research Seminar. Seoul, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2009 May 6 **Lecturer.** 1H & 5W in Medical Research : How, Who, When, Where, What and Why. Kyungpook National University School of Medicine, Research Seminar. Daegu, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2009 Mar 25 **Speaker.** Action mechanism of chemotherapeutic agents in cancer treatment. Clinical Trial Training Course for Cancer Patients. Seoul, Korea, Republic Of. Presenter(s): **Kim DH.** (Presentation to Patients/Public).
- 2008 Oct 15 **Speaker.** Pharmacogenetics in the leukemia treatment. Department of Internal Medicine, Samsung Medical Center, Medical Grand Rounds. Seoul, Korea, Republic Of. Presenter(s): **Kim DH.** (Continuing Education).
- 2008 Oct 1 **Speaker.** Single Nucleotide Polymorphism in the era of targeted therapy. Division of Hematology & Medical Oncology, Samsung Medical Center, Research Seminar. Seoul, Korea, Republic Of. Presenter(s): **Kim DH.**
- 2008 Apr 30 **Speaker.** Single nucleotide polymorphisms and cryopreservation in allogeneic hematopoietic stem cell transplantation. Department of Laboratory Diagnostics and Genetics Samsung Medical Center, Research Seminar. Seoul, Korea, Republic Of. Presenter(s): **Kim DH.**

H. Teaching and Design

My teaching philosophy is to cultivate an excellent clinician-researcher who equipped strong clinical and research skills and research-oriented mindset. As a clinician investigator, I am highly involved in research supervision of multiple level trainees including 13 clinical fellows in BMT/leukemia programs, 4 research fellows, 2 medical/hematology residents, 1 PhD and 1 master course students over last 5 years. As shown in the TES score cards, my TES was in the range of 4.48-4.67 with highly positive feedback and comments. My trainees whom I met during their training were highly encouraged for the development of their research activity and improvement of their clinical and research skills. It is evidenced by the 5 trainees who won the ASH achievement awards and by testimonials provided by the trainees.

1. INNOVATIONS AND DEVELOPMENT IN TEACHING AND EDUCATION

- 2018 Jan - present Faculty Development, Research Ethics Board/University Health Network (REB/UHN)
The Research Ethics Board (REB) exists to ensure that all research involving human participants conducted within the jurisdiction of University Health Network (UHN) meets the required standards of ethical and research conduct.
- 2014 Jan - 2014 Jun Planning committee, Faculty Development, Canadian Blood and Marrow Transplant Group
I was involved in the planning committee for 2014 annual meeting of Canadian blood and marrow transplant group meeting which will be held in Jun 2014.

Dennis Dong Hwan KIM

- 2013 Nov - 2014 Feb Planning committee, Faculty Development, Leukemia update planning committee
I was involved in the planning committee for 2014 leukemia update meeting (hosted by malignant hematology group in Princess Margaret Hospital) which will be held in Mar 2014.
- 2013 Sep - 2014 Feb International collaborative study development in developing country, Postgraduate MD, Faculty of Medicine, Dept of Medicine, Haematology
Department of Hematology, University of Toronto, has a link with Addis Ababa University, College of Health Sciences, School of Medicine. Two of hematology residents had visited Toronto last Sep-Oct 2013. During their stay, we discussed potential international collaborative study of Genome Wide Association Study to identify genetic lock associated with susceptibility to chronic myeloid leukemia in Ethiopian population. The protocol is written and awaiting for funding. Investigators in Ethiopian side are Dr. Amha Gebremedhin (site PI), Dr. Abdulaziz Abubeker and Dr. Fisihatsion Tadesse. And investigators in Canada are Dr. Dennis Kim (site PI) and Dr. Vishal Kukreti.

I. Research Supervision

1. PRIMARY OR CO-SUPERVISION

Multilevel Education

- 2014 Aug - 2015 Oct **Primary Supervisor.** Tanya Adityan, Health Policy, Management and Evaluation. Supervisee Position: Summer student, Supervisee Institution: McMaster University. *CML project.*

Undergraduate Education

- 2015 Nov - 2016 Jul **Primary Supervisor.** Yu Jin Kim, Life Science. Supervisee Position: Summer student, Supervisee Institution: University of Toronto. *CML project.* Supervisor(s): Dennis Kim.

Graduate Education

- 2019 Sep - 2021 Jun **Primary Supervisor.** MSc. Muzaffar Bhati, Medical Science. Supervisee Position: Master, Supervisee Institution: Princess Margaret Cancer Center. *Clonal stromapoesis in leukemias.*
- 2019 Sep - 2021 Jun **Primary Supervisor.** PhD. Muzaffar Bhati, Medical Science. Supervisee Position: PhD, Supervisee Institution: Princess Margaret Cancer Center. *Clonal stromapoesis in leukemias.* Supervisor(s): Dennis Kim.
- 2012 Jan - 2021 Jan **Co-Supervisor.** PhD. TaeHyung Simon Kim. Supervisee Position: Research Fellow, Supervisee Institution: Princess Margaret Cancer Center. *Genomics in leukemia.* Supervisor(s): Zhaolei Zhang.

Undergraduate MD

- 2013 Jun - 2013 Aug **Primary Supervisor.** Year 1. Elizabeth Shin. Supervisee Position: Medical Student, Supervisee Institution: University of Toronto. *Effect of large granular lymphocytosis on transplant outcomes in the patients receiving allogeneic stem cell transplantation and its association with chronic GVHD.* Awards: awarded from CREMS summer research program.

Postgraduate MD

- 2020 Jan - present **Primary Supervisor.** Clinical Fellow. Swe Mar Linn. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Cancer Centre. *Retrospective evaluation of tyrosine kinase inhibitor therapy for GVHD treatment.* Awards: Won the ASH 2020 achievement award.

- 2019 Aug - present **Primary Supervisor.** Clinical Fellow. Igor Novitzky Basso. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Cancer Centre. *Prognostic relevance of refined hepatic GVHD scoring system for outcome after onset of chronic GVHD.* Awards: Won the ASH 2020 achievement award.
- 2021 Apr - 2021 Oct **Primary Supervisor.** Clinical Fellow. Fatima Khadadah. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Cancer Centre. *Retrospective analysis of clinical efficacy and safety profile of ASCIMINIB therapy in Philadelphia positive chronic myeloid leukemia or acute lymphoblastic leukemia.*
- 2020 Aug - 2021 Jul **Primary Supervisor.** Clinical Research Fellow. Myung Hee Chang. Supervisee Position: Clinical Research Fellow, Supervisee Institution: Princess Margaret Cancer Center. *Genomic study of Impact of clonal hematopoiesis in of donor/recipients donors as well as somatic mutation profiles on allogeneic hematopoietic stem cell transplantation outcomes.*
- 2020 Mar - 2022 Feb **Primary Supervisor.** Clinical Research Fellow. Hyewon Lee. Supervisee Position: Clinical Research Fellow, Supervisee Institution: Princess Margaret Cancer Center. *Genomic study of Impact of clonal hematopoiesis in of donor/recipients donors as well as somatic mutation profiles on allogeneic hematopoietic stem cell transplantation outcomes.*
- 2019 Aug - 2020 Aug **Primary Supervisor.** Clinical Fellow. Muhned AlHumaid. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Cancer Centre. *Flow cytometry based MRD and Allogeneic HCT in AML.* Awards: Won the ASH 2020 achievement award.
- 2019 Aug - 2020 Jun **Primary Supervisor.** Clinical Research Fellow. Seong Yoon Yi. Supervisee Position: Clinical Research Fellow, Supervisee Institution: Princess Margaret Cancer Center. *Genomic biomarker discovery in CML.*
- 2019 Jan - 2019 Dec **Primary Supervisor.** Clinical Fellow. Georgina Reyes-Dahner. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. *Prognostic impact of genetic profiles including NGS mutation profiles and cytogenetic abnormality at diagnosis on treatment outcomes following allogeneic hematopoietic stem cell transplant in acute myeloid leukemia.*
- 2018 Sep - 2020 Jul **Primary Supervisor.** Clinical Fellow. Omar Abduljalil. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Cancer Centre. *Retrospectivte evaluation of tyrosine kinase inhibitor therapy for GVHD treatment.*
- 2018 Aug - 2020 Jun **Primary Supervisor.** Clinical Research Fellow (MD). Kyoung Ha Kim. Supervisee Position: Clinical Research Fellow, Supervisee Institution: Princess Margaret Cancer Center. *Genomic study of Impact of clonal hematopoiesis in of donor/recipients donors as well as somatic mutation profiles on allogeneic hematopoietic stem cell transplantation outcomes.*
- 2018 May - 2019 Apr **Primary Supervisor.** Clinical Research Fellow (MD). Yu Cai. Supervisee Position: Clinical Research Fellow, Supervisee Institution: Princess Margaret Cancer Center. *Genomic study of Impact of clonal hematopoiesis in of donor/recipients donors as well as somatic mutation profiles on allogeneic hematopoietic stem cell transplantation outcomes.*
- 2018 Feb - 2019 Jan **Primary Supervisor.** Clinical Research Fellow (MD). Hui Young Lee. Supervisee Position: Clinical Research Fellow, Supervisee Institution: Princess Margaret Cancer Center. *Genomic study of Impact of clonal hematopoiesis in of donor/recipients donors as well as somatic mutation profiles on allogeneic hematopoietic stem cell transplantation outcomes.*
- 2017 Sep - 2019 Jun **Primary Supervisor.** Subspecialty. Roman Shapiro. Supervisee Position: Hematology resident, Supervisee Institution: Princess Margaret Hospital. *Mathematical modelling in MDS using genomic and clinical variables, Non-thesis Project.*
- 2017 Sep - 2019 Jun **Primary Supervisor.** Core Program. Warren Fingrut. Supervisee Position: GIM resident, Supervisee Institution: Princess Margaret Hospital. *Ferritin level as a predictive marker for transplant outcomes, Non-thesis Project.*
- 2016 Sep - 2018 Sep **Primary Supervisor.** Clinical Fellow. Aisling Nee. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. *Retrospectivte study to identify a marker to predict stable MR4.5 after imatinib upfront therapy in CML.*
- 2016 Jul - 2018 Jun **Primary Supervisor.** Clinical Fellow. Ali Alahmari. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. *Retrospectivte study to evaluate the*

- impact of HCT-CI score on the outcomes in the patients developing GVHD.*
- 2016 Jan - 2016 Dec **Primary Supervisor.** Clinical Fellow. Sameer Alamoudi. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *HCT-CI has a prognostic value in acute but not in chronic GVHD specific survival.*
- 2016 Jan - 2016 Dec **Primary Supervisor.** Clinical Fellow. Saud AlHayli. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Refined hepatic GVHD scoring system as prognostic factor after onset of chronic GVHD.*
- 2015 Oct - 2018 Dec **Primary Supervisor.** Clinical Fellow. Wilson Lam. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Prognostic impact of pre-transplant pulmonary function test value on transplant outcomes.*
- 2015 Aug - 2016 Feb **Primary Supervisor.** Clinical Fellow. Sunkyu Park. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Impact of T-cell depletion on the risk of eye/mouth chronic GVHD after unrelated donor transplantation.*
- 2014 Sep - 2019 Jul **Primary Supervisor.** Clinical Fellow. Zeyad Al-Shaibani. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. *Incidence of invasive fungal infections after allogeneic transplantation in the recipients without prior episode of invasive fungal infection and its risk factor.*
- 2014 Apr - 2015 Aug **Primary Supervisor.** Clinical Fellow. Sita Bhella. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. *Moderate/Severe Grade of Chronic Graft Versus Host Disease and Younger Age (Less Than 45 Years Old) Are Risk Factors for Avascular Necrosis in Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.*
- 2014 Feb - 2015 Jul **Primary Supervisor.** Clinical Fellow. Marc Poch Martell. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *HCT-CI has a prognostic value in acute but not in chronic GVHD specific survival.*
- 2013 Dec - 2016 Jul **Primary Supervisor.** Clinical Fellow. Hassan Sibai. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. *Comparison of myeloablative FBT4 versus reduced intensity FBT2 conditioning regimens with fludarabine, busulfan and low-dose TBI in AML/MDS.*
- 2013 Oct - 2015 Aug **Primary Supervisor.** Subspecialty. Mansoor Radwi. Supervisee Position: Hematology Resident, Supervisee Institution: Princess Margaret Hospital. *Pure red cell aplasia after allogeneic transplantation.*
- 2013 Oct - 2014 Jun **Primary Supervisor.** Clinical Fellow. Uday Deotare. Supervisee Position: Clinical Fellow, Supervisee Institution: Princess Margaret Hospital. *Incidence of invasive fungal infections after allogeneic transplantation in the recipients without prior episode of invasive fungal infection and its risk factor.*
- 2013 Sep - 2014 Jan **Primary Supervisor.** Clinical Fellow. Mohamed Shanavas. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Biochemical cutoff value of liver function test for prognostic stratification in patients developed chronic GVHD by the NIH consensus criteria.*
- 2013 Jun - 2015 Dec **Primary Supervisor.** Clinical Fellow. Marc Poch Martell. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Validation of favorable impact of large granular lymphocytosis after allotransplant and exploration of predictive factor.*
- 2013 May - 2013 Dec **Primary Supervisor.** Clinical Fellow. Mohamed Shanavas. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Risk Factors For Chronic Eye and Mouth GVHD In Unrelated Hematopoietic Cell Transplantation: T Cell Depletion Is The Only Risk Factor Identified and Appears To Be Favorable.*
- 2013 Apr - 2013 Dec **Primary Supervisor.** Clinical Fellow. Feras Al-Freih. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Early Recovery Of Absolute Lymphocyte Counts $\geq 0.2 \times 10^9/L$ At Day 21 Can Predict Reduced Risk Of Relapse In Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation.*
- 2013 Apr - 2013 Dec **Primary Supervisor.** Clinical Fellow. Frank Michelis. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *The Modified Pre-Transplant EBMT Risk*

Score Is Superior To The HCT-CI Score In Predicting Overall Survival and Non-Relapse Mortality After Allogeneic Hematopoietic Cell Transplantation In Patients With Acute Myeloid Leukemia.

- 2013 Mar - 2015 Dec **Primary Supervisor.** Clinical Fellow. Feras Al-Freih. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *The prognostic impact of albumin level at day 30 post transplant on the risk of GVHD and survival after transplantation.*
- 2013 Mar - 2013 Dec **Primary Supervisor.** Clinical Fellow. Uhm, Jieun. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Incidence, Risk Factors and Allogeneic Stem Cell Transplant Outcomes In Chronic Sclerotic Gvhd: T-Cell Depletion Is Preventive and Peripheral Blood Stem Cellis a Risk Factor, But Not HLA-Mismatch With No Adverse Impact On Transplant Outcomes.* Awards: attained an "ASH abstract achievement award 2013".
- 2012 Sep - 2014 Aug **Primary Supervisor.** Clinical Fellow. Nada Hamad. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Retrospective comparison of cyclosporine plus mycophenolate GVHD prophylaxis regimen with cyclosporine plus methotrexate esp. for engraftment, risk of GVHD and opportunistic infections.*
- 2012 Jul - 2015 Dec **Primary Supervisor.** Clinical Fellow. Uhm, Jieun. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Comparison of failure-free survival after frontline therapy of steroid alone versus steroid plus azathioprine as steroid sparing agents for chronic GVHD.*
- 2012 Jul - 2015 Dec **Primary Supervisor.** Clinical Fellow. Mohamed Shanavas. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Clinical risk factor analysis predicting successful treatment of chronic GVHD following extracorporeal photopheresis.* Collaborator(s): Dr. David Barth.
- 2012 Jul - 2013 Dec **Primary Supervisor.** Clinical Fellow. Uhm, Jieun. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Retrospective analysis of risk factor for hemorrhagic cystitis following allogeneic hematopoietic stem cell transplantation.*
- 2012 Jul - 2013 Dec **Primary Supervisor.** Visiting professional. Joon Ho Moon. Supervisee Position: Assistant professor, Supervisee Institution: Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea. *Clinical risk factor predicting the development of steroid refractory acute GVHD after allogeneic stem cell transplantation.*
- 2012 Jun - 2013 Dec **Primary Supervisor.** Clinical Fellow. Naheed Alam. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *The risk of steroid refractory acute graft-versus-host disease can be predicted by the risk model using donor IL6 and IFNG genotype along with gut GVHD.* Awards: Selected among the top 8 abstracts for Oral Presentation at the Canadian Blood and Marrow Transplant Group Meeting in Winnipeg, Canada. Collaborator(s): Dr. Wei Xu.
- 2012 Jun - 2013 Mar **Primary Supervisor.** Visiting professional. Joon Ho Moon. Supervisee Position: Assistant professor, Supervisee Institution: Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea. *Prognostic power of chronic GVHD risk score model by IBMTR can be improved with addition of absolute lymphocyte counts and eosinophil counts at the onset of chronic GVHD.* Completed 2013.
- 2012 May - 2012 Dec **Primary Supervisor.** Visiting professional. Joon Ho Moon. Supervisee Position: Assistant professor, Supervisee Institution: Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea. *Validation of NIH global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD specific survival.* Awards: awarded for one of two best poster presentations in Annual meeting of European Bone Marrow Transplant Group meeting 2013 (London, UK). Completed 2012.
- 2012 Mar - 2013 Feb **Primary Supervisor.** Clinical research fellow. Hong Gi Lee. Supervisee Position: Staff physician, Consultant oncologist, Supervisee Institution: Hematology/Oncology, Anyang Sam Medical Center. *Clinical value of bcr/abl transcript measurement at 3 months following tyrosine kinase inhibitor therapy for chronic myeloid leukemia.* Completed 2012.
- 2012 Jan - 2014 Aug **Primary Supervisor.** Clinical Fellow. Feras Al-Freih. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Allogeneic stem cell transplantation in*

acute lymphoblastic leukemia: relation of additional cytogenetic abnormalities with risk of relapse.

- 2012 Jan - 2014 Jun **Primary Supervisor.** Clinical Fellow. Frank Michelis. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Lymphocyte Recovery At Day 28 Post-Transplant Is Predictive Of Relapse In Patients With Acute Myeloid Leukemia Transplanted With Peripheral Blood Stem Cell Grafts.*
- 2011 Oct - 2012 Jun **Primary Supervisor.** Clinical Fellow. Jonathan How. Supervisee Position: Staff physician, Consultant Hematologist, Supervisee Institution: McGill University, Montreal, QC, Canada. *Impact of large granular lymphocyte expansion for the risk of organ specific graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.*
- 2011 Jun - 2012 Dec **Primary Supervisor.** Clinical Fellow. Naheed Alam. Supervisee Position: Clinical fellow, Supervisee Institution: Princess Margaret Hospital. *Peripheral blood stem cell transplant increases the risk of chronic graft-versus-host disease of lung compared to bone marrow transplantation.* Awards: Selected among the top 8 abstracts for Oral Presentation at the Canadian Blood and Marrow Transplant Group Meeting in Toronto, Canada.
- 2011 May - 2011 Aug **Primary Supervisor.** Clinical Fellow. Murtadha Al Khabori. *Favorable impact of donor CMV IgG seropositivity on transplant outcomes following allogeneic stem cell transplantation.,* Completed 2011.
- 2010 Mar - 2011 Feb **Primary Supervisor.** Clinical Fellow. Jun Ho Yi. Supervisee Position: Assistant professor, Supervisee Institution: Division of Hematology/Oncology, Department of Internal Medicine, Han Yang University Hospital, Seoul Korea. *Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype.* Collaborator(s): Dr. Jungwon Huh, Dr. Hyeoung-Joon Kim. Completed 2011.
- 2010 Mar - 2011 Feb **Primary Supervisor.** Clinical Fellow. Sujin Lee. Supervisee Position: Clinical lecturer, Division of hematology/oncology, Supervisee Institution: Samsung Medical Center, Seoul, Korea. *Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.* Collaborator(s): Dr. Chulwon Jung. Completed 2011.
- 2010 Mar - 2011 Feb **Primary Supervisor.** Clinical Fellow. Hee Kyung Ahn. Supervisee Position: Assistant professor, Supervisee Institution: Gacheon University Gil Medical Center, Incheon Korea. *Monosomy karyotype in acute myeloid leukemia predicts adverse treatment outcome with low complete remission rate and worse event-free and overall survival, and associates with high functional activity of p-glycoprotein, MDR1.* Collaborator(s): Dr. Hee Jin Kim. Completed 2011.
- 2009 Mar - 2011 Feb **Primary Supervisor.** Clinical Fellow. Jee Hyun Kong. Supervisee Position: Assistant professor, Supervisee Institution: Yonsei University Wonju Severance Christian Hospital. *Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.* Collaborator(s): Dr. Jeffrey Lipton. Completed 2011.
- 2009 Mar - 2010 Feb **Primary Supervisor.** Clinical Fellow. Jina Yun. Supervisee Position: Assistant professor, Supervisee Institution: Soon Chun Hyang University Bucheon Hospital. *Single Nucleotide Polymorphism (SNP) Approach of Multiple Candidate Pathways Predicting the Risk of Acute / Chronic Graft-Versus-Host Disease or Transplant Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation.* Collaborator(s): Dr. Jeffrey Lipton, Dr. Wei Xu. Completed 2012.
- 2009 Mar - 2010 Feb **Primary Supervisor.** Clinical Fellow. Young Woong Won. Supervisee Position: Assistant professor, Supervisee Institution: Division of hematology/oncology, Han Yang University Guri Hospital. *Retrospective Analysis of Paranasal Sinusitis in Patients Receiving Hematopoietic Stem Cell Transplantation.* Collaborator(s): Dr. Chulwon Jung. Completed 2011.
- 2008 Sep - 2011 Feb **Co-Supervisor.** Clinical Fellow. Seung Tae Lee. Supervisee Position: Assistant professor, Supervisee Institution: Sungkyunkwan University, Samsung Medical Center, Seoul Korea. *A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia.* Collaborator(s): Dr. Jong Won Kim, Dr. Jeffrey Lipton. Completed 2011.
- 2008 Mar - 2009 Feb **Primary Supervisor.** Clinical Fellow. Hyun Jung Jeon. Supervisee Position: Assistant

professor, Supervisee Institution: Kwan Dong University Myungji Hospital. *Retrospective comparison of oral versus intravenous busulfan based regimen in allogeneic stem cell transplantation*. Collaborator(s): Dr. Chulwon Jung. Completed 2009.

2008 Mar - 2009 Feb

Primary Supervisor. Clinical Fellow. Myung Hee Chang. Supervisee Position: Staff physician, Consultant Hematologist, Supervisee Institution: Department of Hematology/oncology, National Health Insurance Service Ilsan Hospital, Korea. *Retrospective analysis of treatment outcomes with anti-thymocyte globulin based therapy for aplastic anemia and predictor for response and survival*. Completed 2009.

2008 Mar - 2009 Feb

Primary Supervisor. Clinical Fellow. Kyung Ha Kim. Supervisee Position: Assistant professor, Supervisee Institution: Soon Chun Hyang University Seoul Hospital. *Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea*. Completed 2010.

J. Creative Professional Activities

1. PROFESSIONAL INNOVATION AND CREATIVE EXCELLENCE

2018 Sep - present

International collaboration in genomics and TFR consortium in chronic myeloid leukemia. My research activities are being translated into clinical practice and international research collaboration. There are two aspects: 1) treatment-free remission (TFR) in the management of the CML patients, and 2) precision medicine in CML for future practice and research collaboration.

With respect to the TFR, our result of Canadian TKI discontinuation trial is leading the change in the CML practice in Canada as well as internationally: This is the first and the only Canadian collaborative clinical trial in CML, with 12 Canadian centers. Based on the result of this study, a lot of community hematologists are adopting this concept of practice into their practice during the CML patient management with good support from Canadian data.

Also, I am a founding member of the international CML Foundation (iCMLf) Treatment-Free Remission Alliance including 14 international CML centers (Canada, Australia, USA, UK, Italy, France, Germany, Finland, Japan, Korea, Brazil and Argentina). This consortium was established with support from the International CML Foundation.

Also for the genomic-based biomarker development and its implementation in CML practice, the result from my research proposes that the practice should incorporate the somatic mutation profiling for TKI drug selection and switch. As there was an urgent need for international collaboration in genomic research in CML, I am playing a leadership role in organization of a research consortium and am one of the key founding members of the International CML Genomic Alliance. This alliance was established in 2018 and consisted of 14 CML treating centers from 10 countries over the world (Canada, Australia, USA, UK, Italy, France, Germany, Finland, Korea and Argentina). Our goal is the realization of a precision medicine-based approach to CML practice in the near future, and facilitation of international collaboration in CML genomic research with the support of the International CML Foundation (iCMLf).

This collaborative effort resulted in the first publication of a review article summarizing the results of researches in the leukemic genome in CML for which I contributed as one of the co-first authors (Leukemia 2019).

2011 Mar - present

Whole exome sequencing in acute leukemia & hematologic diseases.

Dr. Hyeoungjoon Kim: Chonnam National University Hospital, Hwasun, Korea.

With collaboration with Dr. H Kim, I am currently a member of advisory board for the National Project for Personalized Genomic Medicine (PGM21) in Korea.

This international collaboration will broaden my research activity in genomic area and will

facilitate collaboration and partnership.

2008 Sep - present

Genomics and deep sequencing in cancer.
Dr. Jong Won Kim: Samsung Medical Center, Sungkyunkwan University, Korea.
With collaboration with Dr. J Kim, we are currently working on the genomic project to develop predictive model of complete molecular response following imatinib therapy in chronic myeloid leukemia.
This international collaboration will broaden my research activity in genomic area and will facilitate collaboration and partnership.

2013 Sep - 2014 Mar

International collaboration with Ethiopian Trainees.
Department of Hematology, University of Toronto, has a link with Addis Ababa University, College of Health Sciences, School of Medicine. Two of hematology residents had visited Toronto last Sep-Oct 2013. During their stay, we discussed potential international collaborative study of Genome Wide Association Study to identify genetic lock associated with susceptibility to chronic myeloid leukemia in Ethiopian population. The protocol is written and awaiting for funding. Investigators in Ethiopian side are Dr. Amha Gebremedhin (site PI), Dr. Abdulaziz Abubeker and Dr. Fisihatsion Tadesse. And investigators in Canada are Dr. Dennis Kim (site PI) and Dr. Vishal Kukreti.
The initiative of this activity is to motivate research activity in Ethiopia and to cultivate their research skills. This activity will enhance collaboration between the Addis Ababa University, College of Health Sciences, School of Medicine and Faculty of Medicine, University of Toronto.

2011 Jul - 2016 Jun

Activity in International chronic Graft-versus-host disease consortium.
Dr. Stephanie Lee, Dr. Mary Flowers, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA.
In a collaboration with chronic GVHD program at the Fred Hutchinson Cancer Research Center, we are working on validation project of chronic GVHD risk score proposed by the CIBMTR (Center for International Blood and Marrow Transplant Registry).
Allogeneic BMT program at the PMH is the biggest BMT program in Canada and one of the big transplant center in North America. However, the contribution on GVHD research field was not significant. This involvement can improve our contribution of research on this area and can make us to be popular .

2009 Jul - 2014 Feb

International collaboration of genomics in chronic myeloid leukemia.
Dr. Simona Soverini, University of Bologna, Italy
In a collaboration with Bolognian group of chronic myeloid leukemia, we are working on the whole exome sequencing project to identify novel mutation associated with the development of tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Validation samples of responsive and resistant chronic myeloid leukemia will be provided by the Bolognian group. This group is leading the genomics in chronic myeloid leukemia in the world. This international collaboration will broaden my research activity in genomic area and will facilitate collaboration and partnership.

2. CONTRIBUTIONS TO THE DEVELOPMENT OF PROFESSIONAL PRACTICES

2013 Oct - 2015 Mar

Developing a Care Map for Steroid Refractory GvHD.
This is a working group activity focusing on the management of steroid refractory GVHD patients. I initiated and organized a small working group including physician, clinician associate, nurse practitioner, in-patient nurse, dietitian, social worker, rehab expert, and physiotherapist, and currently leading the group. We had biweekly regular meeting and currently writing up of our guideline of management of steroid refractory GVHD patients and SOP. It is the first time to attempt to standardize our practice and management in patients with

Dennis Dong Hwan KIM

steroid refractory GVHD.

This is the first attempt in the allogeneic BMT program at the Princess Margaret Cancer Center to standarize our practice in steroid refractory GVHD patients. It eventually will improve quality of our practice and management as well as continuity of our practice.